

The global burden of hepatitis C

Liver International

29, 74-81

DOI: [10.1111/j.1478-3231.2008.01934.x](https://doi.org/10.1111/j.1478-3231.2008.01934.x)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Glial Fibrillary Acidic Protein (GFAP) as a Mesenchymal marker of Early Hepatic Stellate Cells Activation in Liver Fibrosis in Chronic Hepatitis C Infection.. Pakistan Journal of Medical Sciences, 1969, 30, 1027-32.	0.3	8
2	Managing pediatric hepatitis C: current and emerging treatment options. Therapeutics and Clinical Risk Management, 2009, 5, 651.	0.9	17
3	Chronic hepatitis B and C: update on therapy. Future Virology, 2009, 4, 437-452.	0.9	3
4	Hepatitis C Virus RNA Quantitation in Venous and Capillary Small-Volume Whole-Blood Samples. Journal of Clinical Microbiology, 2009, 47, 3231-3240.	1.8	6
6	Impact of obesity, steatosis and insulin resistance on progression and response to therapy of hepatitis C. Journal of Viral Hepatitis, 2009, 16, 681-688.	1.0	57
7	Liver Resection Improves the Survival of Patients with Multiple Hepatocellular Carcinomas. Annals of Surgical Oncology, 2009, 16, 848-855.	0.7	105
8	Role of α -fetoprotein in hepatocellular carcinoma: prognostication, treatment monitoring or both?. Future Oncology, 2009, 5, 889-899.	1.1	30
9	Intracellular Innate Immune Cascades and Interferon Defenses That Control Hepatitis C Virus. Journal of Interferon and Cytokine Research, 2009, 29, 489-498.	0.5	87
10	AIDS-related and non-AIDS-related mortality in the Asia-Pacific region in the era of combination antiretroviral treatment. Aids, 2009, 23, 2323-2336.	1.0	32
11	Triazole Nucleoside Derivatives Bearing Aryl Functionalities on the Nucleobases Show Antiviral and Anticancer Activity. Mini-Reviews in Medicinal Chemistry, 2010, 10, 806-821.	1.1	51
12	Host genetic basis for hepatitis C virus clearance: a role for blood collection centers. Current Opinion in Hematology, 2010, 17, 550-557.	1.2	9
13	Influencing Factors of Healthcare-Seeking Behaviors in Taiwanese Patients With Hepatitis C. Gastroenterology Nursing, 2010, 33, 414-420.	0.2	3
14	Biomarkers of Liver Injury for Hepatitis Clinical Trials: A Meta-Analysis of Longitudinal Studies. Antiviral Therapy, 2010, 15, 617-631.	0.6	56
15	Prisons as Social Determinants of Hepatitis C Virus and Tuberculosis Infections. Public Health Reports, 2010, 125, 25-33.	1.3	50
16	Predictors of hematological abnormalities in patients with chronic hepatitis C treated with interferon and ribavirin. Annals of Hematology, 2010, 89, 121-125.	0.8	19
17	Comparative efficacy and overall safety of different doses of consensus interferon for treatment of chronic HCV infection: a systematic review and meta-analysis. European Journal of Clinical Pharmacology, 2010, 66, 1071-1079.	0.8	12
18	Antiviral therapy of chronic hepatitis C in patients with advanced liver disease and after liver transplantation. Medical Microbiology and Immunology, 2010, 199, 1-10.	2.6	27
19	Strategies for antiviral screening targeting early steps of virus infection. Virologica Sinica, 2010, 25, 281-293.	1.2	10

#	ARTICLE	IF	CITATIONS
20	Prevalence of anti-HCV Antibodies Among Healthy Asymptomatic Indian Blood Donors and the Current Role of anti-HBc Screening as a Surrogate Marker for HCV Infection. <i>Apollo Medicine</i> , 2010, 7, 298-302.	0.0	1
21	Increased Risk of Transmission of Hepatitis C in Open Heart Surgery Compared With Vascular and Pulmonary Surgery. <i>Annals of Thoracic Surgery</i> , 2010, 90, 1425-1431.	0.7	8
22	Specific human leukocyte antigen class I and II alleles associated with hepatitis C virus viremia. <i>Hepatology</i> , 2010, 51, 1514-1522.	3.6	90
23	Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. <i>Hepatology</i> , 2010, 52, 864-874.	3.6	119
24	An economic analysis of antiviral therapy in patients with advanced hepatitis C virus disease: still not there!. <i>Liver Transplantation</i> , 2010, 16, 697-700.	1.3	1
25	Epidemic history of Hepatitis C virus in Brazil. <i>Infection, Genetics and Evolution</i> , 2010, 10, 886-895.	1.0	26
26	Discovery of benzimidazole-diamide finger loop (Thumb Pocket I) allosteric inhibitors of HCV NS5B polymerase: Implementing parallel synthesis for rapid linker optimization. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 196-200.	1.0	21
27	Benzimidazole Thumb Pocket I finger-loop inhibitors of HCV NS5B polymerase: Improved drug-like properties through C-2 SAR in three sub-series. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 1825-1829.	1.0	13
28	Synthesis and anti-HCV activity of 3,4-oxetane nucleosides. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 4539-4543.	1.0	12
29	Hepatitis C virus nonstructural protein 4B: a journey into unexplored territory. <i>Reviews in Medical Virology</i> , 2010, 20, 117-129.	3.9	101
30	A case-control study of factors associated with resolution of hepatitis C viremia in former blood donors (CME). <i>Transfusion</i> , 2010, 50, 1513-1523.	0.8	14
31	Is the hepatitis C virus epidemic over in Egypt? Incidence and risk factors of new hepatitis C virus infections. <i>Liver International</i> , 2010, 30, 560-566.	1.9	60
32	Treatment of hepatitis C in elderly patients: challenge for the future or present reality?. <i>Liver International</i> , 2010, 30, 493-495.	1.9	1
33	Maternal hepatitis B virus or hepatitis C virus carrier status as an independent risk factor for adverse perinatal outcome. <i>Liver International</i> , 2010, 30, 765-770.	1.9	109
34	The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients. <i>Liver International</i> , 2010, 30, 1019-1026.	1.9	313
35	Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. <i>Liver International</i> , 2010, 30, 1259-1269.	1.9	139
36	Peginterferon α -2a and ribavirin treatment of patients with haemophilia and hepatitis C virus infection: a single-centre study of 367 cases. <i>Liver International</i> , 2010, 30, 1173-1180.	1.9	52
37	Substitution treatment or active intravenous drug use should not be contraindications for antiviral treatment in drug users with chronic hepatitis C. <i>Liver International</i> , 2010, 30, 1454-1460.	1.9	26

#	ARTICLE	IF	CITATIONS
38	Role of Hepatitis C virus core protein in viral-induced mitochondrial dysfunction. <i>Journal of Viral Hepatitis</i> , 2010, 17, 784-793.	1.0	62
39	ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. <i>Nature</i> , 2010, 464, 405-408.	13.7	430
40	Thymalfasin in the treatment of hepatitis B and C. <i>Annals of the New York Academy of Sciences</i> , 2010, 1194, 141-146.	1.8	13
41	Spontaneous clearance of hepatitis C infection post-liver transplant: A rare but real phenomenon? A case report and review of the literature. <i>Annals of Hepatology</i> , 2010, 9, 202-206.	0.6	15
42	Indications for treatment in chronic HCV infection. <i>Annals of Hepatology</i> , 2010, 9, S49-S53.	0.6	3
43	Pay Now or Pay (more) Later: Tracking the Costs of Hepatitis C Infection. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2010, 24, 715-716.	1.8	2
44	Likely transmission of hepatitis C virus through sharing of cutting and perforating instruments in blood donors in the State of Pará, Northern Brazil. <i>Cadernos De Saude Publica</i> , 2010, 26, 837-844.	0.4	22
45	High prevalence of hepatitis C associated with familial history of hepatitis in a small town of south Brazil: efficiency of the rapid test for epidemiological survey. <i>Brazilian Journal of Infectious Diseases</i> , 2010, 14, 483-488.	0.3	7
46	Prevalence and genotyping of hepatitis C virus in blood donors in the state of Pará, Northern Brazil. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2010, 105, 103-106.	0.8	22
47	Prevalence and Risk Factors for Hepatitis C Virus Infection among Young Thai Men. <i>American Journal of Tropical Medicine and Hygiene</i> , 2010, 83, 433-439.	0.6	7
48	Interferon-stimulated gene 15: a dual activity during hepatitis C virus infection. <i>Gut</i> , 2010, 59, 1017-1019.	6.1	1
49	Preclinical Characterization of BI 201335, a C-Terminal Carboxylic Acid Inhibitor of the Hepatitis C Virus NS3-NS4A Protease. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 4611-4618.	1.4	107
50	Amphipathic α -Helix AH2 Is a Major Determinant for the Oligomerization of Hepatitis C Virus Nonstructural Protein 4B. <i>Journal of Virology</i> , 2010, 84, 12529-12537.	1.5	73
51	Changing Trends in Hepatitis C Infection over the Past 50 Years in Japan. <i>Intervirolgy</i> , 2010, 53, 39-43.	1.2	147
52	Genotype Distribution And 5' Utr Nucleotide Changes In Hepatitis C Virus. <i>Medical Journal of the Trakya University</i> , 2010, , .	0.0	3
53	Antiviral Treatment for Hepatitis C Virus Infection after Liver Transplantation. <i>Hepatitis Research and Treatment</i> , 2010, 2010, 1-9.	2.0	2
54	Pegylated Interferon and Ribavirin Treatment for Hepatitis C Virus Infection. <i>Hepatitis Research and Treatment</i> , 2010, 2010, 1-2.	2.0	2
55	Long-Term Effects of Antiviral Therapy in Patients with Chronic Hepatitis C. <i>Hepatitis Research and Treatment</i> , 2010, 2010, 1-9.	2.0	4

#	ARTICLE	IF	CITATIONS
56	Methadone Maintenance Patients' Knowledge, Attitudes, Beliefs, and Experiences Concerning Treatment for Hepatitis C Virus Infection. <i>Substance Use and Misuse</i> , 2010, 45, 496-514.	0.7	14
57	Core as a Novel Viral Target for Hepatitis C Drugs. <i>Viruses</i> , 2010, 2, 1734-1751.	1.5	31
58	MK-7009, a Potent and Selective Inhibitor of Hepatitis C Virus NS3/4A Protease. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 305-311.	1.4	141
59	High prevalence of hepatitis C associated with familial history of hepatitis in a small town of south Brazil. Efficiency of the rapid test for epidemiological survey. <i>Brazilian Journal of Infectious Diseases</i> , 2010, 14, 483-488.	0.3	4
60	Pathology of Chronic Hepatitis B and Chronic Hepatitis C. <i>Clinics in Liver Disease</i> , 2010, 14, 555-575.	1.0	26
61	Natural History of Chronic Hepatitis B. <i>Clinics in Liver Disease</i> , 2010, 14, 381-396.	1.0	156
62	Importance of Ligand Bioactive Conformation in the Discovery of Potent Indole-Diamide Inhibitors of the Hepatitis C Virus NS5B. <i>Journal of the American Chemical Society</i> , 2010, 132, 15204-15212.	6.6	36
63	Manifestations of Chronic Hepatitis C Virus Infection Beyond the Liver. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 1017-1029.	2.4	147
64	Discovery of a 2'-Deoxy-2-fluoro-2-methyluridine Nucleotide Prodrug (PSI-7977) for the Treatment of Hepatitis C Virus. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 7202-7218.	2.9	547
65	Abnormalities of lipid metabolism in hepatitis C virus infection. <i>Gut</i> , 2010, 59, 1279-1287.	6.1	157
66	Activity-based protein profiling of the hepatitis C virus replication in Huh-7 hepatoma cells using a non-directed active site probe. <i>Proteome Science</i> , 2010, 8, 5.	0.7	36
67	Hepatitis C virus infection in blood donors from the state of Puebla, Mexico. <i>Virology Journal</i> , 2010, 7, 18.	1.4	18
68	Anti-HCV reactive volunteer blood donors distribution character and genotypes switch in Xi'an, China. <i>Virology Journal</i> , 2010, 7, 186.	1.4	13
69	Hepatitis C virus infection in Brazilian long-distance truck drivers. <i>Virology Journal</i> , 2010, 7, 205.	1.4	8
70	Albinterferon Alfa-2b Was Not Inferior to Pegylated Interferon- α in a Randomized Trial of Patients With Chronic Hepatitis C Virus Genotype 2 or 3. <i>Gastroenterology</i> , 2010, 139, 1267-1276.e4.	0.6	77
71	Albinterferon Alfa-2b Was Not Inferior to Pegylated Interferon- α in a Randomized Trial of Patients With Chronic Hepatitis C Virus Genotype 1. <i>Gastroenterology</i> , 2010, 139, 1257-1266.	0.6	68
72	Activity-Based Proteome Profiling of Hepatoma Cells during Hepatitis C Virus Replication Using Protease Substrate Probes. <i>Journal of Proteome Research</i> , 2010, 9, 912-923.	1.8	31
73	Discovery of Narlaprevir (SCH 900518): A Potent, Second Generation HCV NS3 Serine Protease Inhibitor. <i>ACS Medicinal Chemistry Letters</i> , 2010, 1, 64-69.	1.3	69

#	ARTICLE	IF	CITATIONS
74	Iron inhibits replication of infectious hepatitis C virus in permissive Huh7.5.1 cells. <i>Journal of Hepatology</i> , 2010, 53, 995-999.	1.8	62
75	Distinct Regions of Human eIF3 Are Sufficient for Binding to the HCV IRES and the 40S Ribosomal Subunit. <i>Journal of Molecular Biology</i> , 2010, 403, 185-196.	2.0	31
76	Socio-behavioral and geographic correlates of prevalent hepatitis C virus infection among young injection drug users in metropolitan Baltimore and Chicago. <i>Drug and Alcohol Dependence</i> , 2010, 111, 136-145.	1.6	31
77	Regulation of Hepatitis C Virus Translation and Infectious Virus Production by the MicroRNA miR-122. <i>Journal of Virology</i> , 2010, 84, 6615-6625.	1.5	282
78	Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. <i>Lancet, The</i> , 2010, 376, 1467-1475.	6.3	313
79	Discovery of a Potent and Selective Noncovalent Linear Inhibitor of the Hepatitis C Virus NS3 Protease (BI 201335). <i>Journal of Medicinal Chemistry</i> , 2010, 53, 6466-6476.	2.9	86
80	Replication of Subgenomic Hepatitis C Virus Replicons in Mouse Fibroblasts Is Facilitated by Deletion of Interferon Regulatory Factor 3 and Expression of Liver-Specific MicroRNA 122. <i>Journal of Virology</i> , 2010, 84, 9170-9180.	1.5	63
81	Disorders associated with systemic or local iron overload: from pathophysiology to clinical practice. <i>Metallomics</i> , 2011, 3, 971.	1.0	48
82	Interferon in the treatment of chronic hepatitis C: a drug caught between past and future. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 301-313.	1.4	15
83	Combined X-ray, NMR, and Kinetic Analyses Reveal Uncommon Binding Characteristics of the Hepatitis C Virus NS3-NS4A Protease Inhibitor BI 201335. <i>Journal of Biological Chemistry</i> , 2011, 286, 11434-11443.	1.6	43
84	Taribavirin in the treatment of hepatitis C. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 1435-1443.	1.9	7
85	Improved Responses to Pegylated Interferon Alfa-2b and Ribavirin by Individualizing Treatment for 24-72 Weeks. <i>Gastroenterology</i> , 2011, 141, 1656-1664.	0.6	40
86	Interferon-Free Regimens: The Near Future, the Likely and the Not So Likely. <i>Clinics in Liver Disease</i> , 2011, 15, 665-675.	1.0	5
87	Inosine Triphosphate Protects Against Ribavirin-Induced Adenosine Triphosphate Loss by Adenylosuccinate Synthase Function. <i>Gastroenterology</i> , 2011, 140, 1314-1321.	0.6	111
88	Resistance to anti-HCV protease inhibitors. <i>Current Opinion in Virology</i> , 2011, 1, 599-606.	2.6	36
89	Discovery of PSI-353661, a Novel Purine Nucleotide Prodrug for the Treatment of HCV Infection. <i>ACS Medicinal Chemistry Letters</i> , 2011, 2, 130-135.	1.3	48
90	Stereoselective Synthesis of PSI-352938: A 2-Deoxy-2-fluoro-2'-methyl-3,5-cyclic Phosphate Nucleotide Prodrug for the Treatment of HCV. <i>Journal of Organic Chemistry</i> , 2011, 76, 3782-3790.	1.7	37
91	Allosteric inhibition of the hepatitis C virus NS5B polymerase: <i>in silico</i> strategies for drug discovery and development. <i>Future Medicinal Chemistry</i> , 2011, 3, 1027-1055.	1.1	39

#	ARTICLE	IF	CITATIONS
92	Synthesis of Vaniprevir (MK-7009): Lactamization To Prepare a 22-Membered Macrocyclic. <i>Journal of Organic Chemistry</i> , 2011, 76, 7804-7815.	1.7	68
93	Structural Frameworks and Key Model Parameters in Cost-Effectiveness Analyses for Current and Future Treatments of Chronic Hepatitis C. <i>Value in Health</i> , 2011, 14, 1068-1077.	0.1	51
94	Coffee Consumption Is Associated With Response to Peginterferon and Ribavirin Therapy in Patients With Chronic Hepatitis C. <i>Gastroenterology</i> , 2011, 140, 1961-1969.	0.6	60
95	Maintenance Therapy With Peginterferon Alfa-2b Does Not Prevent Hepatocellular Carcinoma in Cirrhotic Patients With Chronic Hepatitis C. <i>Gastroenterology</i> , 2011, 140, 1990-1999.	0.6	102
96	Prevalence and risk factors of Hepatitis C among individuals presenting to HIV testing centers, Hawassa city, Southern Ethiopia. <i>BMC Research Notes</i> , 2011, 4, 193.	0.6	16
97	1990–2010: Two Decades of Interferon-Based Therapy. <i>Clinics in Liver Disease</i> , 2011, 15, 473-482.	1.0	8
98	Lack of association of indoleamine 2,3-dioxygenase polymorphisms with interferon-alpha-related depression in hepatitis C. <i>Brain, Behavior, and Immunity</i> , 2011, 25, 1491-1497.	2.0	23
99	Metabolic alterations and chronic hepatitis C: treatment strategies. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2215-2234.	0.9	61
100	Mixing the right hepatitis C inhibitor cocktail. <i>Trends in Molecular Medicine</i> , 2011, 17, 34-46.	3.5	33
101	Hepatitis C virus RNA recombination in cell culture. <i>Journal of Hepatology</i> , 2011, 55, 777-783.	1.8	19
102	EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. <i>Journal of Hepatology</i> , 2011, 55, 245-264.	1.8	1,083
103	Natural killer cells and hepatitis C: action and reaction. <i>Gut</i> , 2011, 60, 268-278.	6.1	84
104	Interleukin 28B Polymorphisms and Hepatitis C—Translating the Association into Clinical Decision Making. <i>Journal of Clinical and Experimental Hepatology</i> , 2011, 1, 27-33.	0.4	4
105	HBV & HCV Immunopathogenesis. , 2011, , .		0
106	The burden of hepatic encephalopathy in Latin America. <i>Annals of Hepatology</i> , 2011, 10, S31-S35.	0.6	4
107	The Present Role of Liver Biopsy in Kidney Transplant Candidates in the Management of Hepatitis B and C Patients. , 0, , .		0
108	Chronic viral hepatitis: epidemiology, molecular biology, and antiviral therapy. <i>Frontiers in Bioscience - Landmark</i> , 2011, 16, 225.	3.0	26
109	Long-Term Persistent GBV-B Infection and Development of a Chronic and Progressive Hepatitis C-Like Disease in Marmosets. <i>Frontiers in Microbiology</i> , 2011, 2, 240.	1.5	20

#	ARTICLE	IF	CITATIONS
110	Evidence of a significant role for Fas-mediated apoptosis in HCV clearance during pegylated interferon plus ribavirin combination therapy. <i>Antiviral Therapy</i> , 2011, 16, 291-298.	0.6	4
112	Risk of kidney cancer and chronic kidney disease in relation to hepatitis C virus infection. <i>European Journal of Cancer Prevention</i> , 2011, 20, 326-330.	0.6	35
113	Directly acting antivirals for hepatitis C and antiretrovirals. <i>Current Opinion in HIV and AIDS</i> , 2011, 6, 514-526.	1.5	35
114	Extra-hepatic replication of the hepatitis C virus: current issues and future directions. <i>Future Virology</i> , 2011, 6, 275-278.	0.9	1
115	NS4B Self-Interaction through Conserved C-Terminal Elements Is Required for the Establishment of Functional Hepatitis C Virus Replication Complexes. <i>Journal of Virology</i> , 2011, 85, 6963-6976.	1.5	107
116	Prevalence and risk factors of HCV infection in Poland. <i>European Journal of Gastroenterology and Hepatology</i> , 2011, 23, 1213-1217.	0.8	49
117	Immunopathogenesis of HIV/hepatitis C virus coinfection. <i>Future Virology</i> , 2011, 6, 1115-1128.	0.9	1
118	Development of a Chimeric Replicon System for Phenotypic Analysis of Ns3 Protease Sequences from HCV Clinical Isolates. <i>Antiviral Therapy</i> , 2011, 16, 705-718.	0.6	20
119	Fluoroquinolones Inhibit HCV by Targeting Its Helicase. <i>Antiviral Therapy</i> , 2012, 17, 467-476.	0.6	31
120	HLA Class II Alleles and Chronic Hepatitis C Virus Infection. <i>Scandinavian Journal of Immunology</i> , 2011, 74, 282-287.	1.3	21
121	Commentary on Caiiffa et al. (2011): The renewed challenge of hepatitis C virus epidemiology among non-injecting drug users. <i>Addiction</i> , 2011, 106, 152-153.	1.7	0
122	Silymarin use and liver disease progression in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis trial. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 33, 127-137.	1.9	67
123	Burden of disease related to hepatitis C and hepatitis B in Spain: a methodological challenge of an unfolding health problem. <i>Journal of Viral Hepatitis</i> , 2011, 18, e453-e460.	1.0	25
124	Future hepatitis C virus treatment: interferon-sparing combinations. <i>Liver International</i> , 2011, 31, 62-67.	1.9	36
125	How to use virological tools for the optimal management of chronic hepatitis C. <i>Liver International</i> , 2011, 31, 3-12.	1.9	19
126	Role of the nurse practitioner in the management of patients with chronic hepatitis C. <i>Journal of the American Academy of Nurse Practitioners</i> , 2011, 23, 410-420.	1.4	9
127	Oral fluid and hepatitis A, B and C: A literature review. <i>Journal of Oral Pathology and Medicine</i> , 2012, 41, 505-516.	1.4	33
128	Virus-specific mechanisms of carcinogenesis in hepatitis C virus associated liver cancer. <i>Oncogene</i> , 2011, 30, 1969-1983.	2.6	187

#	ARTICLE	IF	CITATIONS
129	The Innate Immune Response, Clinical Outcomes, and Ex Vivo HCV Antiviral Efficacy of a TLR7 Agonist (PF-4878691). <i>Clinical Pharmacology and Therapeutics</i> , 2011, 89, 821-829.	2.3	69
130	Colony-forming assays reveal enhanced suppression of hepatitis C virus replication using combinations of direct-acting antivirals. <i>Journal of Virological Methods</i> , 2011, 174, 153-157.	1.0	11
131	Naturally occurring genotype 2b/1a hepatitis C virus in the United States. <i>Virology Journal</i> , 2011, 8, 458.	1.4	29
132	Assessing the impact of educational campaigns on controlling HCV among women in prison settings. <i>Communications in Nonlinear Science and Numerical Simulation</i> , 2012, 17, 1714-1724.	1.7	21
133	Multicenter evaluation of a fully automated third-generation anti-HCV antibody screening test with excellent sensitivity and specificity. <i>Medical Microbiology and Immunology</i> , 2011, 200, 77-83.	2.6	48
134	Hepatic resection with or without adjuvant iodine-131-lipiodol for hepatocellular carcinoma: a comparative analysis. <i>International Journal of Clinical Oncology</i> , 2011, 16, 125-132.	1.0	16
135	NK Cells Prevalence, Subsets and Function in Viral Hepatitis C. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2011, 59, 449-455.	1.0	21
136	Efficacy of combined pegylated interferon and ribavirin therapy in Jewish patients of Israel suffering from chronic hepatitis C. <i>Hepatology International</i> , 2011, 5, 985-990.	1.9	2
137	Update on Current Epidemiologic Trends in Hepatitis C. <i>Current Hepatitis Reports</i> , 2011, 10, 19-26.	0.3	0
138	Hepatitis C Virus and End Stage Renal Disease. <i>Current Hepatitis Reports</i> , 2011, 10, 196-203.	0.3	0
139	Hepatitis C virus subtypes circulating among intravenous drug users in Lisbon, Portugal. <i>Journal of Medical Virology</i> , 2011, 83, 608-615.	2.5	31
140	Prediction and identification-based prediction of Chinese hepatitis C viral-specific cytotoxic T lymphocyte epitopes. <i>Journal of Medical Virology</i> , 2011, 83, 1315-1320.	2.5	7
141	Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR. <i>Hepatology</i> , 2011, 53, 389-395.	3.6	67
142	Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. <i>Hepatology</i> , 2011, 53, 1100-1108.	3.6	55
143	Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C. <i>Hepatology</i> , 2011, 53, 1118-1126.	3.6	122
144	Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. <i>Hepatology</i> , 2011, 54, 20-27.	3.6	245
145	Hepatitis C virus induces interferon- λ and interferon-stimulated genes in primary liver cultures. <i>Hepatology</i> , 2011, 54, 1913-1923.	3.6	157
146	P2 ¹ -P1 ² macrocyclization of P2 phenylglycine based HCV NS3 protease inhibitors using ring-closing metathesis. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 4917-4927.	1.4	12

#	ARTICLE	IF	CITATIONS
147	Potent inhibitors of hepatitis C core dimerization as new leads for anti-hepatitis C agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 2198-2202.	1.0	20
148	Syntheses and initial evaluation of a series of indolo-fused heterocyclic inhibitors of the polymerase enzyme (NS5B) of the hepatitis C virus. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 2925-2929.	1.0	38
149	From benzimidazole to indole-5-carboxamide Thumb Pocket I inhibitors of HCV NS5B polymerase. Part 1: Indole C-2 SAR and discovery of diamide derivatives with nanomolar potency in cell-based subgenomic replicons. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 3658-3663.	1.0	21
150	Synthesis and antiviral activity of cyclopropyl-spirocarbocyclic adenosine, (4 R ,5 S ,6 R ,7 R) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tj 5. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 3982-3985.	1.0	21
151	Drugs in development for chronic hepatitis C: a promising future. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 1611-1622.	1.4	31
152	Immunotherapeutic potential of neutralizing antibodies targeting conserved regions of the HCV envelope glycoprotein E2. <i>Future Microbiology</i> , 2011, 6, 279-294.	1.0	16
153	Nucleotide Prodrugs for HCV Therapy. <i>Antiviral Chemistry and Chemotherapy</i> , 2011, 22, 23-49.	0.3	67
154	Knockdown of USP18 Increases Alpha 2a Interferon Signaling and Induction of Interferon-Stimulating Genes but Does Not Increase Antiviral Activity in Huh7 Cells. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 4311-4319.	1.4	10
155	Dimerization-driven interaction of hepatitis C virus core protein with NS3 helicase. <i>Journal of General Virology</i> , 2011, 92, 101-111.	1.3	31
156	Seroprevalence and Genotype of Hepatitis C Virus among Immigrant Workers from Cambodia and Myanmar in Thailand. <i>Intervirology</i> , 2011, 54, 10-16.	1.2	30
157	Phylodynamics of Hepatitis C Virus Subtype 2c in the Province of Córdoba, Argentina. <i>PLoS ONE</i> , 2011, 6, e19471.	1.1	14
158	Small Molecules Targeting Hepatitis C Virus-Encoded NS5A Cause Subcellular Redistribution of Their Target: Insights into Compound Modes of Action. <i>Journal of Virology</i> , 2011, 85, 6353-6368.	1.5	110
159	Cerebral Glucose Utilisation in Hepatitis C Virus Infection-Associated Encephalopathy. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2011, 31, 2199-2208.	2.4	38
160	Hunting for fibrosis progression genes in hepatitis C patients. <i>Clinical Science</i> , 2011, 120, 285-286.	1.8	0
161	Treatment of Chronic Hepatitis C Infection: Update of the Recommendations from Scientific Leader's Meeting-28th July 2011-Tehran, IR Iran. <i>Hepatitis Monthly</i> , 2011, 11, 703-713.	0.1	2
162	Prevalence of Chronic Hepatitis B and Hepatitis C among First Time Blood Donors in Northeast Bosnia and Herzegovina: An Estimate of Prevalence in General Population. <i>Hepatitis Monthly</i> , 2011, 11, 629-33.	0.1	7
163	Hepatitis C Virus Evasion Mechanisms from Neutralizing Antibodies. <i>Viruses</i> , 2011, 3, 2280-2300.	1.5	53
164	Ribavirin-Induced Anemia in Hepatitis C Virus Patients Undergoing Combination Therapy. <i>PLoS Computational Biology</i> , 2011, 7, e1001072.	1.5	30

#	ARTICLE	IF	CITATIONS
165	Optimal Duration of Treatment for HCV Genotype 1 Infection in Slow Responders: A Meta-Analysis. <i>Hepatitis Monthly</i> , 2011, 11, 612-9.	0.1	5
166	Human Monoclonal Antibody HCV1 Effectively Prevents and Treats HCV Infection in Chimpanzees. <i>PLoS Pathogens</i> , 2012, 8, e1002895.	2.1	160
167	Role of Oxidative Stress in Hepatocarcinogenesis Induced by Hepatitis C Virus. <i>International Journal of Molecular Sciences</i> , 2012, 13, 15271-15278.	1.8	35
168	Pathogenesis of Hepatitis C During Pregnancy and Childhood. <i>Viruses</i> , 2012, 4, 3531-3550.	1.5	62
169	A Pilot Training Program for a Motivational Enhancement Approach to Hepatitis C Virus Treatment Among Individuals in Israeli Methadone Treatment Centers. <i>Substance Use and Misuse</i> , 2012, 47, 56-66.	0.7	7
170	Application of Ring-Closing Metathesis Strategy to the Synthesis of Vaniprevir (MK-7009), a 20-Membered Macrocyclic HCV Protease Inhibitor. <i>Topics in Organometallic Chemistry</i> , 2012, , 135-149.	0.7	7
171	Chronic Hepatitis C in Saudi Arabia: Three Years Local Experience in a University Hospital. <i>Hepatitis Monthly</i> , 2012, 12, e6178.	0.1	10
172	The p7 Protein of Hepatitis C Virus Forms Structurally Plastic, Minimalist Ion Channels. <i>PLoS Computational Biology</i> , 2012, 8, e1002702.	1.5	60
173	Treatment Response and Tolerability of Pegylated Interferon- α Plus Ribavirin Combination Therapy in elderly Patients (\geq 65 years) With Chronic Hepatitis C in Korea. <i>Hepatitis Monthly</i> , 2012, 12, 430-436.	0.1	12
174	Interleukin 28B Gene Polymorphism and Association with Chronic Hepatitis C Therapy Results in Latvia. <i>Hepatitis Research and Treatment</i> , 2012, 2012, 1-4.	2.0	10
175	Is Combination Therapy for Chronic Hepatitis C Toxic for Cardiac Function?. <i>Hepatitis Monthly</i> , 2012, 12, e6254.	0.1	9
176	Efficient Replication of Genotype 3a and 4a Hepatitis C Virus Replicons in Human Hepatoma Cells. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5365-5373.	1.4	117
177	Prospective study of psychiatric side effects during antiviral therapy of chronic hepatitis C in an Egyptian sample. <i>Middle East Current Psychiatry</i> , 2012, 19, 71-77.	0.5	2
178	Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3. <i>Gut</i> , 2012, 61, 128-134.	6.1	76
179	Characterization of Resistance to the Nonnucleoside NS5B Inhibitor Flibuvir in Hepatitis C Virus-Infected Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 1331-1341.	1.4	35
180	Health Care Utilization in HIV-Infected Patients: Assessing the Burden of Hepatitis C Virus Coinfection. <i>AIDS Patient Care and STDs</i> , 2012, 26, 541-545.	1.1	22
181	Amino Acid Residue-Specific Neutralization and Nonneutralization of Hepatitis C Virus by Monoclonal Antibodies to the E2 Protein. <i>Journal of Virology</i> , 2012, 86, 12686-12694.	1.5	29
182	Conserved Glycine 33 Residue in Flexible Domain I of Hepatitis C Virus Core Protein Is Critical for Virus Infectivity. <i>Journal of Virology</i> , 2012, 86, 679-690.	1.5	17

#	ARTICLE	IF	CITATIONS
183	The Molecular Basis of Drug Resistance against Hepatitis C Virus NS3/4A Protease Inhibitors. PLoS Pathogens, 2012, 8, e1002832.	2.1	179
184	Establishment of a Novel Permissive Cell Line for the Propagation of Hepatitis C Virus by Expression of MicroRNA miR122. Journal of Virology, 2012, 86, 1382-1393.	1.5	83
185	Is Hepatitis C Virus Core Antigen an Adequate Marker for Community Screening?. Journal of Clinical Microbiology, 2012, 50, 1989-1993.	1.8	36
186	Novel serine protease inhibitors. Pharmaceutical Patent Analyst, 2012, 1, 457-468.	0.4	3
187	A Formula to Estimate the Optimal Dosage of Ribavirin for the Treatment of Chronic Hepatitis C: Influence of Itpa Polymorphisms. Antiviral Therapy, 2012, 17, 1581-1592.	0.6	6
188	Insight into the Structural Requirements of Nalraprevir-Type Inhibitors of NS3/NS4A Protease Based on HQSAR and Molecular Field Analyses. Combinatorial Chemistry and High Throughput Screening, 2012, 15, 439-450.	0.6	16
189	Alisporivir for the treatment of chronic HCV. Future Virology, 2012, 7, 9-18.	0.9	1
190	Primary, post-primary and non-specific immunoglobulin M responses in HCV infection. Antiviral Therapy, 2012, 17, 1449-1452.	0.6	11
191	Transfusion transmission of HCV, a long but successful road map to safety. Antiviral Therapy, 2012, 17, 1423-1429.	0.6	28
192	Difference in serum complement component C4a levels between hepatitis C virus carriers with persistently normal alanine aminotransferase levels or chronic hepatitis C. Molecular Medicine Reports, 2012, 6, 259-64.	1.1	9
193	Predictors of response to chronic hepatitis C treatment. Future Virology, 2012, 7, 1089-1101.	0.9	7
194	Too low to measure, infectious nonetheless. Blood, 2012, 119, 6181-6182.	0.6	3
195	Curcumin inhibits HCV replication by induction of heme oxygenase-1 and suppression of AKT. International Journal of Molecular Medicine, 2012, 30, 1021-1028.	1.8	58
197	905 RISK FACTORS FOR LOW MINERAL BONE DENSITY IN PATIENTS WITH CHRONIC VIRAL C INFECTION. Journal of Hepatology, 2012, 56, S352.	1.8	3
198	Interferon- β -Stimulated Genes, but Not USP18, Are Expressed in Livers of Patients With Acute Hepatitis C. Gastroenterology, 2012, 143, 777-786.e6.	0.6	57
199	Randomized trial of albinterferon alfa β every 4 weeks for chronic hepatitis C virus genotype 2/3. Journal of Viral Hepatitis, 2012, 19, 623-634.	1.0	9
200	Variants in the ITPA Gene Protect Against Ribavirin-Induced Hemolytic Anemia in HIV/HCV-Coinfected Patients With All HCV Genotypes. Journal of Infectious Diseases, 2012, 205, 376-383.	1.9	31
201	A Pharmacological Profile of Ribavirin and Monitoring of its Plasma Concentration in Chronic Hepatitis C Infection. Journal of Clinical and Experimental Hepatology, 2012, 2, 42-54.	0.4	19

#	ARTICLE	IF	CITATIONS
202	<sc>UK</sc> consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis <sc>C</sc> infected patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 647-662.	1.9	76
203	Nucleoside, Nucleotide, and Non-Nucleoside Inhibitors of Hepatitis C Virus NS5B RNA-Dependent RNA-Polymerase. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 2481-2531.	2.9	253
204	Comprehensive analysis for viral elements and interleukin-28B polymorphisms in response to pegylated interferon plus ribavirin therapy in hepatitis C virus 1B infection. <i>Hepatology</i> , 2012, 56, 1611-1621.	3.6	20
205	Using decision tree learning to predict the responsiveness of hepatitis C patients to drug treatment. <i>FEBS Open Bio</i> , 2012, 2, 98-102.	1.0	11
206	Expected and Actual Case Ascertainment and Treatment Rates for Children Infected with Hepatitis C in Florida and the United States: Epidemiologic Evidence from Statewide and Nationwide Surveys. <i>Journal of Pediatrics</i> , 2012, 161, 915-921.	0.9	59
207	Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein. <i>Virus Research</i> , 2012, 170, 1-14.	1.1	76
208	Viral Hepatitis Among Somali Immigrants in Minnesota: Association of Hepatitis C With Hepatocellular Carcinoma. <i>Mayo Clinic Proceedings</i> , 2012, 87, 17-24.	1.4	36
209	An orally available, small-molecule interferon inhibits viral replication. <i>Scientific Reports</i> , 2012, 2, 259.	1.6	42
210	Economic burden of hepatitis C-associated diseases: Europe, Asia Pacific, and the Americas. <i>Journal of Medical Economics</i> , 2012, 15, 887-896.	1.0	60
211	Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 193-207.	1.4	85
212	Liver Protein Profiling in Chronic Hepatitis C: Identification of Potential Predictive Markers for Interferon Therapy Outcome. <i>Journal of Proteome Research</i> , 2012, 11, 717-727.	1.8	17
213	Peripheral blood cytopenia limiting initiation of treatment in chronic hepatitis C patients otherwise eligible for antiviral therapy. <i>Liver International</i> , 2012, 32, 1113-1119.	1.9	27
214	Hyperuricaemia: another metabolic feature affecting the severity of chronic hepatitis because of <sc>HCV</sc> infection. <i>Liver International</i> , 2012, 32, 1443-1450.	1.9	19
215	Neurological Complications of Hepatitis C Infection. <i>Current Neurology and Neuroscience Reports</i> , 2012, 12, 642-654.	2.0	2
216	Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients. <i>Journal of Hepatology</i> , 2012, 56, 313-319.	1.8	39
217	A functional genomic screen reveals novel host genes that mediate interferon-alpha's effects against hepatitis C virus. <i>Journal of Hepatology</i> , 2012, 56, 326-333.	1.8	60
218	A randomized trial of 48 versus 24 weeks of combination pegylated interferon and ribavirin therapy in genotype 6 chronic hepatitis C. <i>Journal of Hepatology</i> , 2012, 56, 1012-1018.	1.8	34
219	Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study. <i>Journal of Hepatology</i> , 2012, 56, 1247-1253.	1.8	98

#	ARTICLE	IF	CITATIONS
220	A predictive model of treatment outcome in patients with chronic HCV infection using IL28B and PD-1 genotyping. <i>Journal of Hepatology</i> , 2012, 56, 1230-1238.	1.8	19
221	Destabilization of PDK1 by Hsp90 inactivation suppresses hepatitis C virus replication through inhibition of PRK2-mediated viral RNA polymerase phosphorylation. <i>Biochemical and Biophysical Research Communications</i> , 2012, 421, 112-118.	1.0	22
222	Tri-substituted acylhydrazines as tertiary amide bioisosteres: HCV NS5B polymerase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 4288-4292.	1.0	14
223	Pyridofuran substituted pyrimidine derivatives as HCV replication (replicase) inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 5144-5149.	1.0	6
224	Interferon signaling in the liver during hepatitis C virus infection. <i>Cytokine</i> , 2012, 59, 460-466.	1.4	10
225	MK-5172, a Selective Inhibitor of Hepatitis C Virus NS3/4a Protease with Broad Activity across Genotypes and Resistant Variants. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 4161-4167.	1.4	242
226	NS5A: A new target for antiviral drugs in the treatment of hepatitis C virus infection. <i>Hepatology</i> , 2012, 56, 797-799.	3.6	7
227	Hepatitis B and C infection in haemodialysis patients in Libya: prevalence, incidence and risk factors. <i>BMC Infectious Diseases</i> , 2012, 12, 265.	1.3	63
228	The economic burden of advanced liver disease among patients with Hepatitis C Virus: a large state Medicaid perspective. <i>BMC Health Services Research</i> , 2012, 12, 459.	0.9	30
229	IL28B Genetic Variation Is Associated with Spontaneous Clearance of Hepatitis C Virus, Treatment Response, Serum IL-28B Levels in Chinese Population. <i>PLoS ONE</i> , 2012, 7, e37054.	1.1	85
230	Structure based medicinal chemistry approach to develop 4-methyl-7-deazaadenine carbocyclic nucleosides as anti-HCV agent. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 7742-7747.	1.0	21
231	A 2-Deoxy-2-Fluoro-2-C-Methyl Uridine Cyclopentyl Carbocyclic Analog and Its Phosphoramidate Prodrug as Inhibitors of HCV NS5B Polymerase. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2012, 31, 277-285.	0.4	13
232	Management of Patients Coinfected With HCV and HIV: A Close Look at the Role for Direct-Acting Antivirals. <i>Gastroenterology</i> , 2012, 142, 1324-1334.e3.	0.6	78
233	Viral hepatitis: Global goals for vaccination. <i>Journal of Clinical Virology</i> , 2012, 55, 296-302.	1.6	76
234	Interaction of the antiviral drug telaprevir with renal and hepatic drug transporters. <i>Biochemical Pharmacology</i> , 2012, 84, 1096-1102.	2.0	74
235	Public health issues of hepatitis C virus infection. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, 371-380.	1.0	30
236	A highly selective structure-based virtual screening model of Palm I allosteric inhibitors of HCV Ns5b polymerase enzyme and its application in the discovery and optimization of new analogues. <i>European Journal of Medicinal Chemistry</i> , 2012, 57, 468-482.	2.6	9
237	Non-Invasive Prediction of Hepatic Fibrosis in Patients With Chronic HCV Based on the Routine Pre-Treatment Workup. <i>Hepatitis Monthly</i> , 2012, 12, e6718.	0.1	30

#	ARTICLE	IF	CITATIONS
238	Biofluid metabonomics using ¹ H NMR spectroscopy: the road to biomarker discovery in gastroenterology and hepatology. <i>Expert Review of Gastroenterology and Hepatology</i> , 2012, 6, 239-251.	1.4	25
239	Synthesis of the HCV Protease Inhibitor Vaniprevir (MK-7009) Using Ring-Closing Metathesis Strategy. <i>Journal of Organic Chemistry</i> , 2012, 77, 3820-3828.	1.7	65
240	High Serum Palmitic Acid is Associated with Low Antiviral Effects of Interferon-Based Therapy for Hepatitis C Virus. <i>Lipids</i> , 2012, 47, 1053-1062.	0.7	3
241	IL28B: Current and Future Use. <i>Current Hepatitis Reports</i> , 2012, 11, 136-145.	0.3	0
242	Hepatitis C: Epidemiology, Diagnosis, Natural History and Therapy. <i>Contributions To Nephrology</i> , 2012, 176, 1-9.	1.1	59
243	Therapy with TLR7 Agonists Induces Lymphopenia: Correlating Pharmacology to Mechanism in a Mouse Model. <i>Journal of Clinical Immunology</i> , 2012, 32, 1082-1092.	2.0	22
244	Incidence Analyses and Space-Time Cluster Detection of Hepatitis C in Fujian Province of China from 2006 to 2010. <i>PLoS ONE</i> , 2012, 7, e40872.	1.1	6
245	Molecular Survey of Hepatitis C Virus in the Touristic City of Mar Del Plata, Argentina. <i>PLoS ONE</i> , 2012, 7, e44757.	1.1	7
246	Test of IL28B Polymorphisms in Chronic Hepatitis C Patients Treated with PegIFN and Ribavirin Depends on HCV Genotypes: Results from a Meta-Analysis. <i>PLoS ONE</i> , 2012, 7, e45698.	1.1	24
247	Genetic diversity of NS3 protease from Brazilian HCV isolates and possible implications for therapy with direct-acting antiviral drugs. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2012, 107, 254-261.	0.8	20
248	Survival after Locoregional Treatments for Hepatocellular Carcinoma: A Cohort Study in Real-World Patients. <i>Scientific World Journal</i> , The, 2012, 2012, 1-7.	0.8	19
249	Validation and comparison of simple noninvasive models for the prediction of liver fibrosis in chronic hepatitis C. <i>Annals of Hepatology</i> , 2012, 11, 855-861.	0.6	43
250	Mutations in non-structural 5A and rapid viral response to pegylated interferon- α 2b plus ribavirin therapy are associated with therapeutic efficacy in patients with genotype 1b chronic hepatitis C. <i>International Journal of Molecular Medicine</i> , 2012, 30, 1048-1052.	1.8	4
251	Increased mortality in chronic HCV infection. <i>Annals of Hepatology</i> , 2012, 11, 967-968.	0.6	0
252	Risks and Benefits of Liver Biopsy in Focal Liver Disease. , 2012, , .		1
253	New agents for the treatment of hepatitis C virus – focus on telaprevir. <i>Virus Adaptation and Treatment</i> , 0, , 75.	1.5	1
254	Viral Product Trafficking to Mitochondria, Mechanisms and Roles in Pathogenesis. <i>Infectious Disorders - Drug Targets</i> , 2012, 12, 18-37.	0.4	29
255	Structure of Hepatitis C Virus Polymerase in Complex with Primer-Template RNA. <i>Journal of Virology</i> , 2012, 86, 6503-6511.	1.5	110

#	ARTICLE	IF	CITATIONS
256	Hepatitis C virus promotes expression of the 3 β -hydroxysterol 24 α -reductase through Sp1. <i>Journal of Medical Virology</i> , 2012, 84, 733-746.	2.5	17
257	Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: Impaired viral kinetics and therapeutic response. <i>Hepatology</i> , 2012, 56, 444-454.	3.6	61
258	New developments in small molecular compounds for anti-hepatitis C virus (HCV) therapy. <i>Journal of Zhejiang University: Science B</i> , 2012, 13, 56-82.	1.3	10
259	Microwave-assisted synthesis of small molecules targeting the infectious diseases tuberculosis, HIV/AIDS, malaria and hepatitis C. <i>Organic and Biomolecular Chemistry</i> , 2012, 10, 2713.	1.5	49
260	Let-7b is a novel regulator of hepatitis C virus replication. <i>Cellular and Molecular Life Sciences</i> , 2012, 69, 2621-2633.	2.4	107
261	2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines. <i>Liver International</i> , 2012, 32, 2-8.	1.9	101
262	Treatment of patients with genotype 3 chronic hepatitis C—current and future therapies. <i>Liver International</i> , 2012, 32, 141-145.	1.9	23
263	Hepatitis C virus persistence after sustained virological response to antiviral therapy in patients with or without past exposure to hepatitis B virus. <i>Journal of Viral Hepatitis</i> , 2012, 19, 103-111.	1.0	22
264	Critical review of the use of erythropoietin in the treatment of anaemia during therapy for chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2012, 19, 77-87.	1.0	14
265	Randomised clinical trial: the efficacy of treatment, guided by a shorter duration of response, using peginterferon alfa-2a plus ribavirin for hepatitis C virus other than genotypes 2 or 3. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 37-47.	1.9	10
266	Help-seeking and coping with the psychosocial burden of chronic hepatitis C: A qualitative study of patient, hepatologist, and counsellor perspectives. <i>International Journal of Nursing Studies</i> , 2012, 49, 560-569.	2.5	46
267	Novel substituted pyrimidines as HCV replication (replicase) inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 1160-1164.	1.0	11
268	Synthesis and SAR studies of novel heteroaryl fused tetracyclic indole-diamide compounds: Potent allosteric inhibitors of the hepatitis C virus NS5B polymerase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 2866-2871.	1.0	21
269	5-Benzothiazole substituted pyrimidine derivatives as HCV replication (replicase) inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 3229-3234.	1.0	13
270	Do hepatitis B virus and hepatitis C virus co-infections increase hepatocellular carcinoma occurrence through synergistically modulating lipogenic gene expression?. <i>Hepatology Research</i> , 2012, 42, 733-740.	1.8	13
271	Pharmacology and therapeutic potential of interferons. , 2012, 135, 44-53.		143
272	Response-guided therapy for patients with hepatitis C virus genotype 6 infection: a pilot study. <i>Journal of Viral Hepatitis</i> , 2012, 19, 423-430.	1.0	21
273	A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C. <i>Journal of Viral Hepatitis</i> , 2012, 19, 1-26.	1.0	71

#	ARTICLE	IF	CITATIONS
274	Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents. <i>Journal of Viral Hepatitis</i> , 2012, 19, 449-464.	1.0	160
275	Treatment of Non-Genotype 1 Hepatitis C Virus Patients. <i>Current Gastroenterology Reports</i> , 2012, 14, 87-93.	1.1	8
276	HIV and hepatitis C virus coinfection in Canada: challenges and opportunities for reducing preventable morbidity and mortality. <i>HIV Medicine</i> , 2013, 14, 10-20.	1.0	38
277	Development of a sensitive RT-PCR method for amplifying and sequencing near full-length HCV genotype 1 RNA from patient samples. <i>Virology Journal</i> , 2013, 10, 53.	1.4	21
278	TIP47 plays a crucial role in the life cycle of hepatitis C virus. <i>Journal of Hepatology</i> , 2013, 58, 1081-1088.	1.8	61
279	Epidemiology and natural history of HCV infection. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013, 10, 553-562.	8.2	833
280	Development of a Practical, Asymmetric Synthesis of the Hepatitis C Virus Protease Inhibitor MK-5172. <i>Organic Letters</i> , 2013, 15, 4174-4177.	2.4	51
281	Nebivolol treatment increases splanchnic blood flow and portal pressure in cirrhotic rats via modulation of nitric oxide signalling. <i>Liver International</i> , 2013, 33, 561-568.	1.9	16
282	Population-attributable estimates for risk factors associated with hepatitis B and C: policy implications for Pakistan and other South Asian countries. <i>Hepatology International</i> , 2013, 7, 500-507.	1.9	16
283	Allelic inhibition of displacement activity: A simplified one tube allele-specific PCR for evaluation of ITPA polymorphisms. <i>Journal of Virological Methods</i> , 2013, 187, 271-273.	1.0	3
284	Synthesis of novel substituted N-aryl benzamides as hA3G stabilizers and their inhibitory activities against hepatitis C virus replication. <i>Acta Pharmaceutica Sinica B</i> , 2013, 3, 312-321.	5.7	2
285	Identification of a previously undescribed divergent virus from the Flaviviridae family in an outbreak of equine serum hepatitis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, E1407-15.	3.3	141
286	Clinical-guide risk prediction of hepatocellular carcinoma development in chronic hepatitis C patients after interferon-based therapy. <i>British Journal of Cancer</i> , 2013, 109, 2481-2488.	2.9	63
287	Vitamin D status and serum ferritin concentration in chronic hepatitis C virus type 1 infection. <i>Journal of Medical Virology</i> , 2013, 85, 1534-1541.	2.5	18
288	Synthesis and optimization of a novel series of HCV NS3 protease inhibitors: 4-Arylproline analogs. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 4267-4271.	1.0	6
289	Statin therapy improves response to interferon alfa and ribavirin in chronic hepatitis C: A systematic review and meta-analysis. <i>Antiviral Research</i> , 2013, 98, 373-379.	1.9	45
290	Hepatitis C Virus E2 Envelope Glycoprotein Core Structure. <i>Science</i> , 2013, 342, 1090-1094.	6.0	374
291	Identification and comparative analysis of hepatitis C virus-host cell protein interactions. <i>Molecular BioSystems</i> , 2013, 9, 3199.	2.9	46

#	ARTICLE	IF	CITATIONS
292	Host-targeting agents in the treatment of hepatitis C: A beginning and an end?. <i>Antiviral Research</i> , 2013, 100, 555-561.	1.9	42
293	Molecular Epidemiology and Genetic History of Hepatitis C Virus Subtype 3a Infection in Thailand. <i>Intervirology</i> , 2013, 56, 284-294.	1.2	26
294	Treatment of chronic HCV genotype 1 infection with telaprevir: a Bayesian mixed treatment comparison of fixed-length and response-guided treatment regimens in treatment-naïve and “experienced patients. <i>BMC Gastroenterology</i> , 2013, 13, 148.	0.8	3
295	Hepatitis C, mental health and equity of access to antiviral therapy: a systematic narrative review. <i>International Journal for Equity in Health</i> , 2013, 12, 92.	1.5	9
296	Population pharmacokinetics of peginterferon alfa-2b in pediatric patients with chronic hepatitis C. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 2045-2054.	0.8	5
297	The ins and outs of hepatitis C virus entry and assembly. <i>Nature Reviews Microbiology</i> , 2013, 11, 688-700.	13.6	324
298	Nucleotide Prodrugs for the Treatment of HCV Infection. <i>Advances in Pharmacology</i> , 2013, 67, 39-73.	1.2	45
299	Limited Access to Protease Inhibitors Therapy for Chronic HCV in the Region: YES. <i>Current Hepatitis Reports</i> , 2013, 12, 280-287.	0.3	3
300	Hepatitis C infection and hepatocellular carcinoma in liver transplantation: a 20-year experience. <i>Hpb</i> , 2013, 15, 724-731.	0.1	18
301	Moderate, excessive or heavy alcohol consumption: each is significantly associated with increased mortality in patients with chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 703-709.	1.9	63
302	Control of Human Viral Infections by Natural Killer Cells. <i>Annual Review of Immunology</i> , 2013, 31, 163-194.	9.5	391
303	Innate immunity and HCV. <i>Journal of Hepatology</i> , 2013, 58, 564-574.	1.8	124
304	Treatment of chronic hepatitis C virus infection in Japan: update on therapy and guidelines. <i>Journal of Gastroenterology</i> , 2013, 48, 1-12.	2.3	40
305	Future therapies for chronic hepatitis C. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013, 10, 268-276.	8.2	36
306	Synthetic lipophilic antioxidant BO-653 suppresses HCV replication. <i>Journal of Medical Virology</i> , 2013, 85, 241-249.	2.5	5
307	Lack of association of hepatic estrogen receptor-alpha expression with histopathological and biochemical findings in chronic hepatitis C. <i>Pathology Research and Practice</i> , 2013, 209, 727-730.	1.0	2
308	Inhibition of Hepatitis C Virus Infection by DNA Aptamer against Envelope Protein. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 4937-4944.	1.4	37
309	Dry blood spot testing for hepatitis C in people who injected drugs: reaching the populations other tests cannot reach. <i>Frontline Gastroenterology</i> , 2013, 4, 255-262.	0.9	23

#	ARTICLE	IF	CITATIONS
310	Hepatitis C among patients with mental illness in Brazil: an analysis of associated factors. <i>General Hospital Psychiatry</i> , 2013, 35, 129-133.	1.2	12
311	988 OUTCOMES OF HEPATITIS C SCREENING PROGRAMS TARGETED AT RISK GROUPS HIDDEN IN THE GENERAL POPULATION: A SYSTEMATIC REVIEW. <i>Journal of Hepatology</i> , 2013, 58, S406-S407.	1.8	0
312	Association between insulin resistance and sustained virologic response in hepatitis C treatment, genotypes 1 versus 2 and 3: systematic literature review and meta-analysis. <i>Brazilian Journal of Infectious Diseases</i> , 2013, 17, 555-563.	0.3	13
313	Sequential induction of type I and II interferons mediates a long-lasting gene induction in the liver in response to a novel toll-like receptor 9 agonist. <i>Journal of Hepatology</i> , 2013, 58, 743-749.	1.8	7
314	TIP47 is associated with the Hepatitis C virus and its interaction with Rab9 is required for release of viral particles. <i>European Journal of Cell Biology</i> , 2013, 92, 374-382.	1.6	46
315	Is the HCV Pipeline Heading in the Right Direction?. <i>Gastroenterology</i> , 2013, 144, 482-485.	0.6	4
316	Peptide backbone replacement of hepatitis C virus NS3 serine protease C-terminal cleavage product analogs: Discovery of potent succinamide inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 4447-4452.	1.0	3
317	Absolute and relative contraindications to pegylated interferon or ribavirin in the <sc>US</sc> general patient population with chronic hepatitis C: results from a <sc>US</sc> database of over 45,000 <sc>HCV</sc>-infected, evaluated patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 473-481.	1.9	42
318	Interplay between Hepatitis C Virus and Redox Cell Signaling. <i>International Journal of Molecular Sciences</i> , 2013, 14, 4705-4721.	1.8	24
319	Risk of cardiovascular disease in HIV, hepatitis C, or HIV/hepatitis C patients compared to the general population. <i>International Journal of Clinical Practice</i> , 2013, 67, 6-13.	0.8	36
320	How to optimize HCV therapy in genotype 1 patients: management of side effects. <i>Liver International</i> , 2013, 33, 30-34.	1.9	41
321	Assessing the Cost Utility of Response-Guided Therapy in Patients with Chronic Hepatitis C Genotype 1 in the UK Using the MONARCH Model. <i>Applied Health Economics and Health Policy</i> , 2013, 11, 53-63.	1.0	40
322	Innate Immune Responses to Hepatitis C Virus. <i>Current Topics in Microbiology and Immunology</i> , 2013, 369, 219-242.	0.7	38
323	Molecular Mechanism by Which a Potent Hepatitis C Virus NS3-NS4A Protease Inhibitor Overcomes Emergence of Resistance. <i>Journal of Biological Chemistry</i> , 2013, 288, 5673-5681.	1.6	16
324	Acetaminophen-induced acute liver injury in HCV transgenic mice. <i>Toxicology and Applied Pharmacology</i> , 2013, 266, 224-232.	1.3	10
325	Direct-Acting Antiviral Agents for Hepatitis C Virus Infection. <i>Annual Review of Pharmacology and Toxicology</i> , 2013, 53, 427-449.	4.2	84
326	Hepatitis C virus subtyping based on sequencing of the C/E1 and NS5B genomic regions in comparison to a commercially available line probe assay. <i>Journal of Medical Virology</i> , 2013, 85, 815-822.	2.5	40
327	Serum autoantibodies positivity prevalence in patients with chronic <sc>HCV</sc> and impact on pegylated interferon and ribavirin treatment response. <i>Liver International</i> , 2013, 33, 1504-1509.	1.9	17

#	ARTICLE	IF	CITATIONS
328	Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 497-506.	4.6	84
329	Discovery of novel P2 substituted 4-biaryl proline inhibitors of hepatitis C virus NS3 serine protease. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 4436-4440.	1.0	4
331	Regulation of hepatic innate immunity by hepatitis C virus. <i>Nature Medicine</i> , 2013, 19, 879-888.	15.2	264
332	Review of direct-acting antiviral agents for the treatment of chronic hepatitis C. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 1107-1121.	1.9	67
333	Protease Inhibitors for Hepatitis C: Economic Implications. <i>Pharmacoeconomics</i> , 2013, 31, 739-751.	1.7	4
334	IFITM1 is a tight junction protein that inhibits hepatitis C virus entry. <i>Hepatology</i> , 2013, 57, 461-469.	3.6	134
335	Hepatitis C therapy at home: a hospital and home care partnership. <i>British Journal of Nursing</i> , 2013, 22, 518-523.	0.3	2
336	Differentially Expressed Proteins in Chronic Active Hepatitis, Cirrhosis, and HCC Related to HCV Infection in Comparison With HBV Infection: A proteomics study. <i>Hepatitis Monthly</i> , 2013, 13, e8351.	0.1	28
337	Adherence to Chronic Hepatitis C Treatment Regimen: First Report From a Referral Center in Iran. <i>Hepatitis Monthly</i> , 2013, 13, e11038.	0.1	5
338	Association of IL28B Polymorphisms With the Response to Peginterferon Plus Ribavirin Combined Therapy in Polish Patients Infected With HCV Genotype 1 and 4. <i>Hepatitis Monthly</i> , 2013, 13, e13678.	0.1	15
339	Direct Medical Care Costs Associated With Patients Diagnosed With Chronic HCV. <i>Hepatitis Monthly</i> , 2013, 13, e8415.	0.1	12
340	Hepatitis C Virus NS5B Sequence-Based Genotyping Analysis of Patients From the Sharkia Governorate, Egypt. <i>Hepatitis Monthly</i> , 2013, 13, e12706.	0.1	15
341	The Impact of Interleukin 28b Gene Polymorphism on the Virological Response to Combined Pegylated Interferon and Ribavirin Therapy in Chronic HCV Genotype 4 Infected Egyptian Patients Using Data Mining Analysis. <i>Hepatitis Monthly</i> , 2013, 13, e10509.	0.1	17
342	Prevalence and Risk Factors of Hepatitis C Virus Infection in Amol City, North of Iran: A Population-Based Study (2008-2011). <i>Hepatitis Monthly</i> , 2013, 13, e13313.	0.1	26
343	A New Subtype of Hepatitis C Virus Genotype 3: Analysis of Available Evidence. <i>Hepatitis Monthly</i> , 2013, 13, e13380.	0.1	4
344	A Simple Noninvasive Score Based on Routine Parameters can Predict Liver Cirrhosis in Patients With Chronic Hepatitis C. <i>Hepatitis Monthly</i> , 2013, 13, e8352.	0.1	25
345	Diagnostic Performance of Two Point-of-Care Tests for Anti-HCV Detection. <i>Hepatitis Monthly</i> , 2013, 13, e12274.	0.1	9
346	An Overview and Evaluation of Combining an Addiction Liaison Nurse Outpatient Service With Hepatitis C Outpatient Clinics in Glasgow, Scotland. <i>Gastroenterology Nursing</i> , 2013, 36, 98-104.	0.2	1

#	ARTICLE	IF	CITATIONS
347	A Survey of Hepatitis C Treatment Clinical Practice Patterns Using the Newly Approved Protease Inhibitors. <i>Journal of Clinical Gastroenterology</i> , 2013, 47, 800-806.	1.1	3
348	Influence of chronic hepatitis C infection and interferon therapy on natural killer cell subsets among Egyptian patients. <i>Egyptian Liver Journal</i> , 2013, 3, 80-85.	0.3	0
349	Hepatitis C treatment for multimorbid patients with substance use disorder in a primary care-based integrated treatment centre. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 1300-1307.	0.8	17
350	Epidemiology, Clinical Data, and Treatment of Viral Hepatitis in a Large Cohort of Intravenous Drug Users. <i>Journal of Addiction Medicine</i> , 2013, 7, 52-57.	1.4	14
351	Serum Apoptosis Markers Related to Liver Damage in Chronic Hepatitis C: sFas as a Marker of Advanced Fibrosis in Children and Adults While M30 of Severe Steatosis Only in Children. <i>PLoS ONE</i> , 2013, 8, e53519.	1.1	24
352	Safety, Tolerability, and Pharmacokinetics of Ribavirin in Hepatitis C Virus-Infected Patients with Various Degrees of Renal Impairment. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 6097-6105.	1.4	22
353	Morphological and Biochemical Characterization of the Membranous Hepatitis C Virus Replication Compartment. <i>Journal of Virology</i> , 2013, 87, 10612-10627.	1.5	220
354	Metabolic Factors and Chronic Hepatitis C: A Complex Interplay. <i>BioMed Research International</i> , 2013, 2013, 1-12.	0.9	26
355	HBsAg, anti-HCV, anti-HIV 1/2 and syphilis seroprevalence in healthy volunteer blood donors in southeastern Anatolia. <i>Journal of Infection in Developing Countries</i> , 2013, 7, 665-669.	0.5	16
356	Developing blood borne virus services across prisons in Wales, UK. <i>International Journal of Prisoner Health</i> , 2013, 9, 31-39.	0.5	4
357	Viral Hepatitis C Gets Personal - The Value of Human Genomics to Public Health. <i>Public Health Genomics</i> , 2013, 16, 192-197.	0.6	8
358	The interdomain interface in bifunctional enzyme protein 3/4A (NS3/4A) regulates protease and helicase activities. <i>Protein Science</i> , 2013, 22, 1786-1798.	3.1	20
359	Transcript Analysis of P2X Receptors in PBMCs of Chronic HCV Patients: An Insight into Antiviral Treatment Response and HCV-Induced Pathogenesis. <i>Viral Immunology</i> , 2013, 26, 343-350.	0.6	17
360	Interleukin-28B genetic variations and spontaneous clearance of hepatitis C antibody-positive blood donors in China. <i>Transfusion</i> , 2013, 53, 2498-2504.	0.8	5
361	Treatment of severe psoriasis with biological therapies in patients with viral hepatitis B and C. <i>British Journal of Dermatology</i> , 2013, 168, 461-462.	1.4	3
362	Current and emerging antiviral treatments for hepatitis C infection. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 931-943.	1.1	42
363	Target-mediated drug disposition and prolonged liver accumulation of a novel humanized anti-CD81 monoclonal antibody in cynomolgus monkeys. <i>MAbs</i> , 2013, 5, 776-786.	2.6	12
366	Incidence and prevalence of hepatitis C in prisons and other closed settings: Results of a systematic review and meta-analysis. <i>Hepatology</i> , 2013, 58, 1215-1224.	3.6	263

#	ARTICLE	IF	CITATIONS
367	Epidemiology of the viral hepatitis B and C in female prisoners of Metropolitan Regional Prison Complex in the State of Goiás, Central Brazil. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2013, 46, 24-29.	0.4	28
368	Bioactive Foods and Supplements for Protection against Liver Diseases. , 2013, , 557-567.		2
369	The Impact of Inosine Triphosphatase Variants on Hemoglobin Level and Sustained Virologic Response of Chronic Hepatitis C in Korean. <i>Journal of Korean Medical Science</i> , 2013, 28, 1213.	1.1	10
370	Neutralizing Antibodies in Patients with Chronic Hepatitis C, Genotype 1, against a Panel of Genotype 1 Culture Viruses: Lack of Correlation to Treatment Outcome. <i>PLoS ONE</i> , 2013, 8, e62674.	1.1	8
371	Albumin Fusion of Interleukin-28B: Production and Characterization of Its Biological Activities and Protein Stability. <i>PLoS ONE</i> , 2013, 8, e64301.	1.1	4
372	Filling the Knowledge Gap: Measuring HIV Prevalence and Risk Factors among Men Who Have Sex with Men and Female Sex Workers in Tripoli, Libya. <i>PLoS ONE</i> , 2013, 8, e66701.	1.1	28
373	Interferon and Ribavirin Combination Treatment Synergistically Inhibit HCV Internal Ribosome Entry Site Mediated Translation at the Level of Polyribosome Formation. <i>PLoS ONE</i> , 2013, 8, e72791.	1.1	13
374	Persistence of Hepatitis C Virus during and after Otherwise Clinically Successful Treatment of Chronic Hepatitis C with Standard Pegylated Interferon 1±2b and Ribavirin Therapy. <i>PLoS ONE</i> , 2013, 8, e80078.	1.1	14
375	Molecular Epidemiologic Characterization of a Clustering HCV Infection Caused by Inappropriate Medical Care in Heyuan City of Guangdong, China. <i>PLoS ONE</i> , 2013, 8, e82304.	1.1	3
376	HLA-DQB1*03 Confers Susceptibility to Chronic Hepatitis C in Japanese: A Genome-Wide Association Study. <i>PLoS ONE</i> , 2013, 8, e84226.	1.1	35
377	Mitochondrial Dysfunctions and Altered Metals Homeostasis: New Weapons to Counteract HCV-Related Oxidative Stress. <i>Oxidative Medicine and Cellular Longevity</i> , 2013, 2013, 1-10.	1.9	27
378	Update on the management of cirrhosis – focus on cost-effective preventative strategies. <i>ClinicoEconomics and Outcomes Research</i> , 2013, 5, 143.	0.7	36
379	Detection of Hepatitis C Virus Resistant Mutants in the era of Direct Acting Antivirals. <i>American Journal of Infectious Diseases</i> , 2014, 10, 179-183.	0.1	1
380	Hepatitis C in Argentina: epidemiology and treatment. <i>Hepatic Medicine: Evidence and Research</i> , 2014, 6, 35.	0.9	6
381	MiR-942 Mediates Hepatitis C Virus-Induced Apoptosis via Regulation of ISG12a. <i>PLoS ONE</i> , 2014, 9, e94501.	1.1	30
382	Development and Validation of a Clinical Scoring System for Predicting Risk of HCC in Asymptomatic Individuals Seropositive for Anti-HCV Antibodies. <i>PLoS ONE</i> , 2014, 9, e94760.	1.1	39
383	Prediction of Treatment Week Eight Response & Sustained Virologic Response in Patients Treated with Boceprevir Plus Peginterferon Alfa and Ribavirin. <i>PLoS ONE</i> , 2014, 9, e103370.	1.1	4
384	Comparative Molecular Dynamics Simulation of Hepatitis C Virus NS3/4A Protease (Genotypes 1b, 3a and) Tj ETQq1 1 0.784314 rgBT 2014, 9, e104425.	1.1	15

#	ARTICLE	IF	CITATIONS
385	Hepatitis C Worldwide and in Brazil: Silent Epidemicâ€”Data on Disease including Incidence, Transmission, Prevention, and Treatment. Scientific World Journal, The, 2014, 2014, 1-10.	0.8	25
386	Hepatitis C virus in the new era: Perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy. World Journal of Gastroenterology, 2014, 20, 9633.	1.4	135
387	Noninvasive Biomarkers of Liver Fibrosis: An Overview. Advances in Hepatology, 2014, 2014, 1-15.	1.3	47
388	Hepatitis C virus molecular evolution: Transmission, disease progression and antiviral therapy. World Journal of Gastroenterology, 2014, 20, 15992.	1.4	45
389	HCV INFECTION THROUGH PERFORATING AND CUTTING MATERIAL AMONG CANDIDATES FOR BLOOD DONATION IN BELÃ‰M, BRAZILIAN AMAZON. Revista Do Instituto De Medicina Tropical De Sao Paulo, 2014, 56, 511-515.	0.5	8
390	Health policy model: long-term predictive results associated with the management of hepatitis C virus-induced diseases in Italy. ClinicoEconomics and Outcomes Research, 2014, 6, 303.	0.7	19
391	Factors associated with treatment interruption for hepatitis C. Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira, 2014, 60, 29-34.	0.3	1
393	Optimal management of pediatric hepatitis C infection: a review. Pediatric Health, Medicine and Therapeutics, 2014, , 173.	0.7	1
394	Anti-HBc positivity was associated with histological cirrhosis in patients with chronic hepatitis C. Annals of Hepatology, 2014, 13, 20-26.	0.6	32
395	Latin American Association for the Study of the Liver Recommendations on Treatment of Hepatitis C. Annals of Hepatology, 2014, 13, S4-S66.	0.6	28
396	Alopecia universalis after discontinuation of pegylated interferon and ribavirin combination therapy for hepatitis C: a case report. Annals of Hepatology, 2014, 13, 293-296.	0.6	3
397	Value of interleukinâ€‹28Bâ€› genetic polymorphism on retreatment outcomes of chronic hepatitis C genotype 1 relapsers by peginterferon alfa plus ribavirin. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 102-109.	1.4	7
398	Message in a bottle: lessons learned from antagonism of STING signalling during RNA virus infection. Cytokine and Growth Factor Reviews, 2014, 25, 669-679.	3.2	81
399	Interference of HCV replication by cell penetrable human monoclonal scFv specific to NS5B polymerase. MAbs, 2014, 6, 1327-1339.	2.6	16
400	Treatment for cryoglobulinemic and non-cryoglobulinemic peripheral neuropathy associated with hepatitis C virus infection. The Cochrane Library, 2014, , CD010404.	1.5	12
401	Are there national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs? A survey of 33 European countries. BMC Infectious Diseases, 2014, 14, S14.	1.3	12
402	Eltrombopag in patients with chronic hepatitis C and thrombocytopenia. Future Virology, 2014, 9, 9-20.	0.9	0
403	â€œFighting an uphill battleâ€ experience with the HCV triple therapy: a qualitative thematic analysis. BMC Infectious Diseases, 2014, 14, 507.	1.3	9

#	ARTICLE	IF	CITATIONS
404	Increased prevalence of hepatitis C virus subtype 6a in China: a comparison between 2004–2007 and 2008–2011. <i>Archives of Virology</i> , 2014, 159, 3231-3237.	0.9	29
405	Hepatitis C virus: strategies to evade antiviral responses. <i>Future Virology</i> , 2014, 9, 1061-1075.	0.9	31
406	Actualización en el tratamiento de la hepatitis C. <i>Medicine</i> , 2014, 11, 4103-4111.	0.0	0
407	HCV infection frequency and trends among voluntary blood donors in Cluj County (Romania) between 2006 and 2011. <i>Medicine and Pharmacy Reports</i> , 2014, 87, 159-162.	0.2	0
408	Myeloid-Derived Suppressor Cells Are Associated with Viral Persistence and Downregulation of TCR β Chain Expression on CD8+ T Cells in Chronic Hepatitis C Patients. <i>Molecules and Cells</i> , 2014, 37, 66-73.	1.0	47
409	Association of Hcpidin mRNA Expression With Hepatocyte Iron Accumulation and Effects of Antiviral Therapy in Chronic Hepatitis C Infection. <i>Hepatitis Monthly</i> , 2014, 14, e21184.	0.1	17
410	CD81 and Hepatitis C Virus (HCV) Infection. <i>Viruses</i> , 2014, 6, 535-572.	1.5	93
411	Association between TGFB1 915G/C polymorphism and susceptibility to chronic hepatitis C virus infection: A meta-analysis. <i>Biomedical Reports</i> , 2014, 2, 239-244.	0.9	5
412	Higher levels of hepatitis C virus RNA found in blood donors co-infected with HIV as compared to HCV mono-infected donors. <i>Journal of Infection in Developing Countries</i> , 2014, 8, 1068-1071.	0.5	4
413	Genetic Variants in Human Leukocyte Antigen-DP Influence Both Hepatitis C Virus Persistence and Hepatitis C Virus F Protein Generation in the Chinese Han Population. <i>International Journal of Molecular Sciences</i> , 2014, 15, 9826-9843.	1.8	9
414	Factors Associated with Spontaneous Clearance of Hepatitis C Virus in Chinese Population. <i>BioMed Research International</i> , 2014, 2014, 1-6.	0.9	17
415	Simeprevir for the treatment of hepatitis C virus infection. <i>Pharmacogenomics and Personalized Medicine</i> , 2014, 7, 241.	0.4	29
416	A New Sampling Method for Spleen Stiffness Measurement Based on Quantitative Acoustic Radiation Force Impulse Elastography for Noninvasive Assessment of Esophageal Varices in Newly Diagnosed HCV-Related Cirrhosis. <i>BioMed Research International</i> , 2014, 2014, 1-8.	0.9	29
417	The Role of Chemokines in Hepatitis C Virus-Mediated Liver Disease. <i>International Journal of Molecular Sciences</i> , 2014, 15, 4747-4779.	1.8	23
418	Prescription opioid injection and risk of hepatitis C in relation to traditional drugs of misuse in a prospective cohort of street youth. <i>BMJ Open</i> , 2014, 4, e005419-e005419.	0.8	34
419	Testing for hepatitis B virus and HIV in patients with chronic hepatitis C: Screening performance and outcome. <i>Scandinavian Journal of Infectious Diseases</i> , 2014, 46, 686-692.	1.5	4
420	Dried blood spot analysis to assess medication adherence and to inform personalization of treatment. <i>Bioanalysis</i> , 2014, 6, 2825-2838.	0.6	21
421	Failed triple therapy in a treatment-experienced patient with genotype 6 hepatitis C infection. <i>American Journal of Health-System Pharmacy</i> , 2014, 71, 204-208.	0.5	3

#	ARTICLE	IF	CITATIONS
422	Hepatitis C screening beyond <sc>CDC</sc> guidelines in an Egyptian immigrant community. <i>Liver International</i> , 2014, 34, 253-258.	1.9	12
423	12 Years of Universal Access to Hepatitis C Treatment. <i>Journal of the International Association of Providers of AIDS Care</i> , 2014, 13, 560-567.	0.6	5
424	Discovering novel anti-HCV compounds with inhibitory activities toward HCV NS3/4A protease. <i>Acta Pharmacologica Sinica</i> , 2014, 35, 1074-1081.	2.8	12
425	Innate and adaptive immune responses in HCV infections. <i>Journal of Hepatology</i> , 2014, 61, S14-S25.	1.8	245
426	Watchful waiting: role of disease progression on uncertainty and depressive symptoms in patients with chronic Hepatitis C. <i>Journal of Viral Hepatitis</i> , 2014, 21, 727-733.	1.0	8
427	Multi-analyte profile analysis of plasma immune proteins: altered expression of peripheral immune factors is associated with neuropsychiatric symptom severity in adults with and without chronic hepatitis <sc>C</sc> virus infection. <i>Brain and Behavior</i> , 2014, 4, 123-142.	1.0	36
428	A practical guide for antiviral therapy of chronic Hepatitis C. <i>GE Portuguese Journal of Gastroenterology</i> , 2014, 21, 221-230.	0.3	6
429	Outcomes of hepatitis C screening programs targeted at risk groups hidden in the general population: a systematic review. <i>BMC Public Health</i> , 2014, 14, 66.	1.2	34
430	Incidence and cost of treatment-emergent comorbid events in insured patients with chronic hepatitis C virus infection: a retrospective cohort study. <i>BMC Health Services Research</i> , 2014, 14, 429.	0.9	5
431	Evaluation of the Aspartate Aminotransferase/Platelet Ratio Index and Enhanced Liver Fibrosis Tests to Detect Significant Fibrosis Due to Chronic Hepatitis C. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, 370-376.	1.1	23
433	Inhibition of Hepatitis C Virus Infection by DNA Aptamer against NS2 Protein. <i>PLoS ONE</i> , 2014, 9, e90333.	1.1	23
434	Chronic hepatitis C and liver fibrosis. <i>World Journal of Gastroenterology</i> , 2014, 20, 11033.	1.4	178
435	The Risk of Long-term Morbidity and Mortality in Patients With Chronic Hepatitis C. <i>JAMA Internal Medicine</i> , 2014, 174, 204.	2.6	113
436	Effect of HLA on hepatitis C virus clearance and persistence in anti-HCV-positive end-stage renal disease patients. <i>Saudi Journal of Gastroenterology</i> , 2014, 20, 175.	0.5	8
437	Faldaprevir (BI 201335) for the treatment of hepatitis C in patients co-infected with HIV. <i>Expert Review of Anti-Infective Therapy</i> , 2014, 12, 157-164.	2.0	2
438	Enantiomeric Atropisomers Inhibit HCV Polymerase and/or HIV Matrix: Characterizing Hindered Bond Rotations and Target Selectivity. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 1944-1951.	2.9	33
439	Estimating the Incidence and Prevalence of Chronic Hepatitis C Infection in Taiwan Using Back Projection. <i>Value in Health Regional Issues</i> , 2014, 3, 5-11.	0.5	33
440	Evaluation of serum levels of IL-6, TNF- α , IL-10, IL-2 and IL-4 in patients with chronic hepatitis. <i>Inmunologia (Barcelona, Spain: 1987)</i> , 2014, 33, 41-50.	0.1	15

#	ARTICLE	IF	CITATIONS
441	Discovery of Selective Small Molecule Type III Phosphatidylinositol 4-Kinase Alpha (PI4KIII \pm) Inhibitors as Anti Hepatitis C (HCV) Agents. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 2091-2106.	2.9	56
442	IL28B and IL10R \sim 1087 polymorphisms are protective for chronic genotype 1 HCV infection and predictors of response to interferon-based therapy in an East-Central European cohort. <i>BMC Research Notes</i> , 2014, 7, 12.	0.6	12
443	Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study. <i>Journal of Gastroenterology</i> , 2014, 49, 138-147.	2.3	73
444	Influence of low-density lipoprotein cholesterol on virological response to telaprevir-based triple therapy for chronic HCV genotype 1b infection. <i>Antiviral Research</i> , 2014, 104, 102-109.	1.9	10
445	Serum interferon- γ -inducible protein-10 concentrations and IL28B genotype associated with responses to pegylated interferon plus ribavirin with and without telaprevir for chronic hepatitis C. <i>Hepatology Research</i> , 2014, 44, 1208-1216.	1.8	9
446	Efficacy and safety of telaprevir and boceprevir in patients with hepatitis C genotype 1: a meta-analysis. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2014, 39, 14-24.	0.7	22
447	Role of IL28B for chronic hepatitis C treatment toward personalized medicine. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 241-249.	1.4	49
448	Activation and Evasion of Antiviral Innate Immunity by Hepatitis C Virus. <i>Journal of Molecular Biology</i> , 2014, 426, 1198-1209.	2.0	63
449	HCV core protein and virus assembly: what we know without structures. <i>Immunologic Research</i> , 2014, 60, 1-10.	1.3	41
451	Boceprevir and telaprevir-based triple therapy for chronic hepatitis C: virological efficacy and impact on kidney function and model for end-stage liver disease score. <i>Journal of Viral Hepatitis</i> , 2014, 21, e98-e107.	1.0	23
452	Defining the spatial relationship between hepatitis C virus infection and interferon-stimulated gene induction in the human liver. <i>Hepatology</i> , 2014, 59, 2065-2067.	3.6	2
453	Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 137-147.	1.9	74
454	Phylogenetic analysis of hepatitis C virus strains and risk factors associated with infection and viral subtypes among Iranian patients. <i>Journal of Medical Virology</i> , 2014, 86, 1342-1349.	2.5	15
455	Spreading of hepatitis C virus subtypes 1a and 1b through the central region of Argentina. <i>Infection, Genetics and Evolution</i> , 2014, 26, 32-40.	1.0	7
456	The Discovery of Potent Nonstructural Protein 5A (NS5A) Inhibitors with a Unique Resistance Profile-Part 1. <i>ChemMedChem</i> , 2014, 9, 1378-1386.	1.6	22
457	The Discovery of Potent Nonstructural Protein 5A (NS5A) Inhibitors with a Unique Resistance Profile-Part 2. <i>ChemMedChem</i> , 2014, 9, 1387-1396.	1.6	16
458	Common polymorphic effectors of immunity against hepatitis B and C modulate susceptibility to infection and spontaneous clearance in a Moroccan population. <i>Infection, Genetics and Evolution</i> , 2014, 26, 1-7.	1.0	8
459	International variations in childhood cancer in indigenous populations: a systematic review. <i>Lancet Oncology</i> , 2014, 15, e90-e103.	5.1	22

#	ARTICLE	IF	CITATIONS
460	Specific Serotonin Reuptake Inhibitors Prevent Interferon- α -Induced Depression in Patients With Hepatitis C: A Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1452-1460.e3.	2.4	23
461	Stereoselective Lithiation and Carboxylation of Boc-Protected Bicyclopyrrolidine: Synthesis of a Key Building Block for HCV Protease Inhibitor Telaprevir. <i>Organic Process Research and Development</i> , 2014, 18, 1234-1244.	1.3	25
462	Ultradeep Sequencing Study of Chronic Hepatitis C Virus Genotype 1 Infection in Patients Treated with Daclatasvir, Peginterferon, and Ribavirin. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 2105-2112.	1.4	16
463	Novel Peptidomimetic Hepatitis C Virus NS3/4A Protease Inhibitors Spanning the P2-P1 Region. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 249-254.	1.3	13
464	Individualized Therapy for Hepatitis C Infection: Focus on the Interleukin-28B Polymorphism in Directing Therapy. <i>Molecular Diagnosis and Therapy</i> , 2014, 18, 25-38.	1.6	2
465	Inhibition of Hepatitis C Virus Production by Aptamers against the Core Protein. <i>Journal of Virology</i> , 2014, 88, 1990-1999.	1.5	39
466	Therapeutic vaccines against hepatitis C virus. <i>Infection, Genetics and Evolution</i> , 2014, 22, 120-129.	1.0	19
467	Discovery and Preclinical Characterization of the Cyclopropylindolobenzazepine BMS-791325, A Potent Allosteric Inhibitor of the Hepatitis C Virus NS5B Polymerase. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 1855-1879.	2.9	83
468	UK-1 and structural analogs are potent inhibitors of hepatitis C virus replication. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 609-612.	1.0	17
469	Integrated Strategies for Identifying Leads That Target the NS3 Helicase of the Hepatitis C Virus. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 2074-2090.	2.9	17
470	Detection of unamplified HCV RNA in serum using a novel two metallic nanoparticle platform. <i>Clinical Chemistry and Laboratory Medicine</i> , 2014, 52, 565-72.	1.4	9
471	Conformation-Based Restrictions and Scaffold Replacements in the Design of Hepatitis C Virus Polymerase Inhibitors: Discovery of Deleobuvir (BI 207127). <i>Journal of Medicinal Chemistry</i> , 2014, 57, 1845-1854.	2.9	32
472	Development of quantitative method for determination of γ -glutamyl peptides by capillary electrophoresis tandem mass spectrometry: An efficient approach avoiding matrix effect. <i>Journal of Chromatography A</i> , 2014, 1369, 161-169.	1.8	30
473	<i>ITPA</i> genetic variants influence efficacy of PEG-IFN/RBV therapy in older patients infected with HCV genotype 1 and favourable IL28B type. <i>Journal of Viral Hepatitis</i> , 2014, 21, 466-474.	1.0	8
474	Impact of surveillance of hepatitis b and hepatitis c in patients with inflammatory bowel disease under anti-TNF therapies: Multicenter prospective observational study (REPENTINA 3). <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1529-1538.	0.6	45
475	Long-Term Effect on Natural Killer Cells by Interferon- α Therapy on the Outcomes of HCV Infection. <i>Journal of Interferon and Cytokine Research</i> , 2014, 34, 366-375.	0.5	7
476	Antiviral therapy with nucleotide polymerase inhibitors for chronic hepatitis C. <i>Journal of Hepatology</i> , 2014, 61, S91-S97.	1.8	24
477	Global epidemiology and genotype distribution of the hepatitis C virus infection. <i>Journal of Hepatology</i> , 2014, 61, S45-S57.	1.8	1,560

#	ARTICLE	IF	CITATIONS
478	Hepatitis C Virus: Epidemiology and Clinical Features of Related Cancer. , 2014, , 87-112.		0
479	A Double-blind, randomized, placebo-controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK2336805 when given as monotherapy and in combination with peginterferon alfa-2a and ribavirin in hepatitis C virus genotype 1-infected. Liver International, 2014, 34, e89-e95.	1.9	8
480	<i>IFNL3 (IL28B)</i> and <i>IFNL4</i> polymorphisms are associated with treatment response in Thai patients infected with HCV genotype 1, but not with genotypes 3 and 6. Journal of Medical Virology, 2014, 86, 1482-1490.	2.5	21
481	Efficacy and safety of telaprevir (<scp>TVR</scp>) triple therapy in a "real-life" cohort of 102 patients with <scp>HCV</scp> genotype 1: interim analysis after 24 weeks of treatment. Journal of Viral Hepatitis, 2014, 21, 333-340.	1.0	12
482	Derivatives of imidazotriazine and pyrrolotriazine C-nucleosides as potential new anti-HCV agents. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 4984-4988.	1.0	13
483	Phosphorylation of Hepatitis C Virus RNA Polymerases Ser29 and Ser42 by Protein Kinase C-Related Kinase 2 Regulates Viral RNA Replication. Journal of Virology, 2014, 88, 11240-11252.	1.5	20
484	Optimal Management of the Hepatitis C Patient: Review of the AASLD/IDSA Guidelines. Current Hepatology Reports, 2014, 13, 314-320.	0.4	0
485	Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology, 2014, 59, 1293-1302.	3.6	242
486	Cysteine-rich secretory protein 3 inhibits hepatitis C virus at the initial phase of infection. Biochemical and Biophysical Research Communications, 2014, 450, 1076-1082.	1.0	3
487	Randomized, Placebo-Controlled, Single-Ascending-Dose Study of BMS-791325, a Hepatitis C Virus (HCV) NS5B Polymerase Inhibitor, in HCV Genotype 1 Infection. Antimicrobial Agents and Chemotherapy, 2014, 58, 3496-3503.	1.4	30
488	Treatment of chronic viral hepatitis C in children and adolescents: UK experience. Archives of Disease in Childhood, 2014, 99, 505-510.	1.0	25
489	The intracellular inhibition of HCV replication represents a novel mechanism of action by the innate immune Lactoferrin protein. Antiviral Research, 2014, 111, 13-22.	1.9	16
490	Assessing the feasibility of hepatitis C virus vaccine trials: Results from the Hepatitis C Incidence and Transmission Study-community (HITS-c) vaccine preparedness study. Vaccine, 2014, 32, 5460-5467.	1.7	19
491	Preclinical Characterization of BMS-791325, an Allosteric Inhibitor of Hepatitis C Virus NS5B Polymerase. Antimicrobial Agents and Chemotherapy, 2014, 58, 3485-3495.	1.4	56
492	Comparison of first- and second-wave DAAs for HCV GT1: efficacy, safety, tolerability, and regimen complexity. Hepatology International, 2014, 8, 352-364.	1.9	1
493	Chemiluminescent microparticle immunoassay based detection and prevalence of HCV infection in district Peshawar Pakistan. Virology Journal, 2014, 11, 127.	1.4	15
494	Hepatitis C virus-induced hepatocyte cell death and protection by inhibition of apoptosis. Journal of General Virology, 2014, 95, 2204-2215.	1.3	24
495	Long-term maintenance of sustained virological response in liver transplant recipients treated for recurrent hepatitis C. Digestive and Liver Disease, 2014, 46, 440-445.	0.4	3

#	ARTICLE	IF	CITATIONS
496	Intra-host evolution of multiple genotypes of hepatitis C virus in a chronically infected patient with HIV along a 13-year follow-up period. <i>Virology</i> , 2014, 449, 317-327.	1.1	10
497	Resource Utilization and Direct Medical Costs of Chronic Hepatitis C in Thailand: A Heavy but Manageable Economic Burden. <i>Value in Health Regional Issues</i> , 2014, 3, 12-18.	0.5	13
498	Challenges in molecular epidemiology of hepatitis C virus. <i>Journal of Clinical Virology</i> , 2014, 60, 174-176.	1.6	4
499	Efficacy of Immunotherapy With TG4040, Peg-Interferon, and Ribavirin in a Phase 2 Study of Patients With Chronic HCV Infection. <i>Gastroenterology</i> , 2014, 147, 119-131.e3.	0.6	30
500	O impacto da hepatite C em Portugal. <i>GE Jornal Português De Gastreenterologia</i> , 2014, 21, 44-54.	0.0	13
501	The cost-effectiveness of boceprevir for hepatitis C. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2014, 14, 319-334.	0.7	1
502	Discovery and Synthesis of C-Nucleosides as Potential New Anti-HCV Agents. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 679-684.	1.3	32
503	Novel Quinoline-Based P2 ⁺ P4 Macrocyclic Derivatives As Pan-Genotypic HCV NS3/4a Protease Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 264-269.	1.3	22
504	New antiviral agents for the treatment of hepatitis C: ABT-450. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 711-716.	0.9	27
505	Von Willebrand Factor as a new marker for noninvasive assessment of liver fibrosis and cirrhosis in patients with chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 331-338.	1.9	53
506	Preparation and biological evaluation of 1 ⁻ -cyano-2 ⁻ -C-methyl pyrimidine nucleosides as HCV NS5B polymerase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 3092-3095.	1.0	11
507	Serum complements C3 and C4 in chronic HCV infection and their correlation with response to pegylated interferon and ribavirin treatment. <i>Arab Journal of Gastroenterology</i> , 2014, 15, 58-62.	0.4	9
508	Myeloperoxidase gene polymorphism predicts fibrosis severity in women with hepatitis C. <i>Human Immunology</i> , 2014, 75, 766-770.	1.2	6
509	microRNAs: Novel players in hepatitis C virus infection. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2014, 38, 664-675.	0.7	20
510	A 3D structural model and dynamics of hepatitis C virus NS3/4A protease (genotype 4a, strain ED43) suggest conformational instability of the catalytic triad: implications in catalysis and drug resistivity. <i>Journal of Biomolecular Structure and Dynamics</i> , 2014, 32, 950-958.	2.0	9
511	Discovery of Hepatitis C Virus NS3-4A Protease Inhibitors with Improved Barrier to Resistance and Favorable Liver Distribution. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 1770-1776.	2.9	29
512	Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents. <i>Hepatic Medicine: Evidence and Research</i> , 2014, 6, 61.	0.9	27
513	Approaches to hepatitis C treatment and cure using NS5A inhibitors. <i>Infection and Drug Resistance</i> , 2014, 7, 41.	1.1	51

#	ARTICLE	IF	CITATIONS
514	A Protocol for Analyzing Hepatitis C Virus Replication. <i>Journal of Visualized Experiments</i> , 2014, , e51362.	0.2	1
515	The clinical management of HCV in the HIV-infected patient. <i>Antiviral Therapy</i> , 2014, 20, 457-467.	0.6	4
517	Mutational diversity of NS5A and NS3 during triple therapy (telaprevir, pegylated-interferon- α 2b and) Tj ETQq0 0 0 rgBT /Overlock 10 T <i>Journal of Molecular Medicine</i> , 2014, 33, 1652-1656.	1.8	0
518	Effect of Fuzheng Huayu capsule combined with Pegasys on genotype 1 hepatitis C fibrosis and cell apoptosis. <i>Experimental and Therapeutic Medicine</i> , 2014, 8, 1123-1126.	0.8	5
519	The extinction of chronic viral hepatitis?. <i>Clinical Liver Disease</i> , 2015, 6, 75-77.	1.0	2
520	Inhibition of expression of hepatitis C virus 1b genotype core and NS4B genes in HepG2 cells using artificial microRNAs. <i>Molecular Medicine Reports</i> , 2015, 12, 1905-1913.	1.1	1
521	Approaching rational epitope vaccine design for hepatitis C virus with meta-server and multivalent scaffolding. <i>Scientific Reports</i> , 2015, 5, 12501.	1.6	68
522	Hepatic apoptotic markers are not predictors for the virological response to interferon-based therapy in chronic hepatitis C patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 1057-1062.	0.8	3
523	Genotypic distribution and hepatic fibrosis among HIV/HCV co-infected individuals in Southern China: a retrospective cross-sectional study. <i>BMC Infectious Diseases</i> , 2015, 15, 401.	1.3	4
524	Reviews of Research on Risk Factors of Hepatitis C Virus Infection. <i>Infection International</i> , 2015, 4, 6-9.	0.1	0
525	A comparative study of variants of pegylated interferon alpha in treatment of chronic HCV patients. <i>Apmis</i> , 2015, 123, 482-489.	0.9	4
526	Effects of short <scp>RNA</scp> structural analogues against hepatitis <scp>C</scp> virus genotypes 2, 3 and 4 in replicon cells. <i>Journal of Digestive Diseases</i> , 2015, 16, 449-455.	0.7	0
527	Physical and functional interaction between hepatitis C virus NS5A protein and ovarian tumor protein deubiquitinase 7B. <i>Microbiology and Immunology</i> , 2015, 59, 466-476.	0.7	10
528	Role of fibroscan, TGF- β 1, and YKL-40 in the detection of hepatic fibrosis in chronic hepatitis c patients with and without schistosomiasis. <i>Egyptian Liver Journal</i> , 2015, 5, 47-53.	0.3	1
529	Economic evaluation of screening programs for hepatitis C virus infection: evidence from literature. <i>Risk Management and Healthcare Policy</i> , 2015, 8, 45.	1.2	18
530	Modeling Viral Infectious Diseases and Development of Antiviral Therapies Using Human Induced Pluripotent Stem Cell-Derived Systems. <i>Viruses</i> , 2015, 7, 3835-3856.	1.5	26
531	HCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral Therapy. <i>Viruses</i> , 2015, 7, 5328-5342.	1.5	29
532	HLA Preferences for Conserved Epitopes: A Potential Mechanism for Hepatitis C Clearance. <i>Frontiers in Immunology</i> , 2015, 6, 552.	2.2	13

#	ARTICLE	IF	CITATIONS
533	Durable Sustained Virologic Response After Oral Directly Acting Antiviral Therapy Despite Immunosuppressive Treatment. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv091.	0.4	7
534	LC-ESI-MS/MS Analysis and Pharmacokinetics of GP205, an Innovative Potent Macrocyclic Inhibitor of Hepatitis C Virus NS3/4A Protease in Rats. <i>Molecules</i> , 2015, 20, 4319-4336.	1.7	4
535	Interferon-free combination therapies for the treatment of hepatitis C: current insights. <i>Hepatic Medicine: Evidence and Research</i> , 2015, 7, 51.	0.9	52
536	HCV Genotyping from NGS Short Reads and Its Application in Genotype Detection from HCV Mixed Infected Plasma. <i>PLoS ONE</i> , 2015, 10, e0122082.	1.1	14
537	Chaperone-Mediated Autophagy Targets IFNAR1 for Lysosomal Degradation in Free Fatty Acid Treated HCV Cell Culture. <i>PLoS ONE</i> , 2015, 10, e0125962.	1.1	21
538	Rational Design and Adaptive Management of Combination Therapies for Hepatitis C Virus Infection. <i>PLoS Computational Biology</i> , 2015, 11, e1004040.	1.5	19
539	Real-Time PCR Assays for the Quantification of HCV RNA: Concordance, Discrepancies and Implications for Response Guided Therapy. <i>PLoS ONE</i> , 2015, 10, e0135963.	1.1	18
540	IFN- β Inhibits MiR-122 Transcription through a Stat3-HNF4 α Inflammatory Feedback Loop in an IFN- β Resistant HCV Cell Culture System. <i>PLoS ONE</i> , 2015, 10, e0141655.	1.1	13
541	Claudin-6 and Occludin Natural Variants Found in a Patient Highly Exposed but Not Infected with Hepatitis C Virus (HCV) Do Not Confer HCV Resistance In Vitro. <i>PLoS ONE</i> , 2015, 10, e0142539.	1.1	8
542	Correlation between Genetic Variations and Serum Level of Interleukin 28B with Virus Genotypes and Disease Progression in Chronic Hepatitis C Virus Infection. <i>Journal of Immunology Research</i> , 2015, 2015, 1-10.	0.9	20
543	Chronic Hepatitis C: An Overview of Evidence on Epidemiology and Management from a Brazilian Perspective. <i>International Journal of Hepatology</i> , 2015, 2015, 1-10.	0.4	7
544	Inter and inpatient evolution of hepatitis C virus. <i>Annals of Hepatology</i> , 2015, 14, 442-449.	0.6	10
545	Mexican Consensus on the Diagnosis and Management of Hepatitis C Infection. <i>Annals of Hepatology</i> , 2015, 14, S7-S48.	0.6	4
546	Prevalence of hepatitis C virus infection among patients undergoing haemodialysis in Latin America. <i>Annals of Hepatology</i> , 2015, 14, 807-814.	0.6	13
547	Hepatitis C " Overview and Update in Treatment. , 2015, , .		0
548	New Perspective in HCV Clinical and Economical Management of the Current and Future Therapies. , 2015, , .		0
549	EFTUD2 Is a Novel Innate Immune Regulator Restricting Hepatitis C Virus Infection through the RIG-I/MDA5 Pathway. <i>Journal of Virology</i> , 2015, 89, 6608-6618.	1.5	37
550	Hepatitis C virus and antiviral innate immunity: Who wins at tug-of-war?. <i>World Journal of Gastroenterology</i> , 2015, 21, 3786.	1.4	24

#	ARTICLE	IF	CITATIONS
551	Global policy and access to new hepatitis C therapies for people who inject drugs. <i>International Journal of Drug Policy</i> , 2015, 26, 1064-1071.	1.6	14
552	Recombinant expression of the alternate reading frame protein (ARFP) of hepatitis C virus genotype 4a (HCV-4a) and detection of ARFP and anti-ARFP antibodies in HCV-infected patients. <i>Archives of Virology</i> , 2015, 160, 1939-1952.	0.9	10
553	The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 233-244.	0.6	33
554	Assessment of interleukin 28B genotype as a predictor of response to combined therapy with pegylated interferon plus ribavirin in HCV infected Egyptian patients. <i>Cytokine</i> , 2015, 74, 268-272.	1.4	3
555	The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C. <i>Expert Opinion on Drug Discovery</i> , 2015, 10, 1363-1377.	2.5	56
556	Inosine triphosphate pyrophosphohydrolase activity: more accurate predictor for ribavirin-induced anemia in hepatitis C infected patients than ITPA genotype. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015, 53, 2021-9.	1.4	10
557	Flaviviridae Replication Organelles: Oh, What a Tangled Web We Weave. <i>Annual Review of Virology</i> , 2015, 2, 289-310.	3.0	154
558	Effect of IL28B genotype on hepatitis B and C virus infection. <i>Current Opinion in Virology</i> , 2015, 14, 50-55.	2.6	22
559	Prevalence of hepatitis C virus in patients with tuberculosis and its impact in the incidence of anti-tuberculosis drugs induced hepatotoxicity. <i>The Egyptian Journal of Chest Diseases and Tuberculosis</i> , 2015, 64, 91-96.	0.1	8
560	Evaluation of the Elecsys® Anti-HCV II assay for routine hepatitis C virus screening of different Asian Pacific populations and detection of early infection. <i>Journal of Clinical Virology</i> , 2015, 64, 20-27.	1.6	20
561	Cost-effectiveness model for hepatitis C screening and treatment: Implications for Egypt and other countries with high prevalence. <i>Global Public Health</i> , 2015, 10, 296-317.	1.0	55
562	Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimen. <i>The ANRS CO20-CUIC study. Clinics and Research in Hepatology and Gastroenterology</i> , 2015, 39, 443-450.	0.7	5
563	Hepatitis C Virus Attenuates Mitochondrial Lipid β -Oxidation by Downregulating Mitochondrial Trifunctional-Protein Expression. <i>Journal of Virology</i> , 2015, 89, 4092-4101.	1.5	30
564	Virus-driven autoimmunity and lymphoproliferation: the example of HCV infection. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 15-31.	1.3	73
565	IL-26 is overexpressed in chronically HCV-infected patients and enhances TRAIL-mediated cytotoxicity and interferon production by human NK cells. <i>Gut</i> , 2015, 64, 1466-1475.	6.1	49
566	Prodrugs of imidazotriazine and pyrrolotriazine C-nucleosides can increase anti-HCV activity and enhance nucleotide triphosphate concentrations in vitro. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 869-873.	1.0	13
567	Impact of Treatment against Hepatitis C Virus on Overall Survival of Naive Patients with Advanced Liver Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 803-810.	1.4	9
568	AP-2-Associated Protein Kinase 1 and Cyclin G-Associated Kinase Regulate Hepatitis C Virus Entry and Are Potential Drug Targets. <i>Journal of Virology</i> , 2015, 89, 4387-4404.	1.5	100

#	ARTICLE	IF	CITATIONS
569	The Clinical Significance of Autoantibodies in Hepatitis C Patients Submitted to Interferon Treatment. <i>GE Portuguese Journal of Gastroenterology</i> , 2015, 22, 24-27.	0.3	3
570	Cognitive function and endogenous cytokine levels in children with chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2015, 22, 665-670.	1.0	20
571	Insulin resistance as a predictor of early virologic response to HCV therapy among chronic HCV Egyptian Patients. <i>Journal of Medical Virology</i> , 2015, 87, 428-440.	2.5	6
572	Revolution in hepatitis C antiviral therapy. <i>British Medical Bulletin</i> , 2015, 113, 31-44.	2.7	34
573	Predicting the Impact of Adverse Events and Treatment Duration on Medical Resource Utilization-Related Costs in Hepatitis C Genotype 1 Treatment-Naïve Patients Receiving Antiviral Therapy. <i>Pharmacoeconomics</i> , 2015, 33, 409-422.	1.7	4
574	Seroprevalence of hepatitis C infection in type 2 diabetes mellitus. <i>Indian Journal of Endocrinology and Metabolism</i> , 2015, 19, 296.	0.2	12
575	Grazoprevir and elbasvir: a second-generation protease inhibitor and a second-generation NS5A inhibitor in a combination regimen for treatment of chronic hepatitis C. <i>Future Virology</i> , 2015, 10, 691-698.	0.9	1
576	Rapid detection of HCV genotyping 1a, 1b, 2a, 3a, 3b and 6a in a single reaction using two-melting temperature codes by a real-time PCR-based assay. <i>Journal of Virological Methods</i> , 2015, 222, 85-90.	1.0	13
577	Structural Basis for Penetration of the Glycan Shield of Hepatitis C Virus E2 Glycoprotein by a Broadly Neutralizing Human Antibody. <i>Journal of Biological Chemistry</i> , 2015, 290, 10117-10125.	1.6	69
578	Spontaneous Clearance of Hepatitis C Genotype 4 After Liver Replantation. <i>Transplantation Proceedings</i> , 2015, 47, 1234-1237.	0.3	4
579	Methodologies for the Analysis of HCV-Specific CD4+ T Cells. <i>Frontiers in Immunology</i> , 2015, 6, 57.	2.2	8
580	Advanced Molecular Surveillance of Hepatitis C Virus. <i>Viruses</i> , 2015, 7, 1153-1188.	1.5	12
581	Hepatitis C virus seroprevalence in the general female population from 8 countries. <i>Journal of Clinical Virology</i> , 2015, 68, 89-93.	1.6	7
582	Association between risk factors, basal viral load, virus genotype and the degree of liver fibrosis with the response to the therapy in patients with chronic hepatitis C virus infection. <i>Vojnosanitetski Pregled</i> , 2015, 72, 505-509.	0.1	4
583	CD81 and CLDN1 polymorphisms and hepatitis C virus infection susceptibility: A case-control study. <i>Gene</i> , 2015, 567, 87-91.	1.0	7
584	Management of HCV in Cirrhosis—a Rapidly Evolving Landscape. <i>Current Gastroenterology Reports</i> , 2015, 17, 443.	1.1	3
585	Current knowledge and future perspectives on acute hepatitis C infection. <i>Clinical Microbiology and Infection</i> , 2015, 21, 797.e9-797.e17.	2.8	30
586	A cost utility analysis of simeprevir used with peginterferon+sofosbuvir in the management of genotype 1 hepatitis C virus infection, from the perspective of the UK National Health Service. <i>Journal of Medical Economics</i> , 2015, 18, 838-849.	1.0	14

#	ARTICLE	IF	CITATIONS
587	A longitudinal study of hepatitis C virus testing and infection status notification on behaviour change in people who inject drugs. <i>Journal of Epidemiology and Community Health</i> , 2015, 69, 745-752.	2.0	21
588	Changing epidemiology of hepatitis C virus genotypes in the central region of Argentina. <i>Archives of Virology</i> , 2015, 160, 909-915.	0.9	6
589	Hepatitis B and C virus infections among patients with end stage renal disease in a low-resourced hemodialysis center in Vietnam: a cross-sectional study. <i>BMC Public Health</i> , 2015, 15, 192.	1.2	34
590	Risk factors of hepatitis C virus transmission and genotype distribution in former blood donors from Chinese rural area. <i>BMC Public Health</i> , 2015, 15, 184.	1.2	13
591	First-generation protease inhibitor-triple therapy: SVR 24, safety, and predictors of response in a large single center cohort. <i>Virology Journal</i> , 2015, 12, 37.	1.4	11
592	Health in the sustainable development goals: ready for a paradigm shift?. <i>Globalization and Health</i> , 2015, 11, 13.	2.4	263
593	Early IFN type I response: Learning from microbial evasion strategies. <i>Seminars in Immunology</i> , 2015, 27, 85-101.	2.7	42
594	Telaprevir Experience From Turkey. <i>Hepatitis Monthly</i> , 2015, 15, e25639.	0.1	2
595	Extrahepatic manifestations in chronic hepatitis C virus carriers. <i>Lupus</i> , 2015, 24, 469-482.	0.8	46
596	Long-Term Follow-Up of Chronic Hepatitis C Patients Treated with Interferon-Alpha: Risk of Cirrhosis and Hepatocellular Carcinoma in a Single Center over 10 Years. <i>Intervirology</i> , 2015, 58, 14-21.	1.2	0
597	Discovery of HCV NS5B thumb site I inhibitors: Core-refining from benzimidazole to indole scaffold. <i>European Journal of Medicinal Chemistry</i> , 2015, 94, 218-228.	2.6	24
598	Synthesis of Bis-Macrocyclic HCV Protease Inhibitor MK-6325 via Intramolecular sp ² -sp ³ Suzuki-Miyaura Coupling and Ring Closing Metathesis. <i>Organic Letters</i> , 2015, 17, 1533-1536.	2.4	23
599	Combination of pharmacophore hypothesis and molecular docking to identify novel inhibitors of HCV NS5B polymerase. <i>Molecular Diversity</i> , 2015, 19, 529-539.	2.1	3
600	Early virological response may predict treatment response in sofosbuvir-based combination therapy of chronic hepatitis c in a multi-center "real-life" cohort. <i>BMC Gastroenterology</i> , 2015, 15, 97.	0.8	19
601	Hepatitis C Genotype 3: The Remaining Problem. <i>Current Hepatology Reports</i> , 2015, 14, 267-273.	0.4	0
602	Severity of liver disease among chronic hepatitis C patients: An observational study of 4594 patients in five European countries. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 364-371.	1.4	9
603	Hepatitis C virus infection and spontaneous clearance in HTLV-1 and HIV co-infected patients in Salvador, Bahia, Brazil. <i>Brazilian Journal of Infectious Diseases</i> , 2015, 19, 486-491.	0.3	15
604	ITPA and SLC29A1 Genotyping for the Prediction of Ribavirin Dose Reduction in Anti-HCV Triple Therapy with Protease Inhibitors. <i>Pharmacology</i> , 2015, 96, 163-166.	0.9	2

#	ARTICLE	IF	CITATIONS
605	Immunopathogenesis of Hepatitis C Virus Infection. <i>Gastroenterology Clinics of North America</i> , 2015, 44, 735-760.	1.0	11
606	Y-Box Binding Protein 1 Stabilizes Hepatitis C Virus NS5A via Phosphorylation-Mediated Interaction with NS5A To Regulate Viral Propagation. <i>Journal of Virology</i> , 2015, 89, 11584-11602.	1.5	11
607	Micropatterned coculture of primary human hepatocytes and supportive cells for the study of hepatotropic pathogens. <i>Nature Protocols</i> , 2015, 10, 2027-2053.	5.5	119
608	Emerging treatments for chronic hepatitis C. <i>Journal of the Formosan Medical Association</i> , 2015, 114, 204-215.	0.8	32
609	A comprehensive hepatitis C virus risk factors meta-analysis (1989-2013); Do they differ in Egypt?. <i>Liver International</i> , 2015, 35, 489-501.	1.9	37
610	Targeted hepatitis C antibody testing interventions: a systematic review and meta-analysis. <i>European Journal of Epidemiology</i> , 2015, 30, 115-129.	2.5	32
611	NS5B induces up-regulation of the BH3-only protein, BIK, essential for the hepatitis C virus RNA replication and viral release. <i>Virology</i> , 2015, 474, 41-51.	1.1	8
612	Simeprevir (TMC435) once daily with peginterferon-2b and ribavirin in patients with genotype 1 hepatitis C virus infection: The CONCERTO-4 study. <i>Hepatology Research</i> , 2015, 45, 501-513.	1.8	50
613	Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. <i>Gut</i> , 2015, 64, 948-956.	6.1	101
614	Derivation of Phase 3 dosing for peginterferon lambda1a in chronic hepatitis C, Part 2: Exposure-response analyses for efficacy and safety variables. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 73-80.	1.0	8
615	Value of E-gamma-S core in diagnosis of significant, advanced hepatic fibrosis and cirrhosis compared to aspartate aminotransferase-to-platelet ratio index, FIB-4 and Forns' index in chronic hepatitis C virus. <i>Hepatology Research</i> , 2015, 45, 560-570.	1.8	17
616	Identification and full-length molecular characterization of rare hepatitis C virus genotype 5a from India. <i>Archives of Virology</i> , 2015, 160, 329-333.	0.9	3
617	Ribavirin dose reduction during telaprevir/ribavirin/peginterferon therapy overcomes the effect of the ITPA gene polymorphism. <i>Journal of Viral Hepatitis</i> , 2015, 22, 166-174.	1.0	11
618	Hepatitis C Virus. , 0, , 351-361.		0
620	IMPACT OF THE PEGYLATED-INTERFERON AND RIBAVIRIN THERAPY ON THE TREATMENT-RELATED MORTALITY OF PATIENTS WITH CIRRHOSIS DUE TO HEPATITIS C VIRUS. <i>Revista Do Instituto De Medicina Tropical De Sao Paulo</i> , 2016, 58, 37.	0.5	1
621	Performance study of the automated immunoassay test anti-hepatitis C virus VIDAS® for the qualitative detection of antibodies anti-hepatitis C virus. <i>Microbiologia Medica</i> , 2016, 31, .	0.3	2
622	The Impact of Delayed Hepatitis C Viral Load Suppression on Patient Risk: Historical Evidence from the Veterans Administration. <i>Forum for Health Economics and Policy</i> , 2016, 19, 333-351.	0.2	5
623	Conceptual framework for outcomes research studies of hepatitis C: an analytical review. <i>Infection and Drug Resistance</i> , 2016, 9, 101.	1.1	0

#	ARTICLE	IF	CITATIONS
624	Hepatitis C virus prevalence and genotype distribution in Pakistan: Comprehensive review of recent data. <i>World Journal of Gastroenterology</i> , 2016, 22, 1684.	1.4	110
625	Hepatitis C Virus Treatment Access Among Human Immunodeficiency Virus and Hepatitis C Virus (HCV)-Coinfected People Who Inject Drugs in Guangzhou, China: Implications for HCV Treatment Expansion. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw065.	0.4	8
626	Successful outcome of therapy of acute hepatitis C following sexual and parenteral exposure – report of two cases. <i>Clinical and Experimental Hepatology</i> , 2016, 3, 128-131.	0.6	0
627	Prevalence of Hepatitis C Virus Genotypes Among Patients in Countries of the Eastern Mediterranean Regional Office of WHO (EMRO): A Systematic Review and Meta-Analysis. <i>Hepatitis Monthly</i> , 2016, 16, e35558.	0.1	28
628	HCV and Oxidative Stress: Implications for HCV Life Cycle and HCV-Associated Pathogenesis. <i>Oxidative Medicine and Cellular Longevity</i> , 2016, 2016, 1-13.	1.9	62
629	Ion Channels and Oxidative Stress as a Potential Link for the Diagnosis or Treatment of Liver Diseases. <i>Oxidative Medicine and Cellular Longevity</i> , 2016, 2016, 1-17.	1.9	55
630	An outbreak of HCV genotype 6a and 2a infection in South China: Confirmation of iatrogenic transmission by phylogenetic analysis of the NS5B region. <i>Molecular Medicine Reports</i> , 2016, 14, 4285-4292.	1.1	2
631	Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12. <i>World Journal of Gastroenterology</i> , 2016, 22, 8050.	1.4	43
632	The Economic Burden of Hepatitis A, B, and C in South Korea. <i>Japanese Journal of Infectious Diseases</i> , 2016, 69, 18-27.	0.5	21
633	Hepatitis C Virus Infection Induces Autophagy as a Prosurvival Mechanism to Alleviate Hepatic ER-Stress Response. <i>Viruses</i> , 2016, 8, 150.	1.5	64
634	Hepatitis C virus: Promising discoveries and new treatments. <i>World Journal of Gastroenterology</i> , 2016, 22, 6393.	1.4	19
635	A Synthesis of Hepatitis C prevalence estimates in Sub-Saharan Africa: 2000–2013. <i>BMC Infectious Diseases</i> , 2016, 16, 283.	1.3	32
636	Intrinsic Viral Factors Are the Dominant Determinants of the Hepatitis C Virus Response to Interferon Alpha Treatment in Chimeric Mice. <i>PLoS ONE</i> , 2016, 11, e0147007.	1.1	1
637	Discovery of Novel Hepatitis C Virus NS5B Polymerase Inhibitors by Combining Random Forest, Multiple e-Pharmacophore Modeling and Docking. <i>PLoS ONE</i> , 2016, 11, e0148181.	1.1	40
638	The NS4A Cofactor Dependent Enhancement of HCV NS3 Protease Activity Correlates with a 4D Geometrical Measure of the Catalytic Triad Region. <i>PLoS ONE</i> , 2016, 11, e0168002.	1.1	6
639	Treat chronic hepatitis C virus infection in decompensated cirrhosis – pre- or post-liver transplantation? the ironic conundrum in the era of effective and well-tolerated therapy. <i>Journal of Viral Hepatitis</i> , 2016, 23, 408-418.	1.0	69
640	Comparison of Elecsys Anti-HCV II Assay With Other HCV Screening Assays. <i>Journal of Clinical Laboratory Analysis</i> , 2016, 30, 451-456.	0.9	4
641	<i>n</i> <sc>polyunsaturated fatty acid</sc> supplementation reduces insulin resistance in <sc>hepatitis C virus</sc> infected patients: a randomised controlled trial. <i>Journal of Human Nutrition and Dietetics</i> , 2016, 29, 345-353.	1.3	6

#	ARTICLE	IF	CITATIONS
642	High baseline bilirubin and low albumin predict liver decompensation and serious adverse events in <sc>HCV</sc>-infected patients treated with sofosbuvir-containing regimens. <i>Journal of Viral Hepatitis</i> , 2016, 23, 667-676.	1.0	5
643	Host genetic variants influencing the clinical course of hepatitis C virus infection. <i>Journal of Medical Virology</i> , 2016, 88, 185-195.	2.5	46
644	Epidemiology of hepatitis C virus infection in a large Israeli health maintenance organization. <i>Journal of Medical Virology</i> , 2016, 88, 1044-1050.	2.5	14
645	Toward a simple risk assessment screening tool for HCV infection in Egypt. <i>Journal of Medical Virology</i> , 2016, 88, 1767-1775.	2.5	6
646	Why is viral eradication so important in patients with HCV-related cirrhosis?. <i>Antiviral Therapy</i> , 2016, 22, 1-12.	0.6	9
647	Molecular alterations in the carcinogenesis and progression of hepatocellular carcinoma: Tumor factors and background liver factors. <i>Oncology Letters</i> , 2016, 12, 3662-3668.	0.8	14
648	Elevated on-treatment levels of serum IFN-gamma is associated with treatment failure of peginterferon plus ribavirin therapy for chronic hepatitis C. <i>Scientific Reports</i> , 2016, 6, 22995.	1.6	7
649	Molecular characterization of HCV in a Swedish county over 8 years (2002-2009) reveals distinct transmission patterns. <i>Infection Ecology and Epidemiology</i> , 2016, 6, 30670.	0.5	3
650	HCV RNA Activates APCs via TLR7/TLR8 While Virus Selectively Stimulates Macrophages Without Inducing Antiviral Responses. <i>Scientific Reports</i> , 2016, 6, 29447.	1.6	42
651	Biotransformation of Daclatasvir In Vitro and in Nonclinical Species: Formation of the Main Metabolite by Pyrrolidine α -Oxidation and Rearrangement. <i>Drug Metabolism and Disposition</i> , 2016, 44, 809-820.	1.7	10
652	Duplication of the V3 domain in hepatitis C virus (1b) NS5A protein: Clonal analysis and physicochemical properties related to hepatocellular carcinoma occurrence. <i>Journal of Clinical Virology</i> , 2016, 74, 19-25.	1.6	2
653	A Systematic Review of Race and Ethnicity in Hepatitis C Clinical Trial Enrollment. <i>Journal of the National Medical Association</i> , 2016, 108, 24-29.	0.6	30
654	An atom-efficient and convergent approach to the preparation of NS5A inhibitors by C-H activation. <i>Organic and Biomolecular Chemistry</i> , 2016, 14, 3307-3313.	1.5	7
655	Conditions for eradicating hepatitis C in people who inject drugs: A fibrosis aware model of hepatitis C virus transmission. <i>Journal of Theoretical Biology</i> , 2016, 395, 31-39.	0.8	11
656	Dynamic α -fetoprotein, platelets and AST-to-platelet ratio index predict hepatocellular carcinoma in chronic hepatitis C patients with sustained virological response after antiviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1943-1947.	1.3	22
657	Distribution of hepatitis C virus genotypes in volunteer blood donors from Chengdu, China. <i>Archives of Virology</i> , 2016, 161, 1873-1882.	0.9	3
658	Mouse Hepatitis Virus Infection Induces a Toll-Like Receptor 2-Dependent Activation of Inflammatory Functions in Liver Sinusoidal Endothelial Cells during Acute Hepatitis. <i>Journal of Virology</i> , 2016, 90, 9096-9113.	1.5	18
659	A randomized, controlled study of peginterferon lambda-1a/ribavirin \pm daclatasvir for hepatitis C virus genotype 2 or 3. <i>SpringerPlus</i> , 2016, 5, 1365.	1.2	8

#	ARTICLE	IF	CITATIONS
660	Risk of End-Stage Liver Disease in HIV-Viral Hepatitis Coinfected Persons in North America From the Early to Modern Antiretroviral Therapy Eras. <i>Clinical Infectious Diseases</i> , 2016, 63, ciw531.	2.9	60
661	Suppression of Host Innate Immune Response by Hepatitis C Virus via Induction of Autophagic Degradation of TRAF6. <i>Journal of Virology</i> , 2016, 90, 10928-10935.	1.5	40
662	Lindenane sesquiterpenoid dimers from <i>Chloranthus japonicus</i> inhibit HIV-1 and HCV replication. <i>FÅ-toterapÅ-Åç</i> , 2016, 115, 64-68.	1.1	32
663	Pre- and Post-Transplant Antiviral Therapy (HBV, HCV). <i>Visceral Medicine</i> , 2016, 32, 105-109.	0.5	10
664	HCV dispersal patterns among intravenous drug users (IDUs) in Athens metropolitan area. <i>Infection, Genetics and Evolution</i> , 2016, 45, 415-419.	1.0	3
665	Costâ€effectiveness analysis of sofosbuvir, peginterferon and ribavirin in patients with chronic hepatitis C: Early treatment in the initial stage of fibrosis vs. delayed treatment in advanced fibrosis. <i>GastroenterologÅ Y HepatologÅa (English Edition)</i> , 2016, 39, 449-457.	0.0	4
666	The association between chronic hepatitis C infection and cardiovascular risk. <i>Internal Medicine Journal</i> , 2016, 46, 63-70.	0.5	14
667	Potential market size and impact of hepatitis C treatment in lowâ€and middleâ€income countries. <i>Journal of Viral Hepatitis</i> , 2016, 23, 522-534.	1.0	15
668	Hepatitis C genotype distribution in patient and blood donor samples in South Africa for the period 2008â€2012. <i>Journal of Viral Hepatitis</i> , 2016, 23, 881-888.	1.0	9
669	Hepatitis C virus NS3/4a protease inhibitors. <i>Current Opinion in Pharmacology</i> , 2016, 30, 84-92.	1.7	95
670	Relationship between vitamin A deficiency and the thyroid axis in clinically stable patients with liver cirrhosis related to hepatitis C virus. <i>Applied Physiology, Nutrition and Metabolism</i> , 2016, 41, 985-991.	0.9	4
671	3D-QSAR study and design of 4-hydroxyamino Î±-pyranone carboxamide analogues as potential anti-HCV agents. <i>Chemical Physics Letters</i> , 2016, 661, 36-41.	1.2	2
672	A matched comparison study of hepatitis C treatment outcomes in the prison and community setting, and an analysis of the impact of prison release or transfer during therapy. <i>Journal of Viral Hepatitis</i> , 2016, 23, 1009-1016.	1.0	44
673	IQGAP2 is a novel interferon-alpha antiviral effector gene acting non-conventionally through the NF-Î±B pathway. <i>Journal of Hepatology</i> , 2016, 65, 972-979.	1.8	16
674	Limiting the access to direct-acting antivirals against HCV: an ethical dilemma. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 1227-1234.	1.4	16
675	Wide variation in estimates of global prevalence and burden of chronic hepatitis B and C infection cited in published literature. <i>Journal of Viral Hepatitis</i> , 2016, 23, 545-559.	1.0	43
676	Silybin supplementation during HCV therapy with pegylated interferon-Î± plus ribavirin reduces depression and anxiety and increases work ability. <i>BMC Psychiatry</i> , 2016, 16, 398.	1.1	22
677	Seroprevalence of hepatitis C virus among people living with HIV/AIDS in Latin America and the Caribbean: a systematic review. <i>BMC Infectious Diseases</i> , 2016, 16, 663.	1.3	17

#	ARTICLE	IF	CITATIONS
678	Discovery of 2- <i>N</i> -C-Methyl-2- <i>N</i> -C-fluorouridine Phosphoramidate Prodrugs as Inhibitors of Hepatitis C Virus. <i>ACS Medicinal Chemistry Letters</i> , 2016, 7, 1197-1201.	1.3	9
679	Functional differences in hepatitis C virus nonstructural (NS) 3/4A- and 5A-specific T cell responses. <i>Scientific Reports</i> , 2016, 6, 24991.	1.6	0
680	Host Genetics and Responses to Antiviral Therapy in Chronic Hepatitis C. , 2016, , 225-241.		0
681	Process Chemistry in Antiviral Research. <i>Topics in Current Chemistry</i> , 2016, 374, 77.	3.0	4
682	The Strange, Expanding World of Animal Hepaciviruses. <i>Annual Review of Virology</i> , 2016, 3, 53-75.	3.0	79
683	Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes. <i>World Journal of Gastroenterology</i> , 2016, 22, 7824.	1.4	621
684	A disease spectrum for ITPA variation: advances in biochemical and clinical research. <i>Journal of Biomedical Science</i> , 2016, 23, 73.	2.6	26
685	Does Epoetin Beta Still Have a Place in Peginterferon Alpha-2a Plus Ribavirin Treatment Strategies for Chronic Hepatitis C?. <i>Journal of Interferon and Cytokine Research</i> , 2016, 36, 204-214.	0.5	1
686	Suppressor of cytokine signaling 1 expression in peripheral blood mononuclear cells of hepatitis C genotype 1 patients. <i>Journal of the Formosan Medical Association</i> , 2016, 115, 440-444.	0.8	4
688	Hepatitis C virus treatment update " A new era of all-oral HCV treatment. <i>Advances in Digestive Medicine</i> , 2016, 3, 153-160.	0.1	10
689	Simeprevir with peginterferon/ribavirin for patients with hepatitis C virus genotype 1: high frequency of viral relapse in elderly patients. <i>SpringerPlus</i> , 2016, 5, 518.	1.2	4
690	Efficacy and safety of combined pegylated interferon/ribavirin therapy in the management of rheumatological manifestations of chronic HCV patients. <i>Egyptian Rheumatologist</i> , 2016, 38, 53-59.	0.5	4
691	Genetic variation in <i>PTX3</i> and plasma levels associated with hepatocellular carcinoma in patients with <i>HCV</i> . <i>Journal of Viral Hepatitis</i> , 2016, 23, 116-122.	1.0	45
692	Association of Catalase and Glutathione Peroxidase 1 Polymorphisms with Chronic Hepatitis C Outcome. <i>Annals of Human Genetics</i> , 2016, 80, 145-153.	0.3	21
693	Emerging roles of interferon-stimulated genes in the innate immune response to hepatitis C virus infection. <i>Cellular and Molecular Immunology</i> , 2016, 13, 11-35.	4.8	91
694	Process Development of the HCV NS5B Site D Inhibitor MK-8876. <i>Organic Process Research and Development</i> , 2016, 20, 1227-1238.	1.3	8
695	Multiregion deep sequencing of hepatitis C virus: An improved approach for genetic relatedness studies. <i>Infection, Genetics and Evolution</i> , 2016, 38, 138-145.	1.0	9
696	Pan-genotypic Hepatitis C Virus Inhibition by Natural Products Derived from the Wild Egyptian Artichoke. <i>Journal of Virology</i> , 2016, 90, 1918-1930.	1.5	44

#	ARTICLE	IF	CITATIONS
697	Pediatric liver diseases: current challenges and future perspectives. Expert Review of Gastroenterology and Hepatology, 2016, 10, 255-265.	1.4	21
698	Safety and efficacy of ledipasvir+sophosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data. Hepatology, 2016, 63, 437-444.	3.6	55
699	3D-QSAR and molecular docking studies on designing inhibitors of the hepatitis C virus NS5B polymerase. Journal of Molecular Structure, 2016, 1117, 227-239.	1.8	24
700	Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology, 2016, 63, 1493-1505.	3.6	397
701	Optimizing HCV treatment – Moving beyond the cost conundrum. Journal of Hepatology, 2016, 65, 222-225.	1.8	9
702	Interferon-inducible protein SCOTIN interferes with HCV replication through the autolysosomal degradation of NS5A. Nature Communications, 2016, 7, 10631.	5.8	57
703	Cellular Mechanism for Impaired Hepatitis C Virus Clearance by Interferon Associated with IFNL3 Gene Polymorphisms Relates to Intrahepatic Interferon- β Expression. American Journal of Pathology, 2016, 186, 938-951.	1.9	13
704	IFNL4 ss469415590 polymorphism contributes to treatment decisions in patients with chronic hepatitis C virus genotype 1b, but not 2a, infection. Infection, Genetics and Evolution, 2016, 39, 132-140.	1.0	7
705	Resistance analysis and characterization of NITD008 as an adenosine analog inhibitor against hepatitis C virus. Antiviral Research, 2016, 126, 43-54.	1.9	17
706	Burden of Hepatitis C Virus Infection Among Older Adults in Long-Term Care Settings: a Systematic Review of the Literature and Meta-Analysis. Current Infectious Disease Reports, 2016, 18, 13.	1.3	6
707	Characteristics of anti-hepatitis C virus antibody-positive patients in a hospital setting in Douala, Cameroon. International Journal of Infectious Diseases, 2016, 45, 53-58.	1.5	13
708	Characterization of β -taxilin as a novel factor controlling the release of hepatitis C virus. Biochemical Journal, 2016, 473, 145-155.	1.7	10
709	Entry inhibitors: New advances in HCV treatment. Emerging Microbes and Infections, 2016, 5, 1-8.	3.0	52
710	Profile of oxidative stress markers is dependent on vitamin D levels in patients with chronic hepatitis C. Nutrition, 2016, 32, 362-367.	1.1	27
711	Modeling hepatitis C virus transmission among people who inject drugs: Assumptions, limitations and future challenges. Virulence, 2016, 7, 201-208.	1.8	16
712	A Conserved Inhibitory Mechanism of a Lycorine Derivative against Enterovirus and Hepatitis C Virus. Antimicrobial Agents and Chemotherapy, 2016, 60, 913-924.	1.4	44
713	Phylogenetic analysis of a circulating hepatitis C virus recombinant strain 1b/1a isolated in a French hospital centre. Infection, Genetics and Evolution, 2016, 40, 374-380.	1.0	5
714	A Parallel Sliding Region Algorithm to Make Agent-Based Modeling Possible for a Large-Scale Simulation: Modeling Hepatitis C Epidemics in Canada. IEEE Journal of Biomedical and Health Informatics, 2016, 20, 1538-1544.	3.9	6

#	ARTICLE	IF	CITATIONS
715	Daclatasvir + sofosbuvir versus standard of care for hepatitis C genotype 3: a matching-adjusted indirect comparison. <i>Journal of Comparative Effectiveness Research</i> , 2016, 5, 129-139.	0.6	6
716	Searching for anthranilic acid-based thumb pocket 2 HCV NS5B polymerase inhibitors through a combination of molecular docking, 3D-QSAR and virtual screening. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2016, 31, 38-52.	2.5	30
717	Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis. <i>Pharmacogenomics Journal</i> , 2016, 16, 18-29.	0.9	10
718	Distribution of IL28B Polymorphism in a Cohort of Italians and Immigrants with HCV Infection: Association with Viraemia, Stage of Fibrosis and Response to Treatment. <i>Journal of Immigrant and Minority Health</i> , 2017, 19, 876-882.	0.8	2
719	Integration of VEGF and Î±-SMA Expression Improves the Prediction Accuracy of Fibrosis in Chronic Hepatitis C Liver Biopsy. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2017, 25, 261-270.	0.6	11
720	Efficacy of daclatasvir/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1. <i>Journal of Gastroenterology</i> , 2017, 52, 94-103.	2.3	38
721	Chronic hepatitis C: less of a problem than first thought?. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 146-147.	3.7	4
722	Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 161-176.	3.7	1,619
723	Sofosbuvir-based treatment regimens: real life results of 14 409 chronic <sc>HCV</sc> genotype 4 patients in Egypt. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 681-687.	1.9	65
724	Pegylated interferon Î±/ribavirin therapy enhances bone mineral density in children with chronic genotype 4 HCV infection. <i>World Journal of Pediatrics</i> , 2017, 13, 346-352.	0.8	4
725	Ongoing incident hepatitis C virus infection among people with a history of injecting drug use in an Australian prison setting, 2005-2014: The <sc>HITS</sc> study. <i>Journal of Viral Hepatitis</i> , 2017, 24, 733-741.	1.0	61
726	Hepatitis C virus may have an entero-hepatic cycle which could be blocked with ezetimibe. <i>Medical Hypotheses</i> , 2017, 102, 51-55.	0.8	1
727	Unraveling the structural basis of grazoprevir potency against clinically relevant substitutions in hepatitis C virus NS3/4A protease from genotype 1a. <i>Journal of Biological Chemistry</i> , 2017, 292, 6202-6212.	1.6	9
728	A single-step multiplex quantitative real time polymerase chain reaction assay for hepatitis C virus genotypes. <i>Journal of Translational Internal Medicine</i> , 2017, 5, 34-42.	1.0	2
729	Hepatitis C in a Mobile Low-Threshold Methadone Program. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 657-662.	0.8	9
730	Discovery and mechanism of action of Novel Baicalein modified derivatives as potent antihepatitis agent. <i>Virology</i> , 2017, 507, 199-205.	1.1	6
731	Discovery of Î²-d-2â€²-deoxy-2â€²-dichlorouridine nucleotide prodrugs as potent inhibitors of hepatitis C virus replication. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 3468-3471.	1.0	17
732	Hepatitis C Virus Genotyping Using Next-Generation Sequencing: An Efficient Alternative to Sanger Sequencing. <i>Archives of Pathology and Laboratory Medicine</i> , 2017, 141, 323-324.	1.2	2

#	ARTICLE	IF	CITATIONS
733	2â€²-Chloro,2â€²-fluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in Culture. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 5424-5437.	2.9	23
734	Prediction of viral loads for diagnosis of Hepatitis C infection in human plasma samples using Raman spectroscopy coupled with partial least squares regression analysis. <i>Journal of Raman Spectroscopy</i> , 2017, 48, 697-704.	1.2	61
735	Hepatitis C Virus and Kidney Disease: Evidence, Hope, and Hurdles. <i>Nephron</i> , 2017, 136, 51-53.	0.9	2
736	Detection of high biliary and fecal viral loads in patients with chronic hepatitis C virus infection. <i>GastroenterologÃa Y HepatologÃa</i> , 2017, 40, 339-347.	0.2	1
737	Clinical evaluation of sofosbuvir/ledipasvir in patients with chronic hepatitis C genotype 1 with and without prior daclatasvir/asunaprevir therapy. <i>Hepatology Research</i> , 2017, 47, 1308-1316.	1.8	36
738	Why highly effective drugs are not enough: the need for an affordable solution to eliminating HCV. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 583-594.	1.3	33
739	Does active hepatitis C virus infection increase the risk for infection due to <i>Staphylococcus aureus</i> ?. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2017, 36, 1217-1223.	1.3	10
740	Hepatitis C virus NS3 protein enhances hepatocellular carcinoma cell invasion by promoting PPM1A ubiquitination and degradation. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 42.	3.5	23
741	Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States. <i>Journal of Medical Economics</i> , 2017, 20, 692-702.	1.0	7
742	The practical management of chronic hepatitis C infection in Japan - dual therapy of daclatasvir + asunaprevir. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 103-113.	1.4	6
743	Current level of evidence on causal association between hepatitis C virus and type 2 diabetes: A review. <i>Journal of Advanced Research</i> , 2017, 8, 149-159.	4.4	39
744	Effectiveness and safety of ombitasvir, paritaprevir, ritonavir Å± dasabuvir Å± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2017, 24, 226-237.	1.0	22
745	Relationship between sex hormones and RIG-I signaling in peripheral blood mononuclear cells of patients infected with hepatitis C virus. <i>Experimental and Therapeutic Medicine</i> , 2017, 14, 2728-2732.	0.8	4
746	Effect of Chronic Hepatitis C Virus Treatment by Combination Therapy on Cardiovascular System. <i>Clinical Medicine Insights: Cardiology</i> , 2017, 11, 117954681771320.	0.6	9
747	Synthesis and anti-HCV activity of a series of Î²- d -2â€²-deoxy-2â€²-dibromo nucleosides and their corresponding phosphoramidate prodrugs. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 5296-5299.	1.0	12
748	Hepatitis C Virus-Associated Cancers. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1018, 129-146.	0.8	23
749	Subtyping of hepatitis C virus with high resolution mass spectrometry. <i>Clinical Mass Spectrometry</i> , 2017, 4-5, 19-24.	1.9	8
750	Chemical genetics-based development of small molecules targeting hepatitis C virus. <i>Archives of Pharmacal Research</i> , 2017, 40, 1021-1036.	2.7	6

#	ARTICLE	IF	CITATIONS
751	Oxidative Stress and Immune Responses During Hepatitis C Virus Infection in <i>Tupaia belangeri</i> . <i>Scientific Reports</i> , 2017, 7, 9848.	1.6	18
752	Management and Treatment of Chronic HBV and HCV Co-Infection and the Impact of Anti-Viral Therapy. <i>Current Hepatology Reports</i> , 2017, 16, 169-177.	0.4	3
753	Cost-effectiveness analysis of two treatment strategies for chronic hepatitis C before and after access to direct-acting antivirals in Spain. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2017, 40, 433-446.	0.0	7
754	Análisis coste-efectividad de dos estrategias de tratamiento para la hepatitis C crónica: antes y después del acceso a los agentes antivirales de acción directa en España. <i>Gastroenterología Y Hepatología</i> , 2017, 40, 433-446.	0.2	16
755	Estudio de impacto presupuestal de Daclatasvir asociado a Asunaprevir desde la perspectiva del sistema de salud público chileno. <i>Value in Health Regional Issues</i> , 2017, 14, 28-32.	0.5	1
756	Long-term challenges and perspectives of pre-adolescent liver disease. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 435-445.	3.7	20
757	Clinical Evaluation of Therap C Vaccine in Combined Treatment with Interferon and Ribavirin in Patients with Hepatitis C. <i>Current Therapeutic Research</i> , 2017, 85, 20-28.	0.5	1
758	Unconjugated interferon- ϵ stimulated gene 15 specifically interacts with the hepatitis C virus NS5A protein via domain I. <i>Microbiology and Immunology</i> , 2017, 61, 287-292.	0.7	9
759	Interferons command Trim22 to fight against viruses. <i>Cellular and Molecular Immunology</i> , 2017, 14, 794-796.	4.8	17
760	DOT-C: A cluster randomised feasibility trial evaluating directly observed anti-HCV therapy in a population receiving opioid substitute therapy from community pharmacy. <i>International Journal of Drug Policy</i> , 2017, 47, 126-136.	1.6	51
761	Discovery of Novel Nucleotide Prodrugs with Improved Potency Against HCV Variants Carrying NS5B S282T Mutation. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 6077-6088.	2.9	8
762	EGFR rs11506105 and IFNL3 SNPs but not rs8099917 are strongly associated with treatment responses in Iranian patients with chronic hepatitis C. <i>Genes and Immunity</i> , 2017, 18, 144-151.	2.2	11
763	Cell division cycle 34 is highly expressed in hepatitis C virus-positive hepatocellular carcinoma with favorable phenotypes. <i>Biomedical Reports</i> , 2017, 7, 41-46.	0.9	3
764	Detection of high biliary and fecal viral loads in patients with chronic hepatitis C virus infection. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2017, 40, 339-347.	0.0	1
765	Combination of sofosbuvir, pegylated-interferon and ribavirin for treatment of hepatitis C virus genotype 1 infection: a systematic review and meta-analysis. <i>DARU, Journal of Pharmaceutical Sciences</i> , 2017, 25, 11.	0.9	26
766	Prevalence of HCV Infection in General Population of District Malakand, Pakistan: A Comparative Analysis of the Diagnostic Techniques. <i>Arabian Journal for Science and Engineering</i> , 2017, 42, 2201-2205.	1.7	0
767	Role of Interleukin-22 in chronic liver injury. <i>Cytokine</i> , 2017, 98, 107-114.	1.4	25
768	Knowledge, attitude and behaviour regarding hepatitis C virus infection amongst Brazilian dental students. <i>European Journal of Dental Education</i> , 2017, 21, e76-e82.	1.0	10

#	ARTICLE	IF	CITATIONS
769	Comparative treatment effectiveness of direct acting antiviral regimens for hepatitis C: Data from the Veterans administration. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1136-1142.	1.4	28
770	New potent biaryl sulfate-based hepatitis C virus inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2017, 125, 87-100.	2.6	8
771	Safety Profile of Telaprevir-Based Triple Therapy in Elderly Patients: A Real-World Retrospective Cohort Study. <i>Biological and Pharmaceutical Bulletin</i> , 2017, 40, 1525-1529.	0.6	0
772	Efficacy and safety of direct-acting antiviral therapy in previous hard-to-treat patients with recurrent hepatitis C virus infection after liver transplantation: a real-world cohort. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 2131-2138.	2.0	11
773	Prevalence of Diabetes Type 2 in Hepatitis C Infected Patients in Kpk, Pakistan. <i>BioMed Research International</i> , 2017, 2017, 1-4.	0.9	3
774	Association of Toll-Like Receptor 3 Single-Nucleotide Polymorphisms and Hepatitis C Virus Infection. <i>Journal of Immunology Research</i> , 2017, 2017, 1-11.	0.9	18
775	Initial results of efficacy and safety of Sofosbuvir among Pakistani Population: A real life trial Hepatitis Eradication Accuracy Trial of Sofosbuvir (HEATS). <i>Pakistan Journal of Medical Sciences</i> , 2017, 33, 48-52.	0.3	9
776	HIV and hepatitis B and C co-infection among people who inject drugs in Zanzibar. <i>BMC Public Health</i> , 2017, 17, 917.	1.2	15
777	Diagnostic accuracy of tests to detect Hepatitis C antibody: a meta-analysis and review of the literature. <i>BMC Infectious Diseases</i> , 2017, 17, 695.	1.3	89
778	Natural Killer Cells in HCV Infection. <i>Journal of Clinical & Cellular Immunology</i> , 2017, 08, .	1.5	0
779	Exposure source prevalence is associated with gender in hepatitis C virus patients from Rio de Janeiro, Brazil. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2017, 112, 632-639.	0.8	7
780	Interrelationship of hepatitis C virus genotypes with patient characteristics in Bahrain. <i>Hepatic Medicine: Evidence and Research</i> , 2017, Volume 9, 7-11.	0.9	3
781	Statins and the risk of cirrhosis in hepatitis B or C patients: a systematic review and dose-response meta-analysis of observational studies. <i>Oncotarget</i> , 2017, 8, 59666-59676.	0.8	10
782	Prevalence of hepatitis C virus infection among hemodialysis patients in the Middle-East: A systematic review and meta-analysis. <i>World Journal of Gastroenterology</i> , 2017, 23, 151.	1.4	53
783	Lack of Association between Hepatitis C Virus core Gene Variation 70/91aa and Insulin Resistance. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1444.	1.8	2
784	Successful Treatment of Oral Lichen Planus with Direct-Acting Antiviral Agents after Liver Transplantation for Hepatitis C Virus-Associated Hepatocellular Carcinoma. <i>Case Reports in Gastroenterology</i> , 2018, 11, 701-710.	0.3	9
785	Longitudinal injecting risk behaviours among people with a history of injecting drug use in an Australian prison setting: The HITS-p study. <i>International Journal of Drug Policy</i> , 2018, 54, 18-25.	1.6	46
786	Safety of biologic agents for psoriasis in patients with viral hepatitis. <i>Journal of Dermatological Treatment</i> , 2018, 29, 553-556.	1.1	11

#	ARTICLE	IF	CITATIONS
787	Pharmacokinetics, Safety, and Tolerability of Single-Dose Elbasvir in Participants with Hepatic Impairment. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2018, 43, 321-329.	0.6	4
788	Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: a meta-analysis. <i>Gut</i> , 2018, 67, 2025-2034.	6.1	104
789	A facile synthesis of 3D NiFe ₂ O ₄ nanospheres anchored on a novel ionic liquid modified reduced graphene oxide for electrochemical sensing of ledipasvir: Application to human pharmacokinetic study. <i>Biosensors and Bioelectronics</i> , 2018, 109, 164-170.	5.3	70
790	The effect of the first-generation HCV-protease inhibitors boceprevir and telaprevir and the relation to baseline NS3 resistance mutations in genotype 1: experience from a small Swedish cohort. <i>Upsala Journal of Medical Sciences</i> , 2018, 123, 50-56.	0.4	6
791	The seroprevalence of hepatitis B, hepatitis C, and human immunodeficiency virus in patients undergoing septoplasty. <i>Brazilian Journal of Otorhinolaryngology</i> , 2018, 84, 34-39.	0.4	3
792	A critical review on hepatoprotective effects of bioactive food components. <i>Critical Reviews in Food Science and Nutrition</i> , 2018, 58, 1165-1229.	5.4	45
793	Should we treat acute hepatitis C? A decision and cost-effectiveness analysis. <i>Hepatology</i> , 2018, 67, 837-846.	3.6	61
794	Maternal viral mimetic administration at the beginning of fetal hypothalamic nuclei development accelerates puberty in female rat offspring. <i>Canadian Journal of Physiology and Pharmacology</i> , 2018, 96, 506-514.	0.7	4
795	Authentic Patient-Derived Hepatitis C Virus Infects and Productively Replicates in Primary CD4 ⁺ and CD8 ⁺ T Lymphocytes <i>In Vitro</i> . <i>Journal of Virology</i> , 2018, 92, .	1.5	15
796	Prediction of Health Utility Scores in Patients with Chronic Hepatitis C Using the Chronic Liver Disease Questionnaire-Hepatitis C Version (CLDQ-HCV). <i>Value in Health</i> , 2018, 21, 612-621.	0.1	8
797	Impact of hepatitis C virus (HCV) antiviral treatment on the need for liver transplantation (LT). <i>Liver International</i> , 2018, 38, 1022-1027.	1.9	20
798	Usefulness of semiquantitative PCR-invaser assay for selecting candidates for daclatasvir plus asunaprevir combination therapy among patients with hepatitis C virus genotype 1b. <i>Hepatology Research</i> , 2018, 48, 255-263.	1.8	2
799	Hepatitis C virus plays with fire and yet avoids getting burned. A review for clinicians on processing bodies and stress granules. <i>Liver International</i> , 2018, 38, 388-398.	1.9	5
800	Efficacy and safety of sofosbuvir-based, interferon-free therapy. <i>Zeitschrift Fur Rheumatologie</i> , 2018, 77, 621-628.	0.5	8
801	Mechanisms of Disease. , 2018, , 145-157.		0
802	Sofosbuvir-Based Therapy in the Pre-Liver Transplant Setting: The Canadian National Experience. <i>Annals of Hepatology</i> , 2018, 17, 437-443.	0.6	5
803	HEPATITIS C IN THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM: BURDEN OF DISEASE. <i>Arquivos De Gastroenterologia</i> , 2018, 55, 329-337.	0.3	8
804	Metabolic Factors and Their Influence on the Clinical Course and Response to HCV Treatment. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
805	Epidemiology, Natural History, and Diagnosis of Hepatitis C. , 2018, , 428-445.e8.		1
806	An Educational Needs Assessment for Patients with Liver Disease. <i>Journal of the Canadian Association of Gastroenterology</i> , 2018, 1, 54-59.	0.1	6
807	Hepatitis C virus infections and associated risk factors in patients with diabetes mellitus; case control study in North West Tigray, Ethiopia. <i>BMC Research Notes</i> , 2018, 11, 873.	0.6	5
808	Clinical effectiveness of pharmacy-led versus conventionally delivered antiviral treatment for hepatitis C in patients receiving opioid substitution therapy: a study protocol for a pragmatic cluster randomised trial. <i>BMJ Open</i> , 2018, 8, e021443.	0.8	12
809	Hepatitis C and pregnancy outcomes: a systematic review protocol. <i>BMJ Open</i> , 2018, 8, e024288.	0.8	7
810	Correlation of IL28B rs12979860 genotype and gender with spontaneous clearance of HCV infection: a Pakistani cross-section study. <i>Personalized Medicine</i> , 2018, 15, 495-502.	0.8	2
811	Vitamin D binding protein polymorphisms influence susceptibility to hepatitis C virus infection in a high-risk Chinese population. <i>Gene</i> , 2018, 679, 405-411.	1.0	14
812	Seroprevalence of hepatitis B and C in Nepal: a systematic review (1973–2017). <i>Hepatology, Medicine and Policy</i> , 2018, 3, 10.	1.7	6
813	Molecular surveillance of HCV mono-infection and HCV-HBV co-infection in symptomatic population at Hyderabad, Pakistan. <i>African Health Sciences</i> , 2018, 18, 531.	0.3	1
814	Evaluation of efficacy of serological methods for detection of HCV infection in blood donors: A single centre experience. <i>Pakistan Journal of Medical Sciences</i> , 2018, 34, 1204-1208.	0.3	4
815	HCV non-structural NS4A protein of genotype 3a induces mitochondria mediated death by activating Bax and the caspase cascade. <i>Microbial Pathogenesis</i> , 2018, 124, 346-355.	1.3	9
816	The Curtius Rearrangement: Applications in Modern Drug Discovery and Medicinal Chemistry. <i>ChemMedChem</i> , 2018, 13, 2351-2373.	1.6	66
817	Sulfur(VI) fluoride exchange as a key reaction for synthesizing biaryl sulfate core derivatives as potent hepatitis C virus NS5A inhibitors and their structure–activity relationship studies. <i>RSC Advances</i> , 2018, 8, 31803-31821.	1.7	9
818	Hepatitis C virus genotype 3: clinical features, current and emerging viral inhibitors, future challenges. <i>Annals of Gastroenterology</i> , 2018, 31, 541-551.	0.4	15
819	Treatment of Dyslipidemia in Common Liver Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1189-1196.	2.4	32
820	Effectiveness and tolerability of direct-acting antivirals for chronic hepatitis C patients in a Southern state of Brazil. <i>Brazilian Journal of Infectious Diseases</i> , 2018, 22, 186-192.	0.3	17
821	Determination of anti-HCV and quantification of HCV-RNA and IP-10 from dried blood spots sent by regular mail. <i>PLoS ONE</i> , 2018, 13, e0201629.	1.1	4
822	The Medicinal Chemistry of Antihepatitis Agents III. , 2018, , 133-210.		1

#	ARTICLE	IF	CITATIONS
823	Iatrogenic Hepatitis C Virus Transmission and Safe Injection Practices. Journal of the American Osteopathic Association, The, 2018, 118, 311.	1.7	5
824	Hepatitis C Treatment in the Era of Direct-Acting Antiviral Agents. , 2018, , 209-246.		3
825	Treatment with direct-acting antivirals in a multicenter cohort of HCV-infected inmates in Italy. International Journal of Drug Policy, 2018, 59, 50-53.	1.6	33
826	Neurological manifestations in chronic hepatitis C patients receiving care in a reference hospital in sub-Saharan Africa: A cross-sectional study. PLoS ONE, 2018, 13, e0192406.	1.1	14
827	ADAR1 affects HCV infection by modulating innate immune response. Antiviral Research, 2018, 156, 116-127.	1.9	27
828	The implication of CRISPR/Cas9 genome editing technology in combating human oncoviruses. Journal of Medical Virology, 2019, 91, 1-13.	2.5	11
829	The Protective Effect of Humanin Derivative AGA(C8R)-HNG17 Against Acetaminophen-Induced Liver Injury in Mice. International Journal of Peptide Research and Therapeutics, 2019, 25, 565-571.	0.9	2
830	Management of HCV patients in cases of direct-acting antiviral failure. Expert Review of Gastroenterology and Hepatology, 2019, 13, 839-848.	1.4	8
831	Diagnostic and Interventional Radiology. , 2019, , 67-97.		0
832	<p>Computational analysis of naturally occurring resistance-associated substitutions in genes NS3, NS5A, and NS5B among 86 subtypes of hepatitis C virus worldwide</p>. Infection and Drug Resistance, 2019, Volume 12, 2987-3015.	1.1	10
833	HCV infection causes cirrhosis in human by step-wise regulation of host genes involved in cellular functioning and defense during fibrosis: Identification of bio-markers. Genes and Diseases, 2019, 6, 304-317.	1.5	9
834	<p>Efficacy of direct-acting antiviral therapy for hepatitis C viral infection. Real-life experience in Bahrain. Hepatic Medicine: Evidence and Research, 2019, Volume 11, 69-78.	0.9	3
835	<p>Grazoprevir/elbasvir in peginterferon alfa plus ribavirin experienced patients with chronic genotype 1 HCV/HIV co-infection: a non-randomized, open-label clinical trial. Infection and Drug Resistance, 2019, Volume 12, 937-945.	1.1	5
836	The Invention of Grazoprevir: An HCV NS3/4a Protease Inhibitor. Topics in Medicinal Chemistry, 2019, , 355-387.	0.4	3
837	Humanized Mouse Models for the Study of Hepatitis C and Host Interactions. Cells, 2019, 8, 604.	1.8	12
838	Hepatitis C virus screening and treatment in Irish prisons from nurse managers's perspectives - a qualitative exploration. BMC Nursing, 2019, 18, 23.	0.9	3
839	Acute Hepatitis C. , 2019, , 197-217.		0
840	Principal components analysis of Raman spectral data for screening of Hepatitis C infection. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2019, 221, 117173.	2.0	36

#	ARTICLE	IF	CITATIONS
841	Development of Stability Indicating Assay Method for Separation and Identification of Degradation Products of Daclatasvir Dihydrochloride by LC-ESI-QTOF-MS/MS. <i>Analytical Chemistry Letters</i> , 2019, 9, 209-222.	0.4	2
842	Non-invasive Fibrosis Assessment of Patients with Hepatitis C: Application of Society Guidelines to Clinical Practice. <i>Current Hepatology Reports</i> , 2019, 18, 249-258.	0.4	4
843	Quantitative structure-activity relationship and molecular docking studies of some series of imidazole derivatives as anti-hepatitis C drug. <i>Bayero Journal of Pure and Applied Sciences</i> , 2019, 11, 57.	0.1	0
844	Circulating and inducible IL-32 \pm in chronic hepatitis C virus infection. <i>Canadian Liver Journal</i> , 2019, 2, 23-30.	0.3	0
845	Hierarchical assessment of host factors influencing the spontaneous resolution of hepatitis C infection. <i>Brazilian Journal of Microbiology</i> , 2019, 50, 147-155.	0.8	0
846	Prevalence and risk factors associated with hepatitis C among Brazilian male patients with haemophilia: A long-term follow-up. <i>Haemophilia</i> , 2019, 25, 447-455.	1.0	7
847	Acute Hepatitis C. , 2019, , 45-65.		0
848	A Review of Acute Viral Hepatitides Including Hepatitis E. , 2019, , 77-107.		1
849	Quantitative systems pharmacology of interferon alpha administration: A multi-scale approach. <i>PLoS ONE</i> , 2019, 14, e0209587.	1.1	7
850	Impact of hepatitis C treatment on pain intensity, prescription opioid use and arthritis. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 592-598.	0.9	5
851	Sequence variability of HCV 3a isolates based on core gene in patients from Lahore, Pakistan. <i>Future Virology</i> , 2019, 14, 641-653.	0.9	3
852	<p>A Randomized Controlled Trial to Assess the Impact of Clinical Pharmacy Interventions on Treatment Outcomes, Health Related Quality of Life and Medication Adherence Among Hepatitis C Patients</p>. <i>Patient Preference and Adherence</i> , 2019, Volume 13, 2089-2100.	0.8	14
853	THE COURSE OF HEPATITIS C INFECTION AND RESPONSE TO ANTI-VIRAL THERAPY IN PATIENTS WITH THALASSEMIA MAJOR AND HEPATITIS C INFECTION: A LONGITUDINAL, PROSPECTIVE STUDY.. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2019, 11, e2019060.	0.5	12
854	Hepatitis C virus and risk of extrahepatic malignancies: a case-control study. <i>Scientific Reports</i> , 2019, 9, 19444.	1.6	26
855	HIV/HCV co-infection and associated risk factors among injecting drug users in Dar es Salaam, Tanzania: potential for HCV elimination. <i>Harm Reduction Journal</i> , 2019, 16, 68.	1.3	9
856	Pathogenesis and Immune Response Caused by Vector-Borne and Other Viral Infections in a Tupaia Model. <i>Microorganisms</i> , 2019, 7, 686.	1.6	6
857	The Influence of Antiretroviral Therapy on Hepatitis C Virus Viral Load and Liver Fibrosis in Human Immunodeficiency Virus-Coinfected Patients: An Observational Study. <i>Intervirolgy</i> , 2019, 62, 182-190.	1.2	1
858	Hepatitis C virus infection is associated with hepatic and adipose tissue insulin resistance that improves after viral cure. <i>Clinical Endocrinology</i> , 2019, 90, 440-448.	1.2	16

#	ARTICLE	IF	CITATIONS
859	Highly Diastereoselective Synthesis of a HCV NS5B Nucleoside Polymerase Inhibitor. <i>Journal of Organic Chemistry</i> , 2019, 84, 4780-4795.	1.7	5
860	Dynamic changes in innate immune responses during direct-acting antiviral therapy for HCV infection. <i>Journal of Viral Hepatitis</i> , 2019, 26, 362-372.	1.0	21
861	Recombinant streptavidin fusion proteins as signal reporters in rapid test of human hepatitis C virus infection. <i>Journal of Clinical Laboratory Analysis</i> , 2019, 33, e22701.	0.9	5
862	Evaluation of cost-effectiveness of peginterferon plus ribavirin for chronic hepatitis C treatment and direct-acting antiviral agents among HIV-infected patients in the prison and community settings. <i>Journal of Microbiology, Immunology and Infection</i> , 2019, 52, 556-562.	1.5	15
863	Clinical Characteristics and Outcome of Morbidly Obese Bariatric Patients with Concurrent Hepatitis C Viral Infection. <i>Obesity Surgery</i> , 2019, 29, 828-834.	1.1	2
864	Synthesis of 2-Methyl-6-methoxyguanosine from the Parent Ribonucleoside Guanosine. <i>Journal of Organic Chemistry</i> , 2019, 84, 4646-4652.	1.7	4
865	Correlates of subjective hepatitis C knowledge among clinical staff in US drug treatment programs. <i>Zeitschrift Fur Gesundheitswissenschaften</i> , 2020, 28, 401-409.	0.8	0
866	Lifestyle and Cancer Prevention. , 2020, , 337-374.e12.		3
867	The Significance of HCV Viral Load in the Incidence of HCC: a Correlation Between Mir-122 and CCL2. <i>Journal of Gastrointestinal Cancer</i> , 2020, 51, 412-417.	0.6	13
868	Possible Association of Elevated Plasma Levels of Growth Arrest-Specific Protein 6 and the Soluble Form of Tyrosine Kinase Receptor Axl with Low Hepatitis C Viral Load in Patients with Type 2 Diabetes Mellitus. <i>Viral Immunology</i> , 2020, 33, 105-111.	0.6	3
869	Optimization of a sensitive and robust strategy for micellar electrokinetic chromatographic analysis of sofosbuvir in combination with its co-formulated hepatitis C antiviral drugs. <i>Journal of Chromatography A</i> , 2020, 1616, 460795.	1.8	9
870	Resistencia a la insulina en pacientes egipcios no diabéticos infectados con el virus de hepatitis C crónica. <i>Revista De Gastroenterología De México</i> , 2020, 85, 173-179.	0.4	1
871	Increased cancer rates in patients with chronic hepatitis C. <i>Liver International</i> , 2020, 40, 685-693.	1.9	22
872	Morbidity and mortality during hepatitis C treatment using sofosbuvir and daclatasvir with or without ribavirin, in a cohort of Egyptian patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 1046-1053.	0.8	0
873	Rapid virologic response in chronic hepatitis C genotype 1: Evaluation of pretreatment factors in patients. <i>Arab Journal of Gastroenterology</i> , 2020, 21, 278-281.	0.4	0
874	Benzothiazoles as potential antiviral agents. <i>Journal of Pharmacy and Pharmacology</i> , 2020, 72, 1459-1480.	1.2	57
875	Surface Enhanced Raman Spectroscopy of the serum samples for the diagnosis of Hepatitis C and prediction of the viral loads. <i>Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy</i> , 2020, 242, 118729.	2.0	56
876	Hepatitis C virus infection characteristics and treatment outcomes in Canadian immigrants. <i>BMC Public Health</i> , 2020, 20, 1345.	1.2	7

#	ARTICLE	IF	CITATIONS
877	Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure Characteristics. <i>Clinical Infectious Diseases</i> , 2021, 73, e3288-e3295.	2.9	21
878	Prevalence and high risk behaviours associated with HCV testing among people who inject drugs: a systematic review and Meta-analysis. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2020, 15, 64.	1.0	17
879	Discovery and Chemical Development of the Use-Dependent Sodium Channel Blocker Vixotrigine for the Treatment of Pain. <i>ACS Symposium Series</i> , 2020, , 1-42.	0.5	0
880	Discovery of novel Hepatitis C virus inhibitor targeting multiple allosteric sites of NS5B polymerase. <i>Infection, Genetics and Evolution</i> , 2020, 84, 104371.	1.0	13
881	Hepatitis C virus- related cryoglobulinemic vasculitis: A review of the role of the new direct antiviral agents (DAAs) therapy. <i>Autoimmunity Reviews</i> , 2020, 19, 102589.	2.5	21
882	Predictors of hepatocellular carcinoma after hepatitis C virus eradication following direct-acting antiviral treatment: relationship with serum zinc. <i>Journal of Clinical Biochemistry and Nutrition</i> , 2020, 66, 245-252.	0.6	10
883	Insulin resistance in nondiabetic Egyptian patients with chronic hepatitis C virus. <i>Revista De GastroenterologĀa De MĀxico (English Edition)</i> , 2020, 85, 173-179.	0.1	1
884	Cumulative/dynamic ROC curve estimation under interval censorship. <i>Journal of Statistical Computation and Simulation</i> , 2020, 90, 1570-1590.	0.7	6
885	A review of clinical pharmacogenetics Studies in African populations. <i>Personalized Medicine</i> , 2020, 17, 155-170.	0.8	35
886	Genetic contribution of endoplasmic reticulum aminopeptidase 1 polymorphisms to liver fibrosis progression in patients with HCV infection. <i>Journal of Molecular Medicine</i> , 2020, 98, 1245-1254.	1.7	1
887	Treatment of refractory oral lichen planus using direct antiviral agents in a patient with chronic hepatitis C: A case report. <i>Oral Science International</i> , 2020, 17, 213-217.	0.3	5
888	Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives. <i>Cells</i> , 2020, 9, 875.	1.8	516
889	Plasma Lipidomic Fingerprinting to Distinguish among Hepatitis C-related Hepatocellular Carcinoma, Liver Cirrhosis, and Chronic Hepatitis C using MALDI-TOF Mass Spectrometry: a Pilot Study. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 24, 43-49.	0.5	8
890	DeepLiverNet: a deep transfer learning model for classifying liver stiffness using clinical and T2-weighted magnetic resonance imaging data in children and young adults. <i>Pediatric Radiology</i> , 2021, 51, 392-402.	1.1	10
891	High seroprevalence of viral hepatitis among animal handlers in Abeokuta, Ogun State, Nigeria. <i>Journal of Immunoassay and Immunochemistry</i> , 2021, 42, 34-47.	0.5	1
892	Effect of Direct Acting Anti-Hepatitis C Drugs on the Heart. <i>The Egyptian Journal of Hospital Medicine</i> , 2021, 82, 106-114.	0.0	0
893	Thiophen urea derivatives as a new class of hepatitis C virus entry inhibitors. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2021, 36, 462-468.	2.5	4
894	Neuropathies. , 2021, , 842-874.e4.		0

#	ARTICLE	IF	CITATIONS
895	Increasing Seroprevalence of Hepatitis C Virus among Blood Donors - A 3 Year Study in North India. <i>Journal of Evidence Based Medicine and Healthcare</i> , 2021, 8, 379-383.	0.0	0
896	Validated High-performance Liquid Chromatography Method for the Determination of JW5624, A New Class Of Hepatitis C Virus Inhibitor, in Rat Plasma and its Application in the Pharmacokinetic Study of JW5624. <i>Drug Research</i> , 2021, 71, 312-316.	0.7	0
897	Study of membrane deformations induced by Hepatitis C protein NS4B and its terminal amphipathic peptides. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2021, 1863, 183537.	1.4	1
899	EVALUATION OF A STRATEGY TO DETECT ACTIVE HCV INFECTION USING A COMBINATION OF ELISA & TRI DOT ASSAY. , 2021, , 79-81.		0
900	Detection of circulating HCV recombinant form RF1_2k/1b in blood serum of patients by real-time RT-PCR. <i>Klinicheskaya Laboratornaya Diagnostika</i> , 2021, 66, 122-128.	0.2	0
901	Hepatitis C virus-related cryoglobulinemic vasculitis. <i>Minerva Medica</i> , 2021, 112, 175-187.	0.3	8
903	Metabolic complications of hepatitis C virus infection. <i>World Journal of Gastroenterology</i> , 2021, 27, 1267-1282.	1.4	29
905	TRIM22. A Multitasking Antiviral Factor. <i>Cells</i> , 2021, 10, 1864.	1.8	21
906	Tree Shrew as an Emerging Small Animal Model for Human Viral Infection: A Recent Overview. <i>Viruses</i> , 2021, 13, 1641.	1.5	16
907	Global stability of a diffusive HCV infections epidemic model with nonlinear incidence. <i>Journal of Applied Mathematics and Computing</i> , 0, , 1.	1.2	4
908	The age, bilirubin and albumin (ABA) index: a novel noninvasive index for predicting liver fibrosis in patients with chronic hepatitis C infection. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, e290-e296.	0.8	1
909	Viral Hepatitis C. <i>Molecular Pathology Library</i> , 2011, , 569-588.	0.1	1
910	Hepatitis C Virus and Hepatocellular Carcinoma. , 2012, , 571-583.		2
911	Fuzziness in the Core of the Human Pathogenic Viruses HCV and HIV. <i>Advances in Experimental Medicine and Biology</i> , 2012, 725, 142-158.	0.8	8
913	Discovery and Development of Omecamtiv Mecarbil: A Novel Cardiac Myosin Activator for the Potential Treatment of Systolic Heart Failure. <i>ACS Symposium Series</i> , 2020, , 99-126.	0.5	1
914	Melflufen: A Journey from Discovery to Multi-Kilogram Production. <i>ACS Symposium Series</i> , 2020, , 157-177.	0.5	4
915	HCV Replication Inhibitors That Interact with NS4B. <i>RSC Drug Discovery Series</i> , 2013, , 111-145.	0.2	3
916	Can hepatitis C virus core antigen be used as a reliable marker of viral load for hepatitis C virus infection in genotype 4?. <i>Egyptian Liver Journal</i> , 2017, 7, 1-4.	0.3	1

#	ARTICLE	IF	CITATIONS
917	Detection of host immune responses in acute phase sera of spontaneous resolution versus persistent hepatitis C virus infection. <i>Journal of General Virology</i> , 2012, 93, 1673-1679.	1.3	8
918	Chemokine antagonism in chronic hepatitis C virus infection. <i>Journal of Clinical Investigation</i> , 2011, 121, 25-27.	3.9	19
919	Current status and emerging challenges in the treatment of hepatitis C virus genotypes 4 to 6. <i>World Journal of Clinical Cases</i> , 2015, 3, 210.	0.3	10
920	Five Laboratory Tests Predict Patient Risk and Treatment Response in Hepatitis C: Veterans Affairs Data from 1999-2010. <i>Universal Journal of Medical Science</i> , 2016, 4, 10-20.	0.4	1
921	Effects of HCV on Basal and Tat-Induced HIV LTR Activation. <i>PLoS ONE</i> , 2013, 8, e64956.	1.1	15
922	Can Antidepressants Prevent Pegylated Interferon- α /Ribavirin-Associated Depression in Patients with Chronic Hepatitis C: Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled Trials?. <i>PLoS ONE</i> , 2013, 8, e76799.	1.1	11
923	Hepatitis C Virus Infection Causes Iron Deficiency in Huh7.5.1 Cells. <i>PLoS ONE</i> , 2013, 8, e83307.	1.1	14
924	HCV Genotypes, Characterization of Mutations Conferring Drug Resistance to Protease Inhibitors, and Risk Factors among Blood Donors in São Paulo, Brazil. <i>PLoS ONE</i> , 2014, 9, e86413.	1.1	30
925	Plasma Sphingolipids as Potential Indicators of Hepatic Necroinflammation in Patients with Chronic Hepatitis C and Normal Alanine Aminotransferase Level. <i>PLoS ONE</i> , 2014, 9, e95095.	1.1	16
926	Diversity of Killer Cell Immunoglobulin-Like Receptor (KIR) Genotypes and KIR2DL2/3 Variants in HCV Treatment Outcome. <i>PLoS ONE</i> , 2014, 9, e99426.	1.1	12
927	Proteomic Analysis of Mitochondrial-Associated ER Membranes (MAM) during RNA Virus Infection Reveals Dynamic Changes in Protein and Organelle Trafficking. <i>PLoS ONE</i> , 2015, 10, e0117963.	1.1	91
928	Projections of the Current and Future Disease Burden of Hepatitis C Virus Infection in Malaysia. <i>PLoS ONE</i> , 2015, 10, e0128091.	1.1	21
929	Spatiotemporal Scan and Age-Period-Cohort Analysis of Hepatitis C Virus in Henan, China: 2005–2012. <i>PLoS ONE</i> , 2015, 10, e0129746.	1.1	6
930	Interactions between Hepatitis C Virus and the Human Apolipoprotein H Acute Phase Protein: A Tool for a Sensitive Detection of the Virus. <i>PLoS ONE</i> , 2015, 10, e0140900.	1.1	10
931	Cost Effectiveness of Daclatasvir/Asunaprevir Versus Peginterferon/Ribavirin and Protease Inhibitors for the Treatment of Hepatitis c Genotype 1b Naïve Patients in Chile. <i>PLoS ONE</i> , 2015, 10, e0141660.	1.1	13
932	In Silico Design and Experimental Validation of siRNAs Targeting Conserved Regions of Multiple Hepatitis C Virus Genotypes. <i>PLoS ONE</i> , 2016, 11, e0159211.	1.1	27
933	The impact of HCV therapy in a high HIV-HCV prevalence population: A modeling study on people who inject drugs in Ho Chi Minh City, Vietnam. <i>PLoS ONE</i> , 2017, 12, e0177195.	1.1	9
934	The N-terminal Helical Region of the Hepatitis C Virus p7 Ion Channel Protein Is Critical for Infectious Virus Production. <i>PLoS Pathogens</i> , 2015, 11, e1005297.	2.1	18

#	ARTICLE	IF	CITATIONS
935	Hepatitis C virus infection inhibits a Src-kinase regulatory phosphatase and reduces T cell activation in vivo. <i>PLoS Pathogens</i> , 2017, 13, e1006232.	2.1	14
936	Peginterferon Lambda-1a, a New Therapeutic for Hepatitis C Infection, from Bench to Clinic. <i>Journal of Clinical and Translational Hepatology</i> , 2016, 1, 116-24.	0.7	9
937	Inflammatory Biomarkers and Liver Histopathology in Non-Uremic and Uremic Chronic Hepatitis C Patients. <i>Acta Medica (Hradec Kralove)</i> , 2017, 60, 71-75.	0.2	7
938	Benefits of Curing Hepatitis C Infection. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 23, 85-90.	0.5	15
939	Prevalence and epidemiology of chronic hepatitis C among prisoners of Mato Grosso do Sul State, Brazil. <i>Journal of Venomous Animals and Toxins Including Tropical Diseases</i> , 2011, 17, 216-222.	0.8	8
943	HCV core protein binds to gC1qR to induce A20 expression and inhibit cytokine production through MAPKs and NF- κ B signaling pathways. <i>Oncotarget</i> , 2016, 7, 33796-33808.	0.8	27
944	The correlation between RT-PCR and ELISA assay on hepatitis C positive serum samples. <i>Pure and Applied Biology</i> , 2016, 5, .	0.1	2
945	Health Policy Model: Long-Term Predictive Results Associated with the Management of HCV-Induced Diseases in Italy. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
946	Resistance Mutations Against HCV Protease Inhibitors and Antiviral Drug Design. <i>Current Pharmaceutical Design</i> , 2014, 20, 694-703.	0.9	10
947	An Overview of Hepatitis C Vaccines. <i>Recent Patents on Inflammation and Allergy Drug Discovery</i> , 2014, 8, 85-91.	3.9	9
948	Association of C-myc and p53 Gene Expression and Polymorphisms with Hepatitis C (HCV) Chronic Infection, Cirrhosis and Hepatocellular Carcinoma (HCC) Stages in Egypt. <i>Asian Pacific Journal of Cancer Prevention</i> , 2017, 18, 2049-2057.	0.5	5
949	High effectiveness of peginterferon alfa-2a plus ribavirin therapy in Korean patients with chronic hepatitis C in clinical practice. <i>Clinical and Molecular Hepatology</i> , 2013, 19, 60.	4.5	8
950	KASL clinical practice guidelines: Management of Hepatitis C. <i>Clinical and Molecular Hepatology</i> , 2014, 20, 89.	4.5	35
951	KASL clinical practice guidelines: management of hepatitis C. <i>Clinical and Molecular Hepatology</i> , 2016, 22, 76-139.	4.5	68
952	Hepatitis C virus induced insulin resistance impairs response to anti viral therapy. <i>World Journal of Gastroenterology</i> , 2012, 18, 212.	1.4	52
953	Checkmate to liver biopsy in chronic hepatitis C?. <i>World Journal of Gastroenterology</i> , 2012, 18, 5514.	1.4	21
954	Role of T cell death in maintaining immune tolerance during persistent viral hepatitis. <i>World Journal of Gastroenterology</i> , 2013, 19, 1877.	1.4	16
955	Sustained virological response: A milestone in the treatment of chronic hepatitis C. <i>World Journal of Gastroenterology</i> , 2013, 19, 2793.	1.4	62

#	ARTICLE	IF	CITATIONS
956	Are metabolic factors still important in the era of direct antiviral agents in patients with chronic hepatitis C?. World Journal of Gastroenterology, 2013, 19, 6947.	1.4	11
957	Burden of pediatric hepatitis C. World Journal of Gastroenterology, 2013, 19, 7880.	1.4	102
958	Non-invasive prediction of forthcoming cirrhosis-related complications. World Journal of Gastroenterology, 2014, 20, 2613.	1.4	13
959	Hepatitis C virus and metabolic disorder interactions towards liver damage and atherosclerosis. World Journal of Gastroenterology, 2014, 20, 2825.	1.4	31
960	Interferon-associated retinopathy risk in patients with diabetes and hypertensive hepatitis C. World Journal of Gastroenterology, 2014, 20, 7505.	1.4	7
961	Early viral kinetics during hepatitis C virus genotype 6 treatment according toll28Bpolymorphisms. World Journal of Gastroenterology, 2014, 20, 10599.	1.4	3
962	New treatments for chronic hepatitis C: An overview for paediatricians. World Journal of Gastroenterology, 2014, 20, 15965.	1.4	14
963	Gender specific medicine in liver diseases: A point of view. World Journal of Gastroenterology, 2014, 20, 2127.	1.4	47
964	Interferon-free regimens for the treatment of hepatitis C virus in liver transplant candidates or recipients. World Journal of Gastroenterology, 2015, 21, 9526.	1.4	23
965	Thyroid dysfunction in Chinese hepatitis C patients: Prevalence and correlation with TPOAb and CXCL10. World Journal of Gastroenterology, 2015, 21, 9765.	1.4	3
966	Impact of new treatment options for hepatitis C virus infection in liver transplantation. World Journal of Gastroenterology, 2015, 21, 10760.	1.4	24
967	Re-re-treatment of hepatitis C virus: Eight patients who relapsed twice after direct-acting-antiviral drugs. World Journal of Gastroenterology, 2015, 21, 12430.	1.4	4
968	Retreatment with peginterferon and ribavirin in chronic hepatitis C. World Journal of Gastroenterology, 2015, 21, 1994.	1.4	2
969	Nuclear magnetic resonance based metabolomics and liver diseases: Recent advances and future clinical applications. World Journal of Gastroenterology, 2016, 22, 417.	1.4	36
970	S-adenosyl-L-methionine modifies antioxidant-enzymes, glutathione-biosynthesis and methionine adenosyltransferases-1/2 in hepatitis C virus-expressing cells. World Journal of Gastroenterology, 2016, 22, 3746.	1.4	16
971	MicroRNAs as possible biomarkers for diagnosis and prognosis of hepatitis B- and C-related-hepatocellular-carcinoma. World Journal of Gastroenterology, 2016, 22, 3907.	1.4	55
972	Epidemiology of hepatitis C in Greece. World Journal of Gastroenterology, 2016, 22, 8094.	1.4	14
973	New real-time-PCR method to identify single point mutations in hepatitis C virus. World Journal of Gastroenterology, 2016, 22, 9604.	1.4	5

#	ARTICLE	IF	CITATIONS
974	Hepatitis C virus NS5A region mutation in chronic hepatitis C genotype 1 patients who are non-responders to two or more treatments and its relationship with response to a new treatment. <i>World Journal of Gastroenterology</i> , 2017, 23, 4538.	1.4	7
975	Dramatic response of hepatitis C patients chronically infected with hepatitis C virus genotype 3 to sofosbuvir-based therapies in Punjab, Pakistan: A prospective study. <i>World Journal of Gastroenterology</i> , 2017, 23, 7899-7905.	1.4	8
976	Effect of HCV treatment response on insulin resistance: A systematic review and meta-analysis. <i>Experimental and Therapeutic Medicine</i> , 2019, 18, 3568-3578.	0.8	5
977	Platelet count is associated with sustained virological response rates in treatments for chronic hepatitis C. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 989-997.	0.7	2
978	Protease inhibitors: Silver bullets for chronic hepatitis C infection?. <i>Cleveland Clinic Journal of Medicine</i> , 2012, 79, 213-222.	0.6	22
979	Newer direct-acting antivirals for hepatitis C virus infection: Perspectives for India. <i>Indian Journal of Medical Research</i> , 2017, 146, 23.	0.4	16
980	Emerging resistance to directly-acting antiviral therapy in treatment of chronic Hepatitis C infection – A brief review of literature. <i>Journal of Family Medicine and Primary Care</i> , 2020, 9, 531.	0.3	9
981	Comparison between FIB-4 Index and Fibroscan as Marker of Fibrosis in Chronic HCV Infection in Egyptian Patients. <i>Open Journal of Gastroenterology</i> , 2014, 04, 383-391.	0.1	5
982	Cancer and Infectious Causes. <i>Open Journal of Medical Microbiology</i> , 2014, 04, 161-177.	0.1	2
983	Hepatitis B, Hepatitis C and HIV in Pregnant Women in the Community in the Democratic Republic of Congo. <i>World Journal of AIDS</i> , 2015, 05, 124-130.	0.1	15
984	Hepatitis C genotype 6: A concise review and response-guided therapy proposal. <i>World Journal of Hepatology</i> , 2013, 5, 496.	0.8	26
985	Sofosbuvir treatment and hepatitis C virus infection. <i>World Journal of Hepatology</i> , 2016, 8, 183.	0.8	15
986	Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C. <i>World Journal of Hepatology</i> , 2017, 9, 352.	0.8	50
987	Interferons and hepatitis C virus. <i>Swiss Medical Weekly</i> , 2012, 142, w13586.	0.8	23
988	Hepatitis B and C in Switzerland – healthcare provider initiated testing for chronic hepatitis B and C infection. <i>Swiss Medical Weekly</i> , 2013, 143, w13793.	0.8	23
989	The Role of FGL2 in the Pathogenesis and Treatment of Hepatitis C Virus Infection. <i>Rambam Maimonides Medical Journal</i> , 2010, 1, e0004.	0.4	15
990	Pathogenesis and clinical consequences of iron overload in chronic hepatitis C -- impact of host and viral factors related to iron metabolism. <i>Biotechnology</i> , 2011, 1, 54-65.	0.3	5
991	Prevailing genotypes of hepatitis C virus in Saudi Arabia: a systematic analysis of evidence. <i>Annals of Saudi Medicine</i> , 2013, 33, 1-5.	0.5	10

#	ARTICLE	IF	CITATIONS
992	PREDICTORS OF SUSTAINED VIROLOGICAL RESPONSE (SVR) TO PEGYLATED INTERFERON ALPHA (PEG-IFN $\hat{\pm}$) AND RIBAVIRIN (RBV) IN PATIENTS WITH CHRONIC HEPATITIS C INFECTED WITH GENOTYPE 1. Journal of IMAB, 2011, 17, 1, 197-199.	0.1	1
993	The Prevalence and Subtype Distribution of Hepatitis C Virus Infection among Hemodialysis Patients in a Private Hospital in Surabaya, Indonesia. Microbiology Indonesia, 2012, 6, 173-179.	0.2	4
994	Obstacles Facing Primary Health Care Physicians in Diagnosing and Managing Depressed Patients in the Tabuk Area of Saudi Arabia. World Family Medicine Journal/Middle East Journal of Family Medicine, 2013, 11, 4-9.	0.1	3
995	Seroprevalences of Hepatitis B and Hepatitis C among healthcare workers in Tire State Hospital. Dicle Medical Journal, 0, , 267-270.	0.2	4
996	The follow-up results with sustained virologic response in chronic hepatitis C patients in ÅžanlÅ±urfa/Turkey. Journal of Microbiology and Infectious Diseases, 2012, 2, 141-20.	0.1	2
997	A Comprehensive Long-Term Prognosis of Chronic Hepatitis C Patients With Antiviral Therapy; A Meta-Analysis of Studies From 2008 to 2014. Hepatitis Monthly, 2015, 15, e27181.	0.1	8
998	Distribution of Hepatitis C Virus Genotypes in Bahrain. Hepatitis Monthly, 2015, 15, e30300.	0.1	9
999	Changing Pattern of Clinical Epidemiology on Hepatitis C Virus Infection in Southwest China. Hepatitis Monthly, 2012, 12, 196-204.	0.1	28
1000	Changing pattern of clinical epidemiology on hepatitis C virus infection in southwest china. Hepatitis Monthly, 2012, 12, 196-204.	0.1	27
1001	Role of IL28-B Polymorphism (rs12979860) on Sustained Virological Response to Pegylated Interferon/Ribavirin in Iranian Patients With Chronic Hepatitis C. Iranian Red Crescent Medical Journal, 2016, 18, e28566.	0.5	5
1002	Prevalence of Chronic Hepatitis B and Hepatitis C among First Time Blood Donors in Northeast Bosnia and Herzegovina: An Estimate of Prevalence in General Population. Hepatitis Monthly, 2011, 11, 629-633.	0.1	10
1003	Optimal Duration of Treatment for HCV Genotype 1 Infection in Slow Responders: A Meta-Analysis. Hepatitis Monthly, 2011, 11, 612-619.	0.1	6
1004	Effectiveness and safety of first-generation protease inhibitors in real-world patients with hepatitis C virus genotype 1 infection in Brazil: a multicenter study. Clinics, 2017, 72, 378-385.	0.6	3
1005	A Review of the Natural History of Chronic Hepatitis C Infection. North American Journal of Medicine & Science, 2014, 07, 001.	3.8	7
1006	A Recurrent Case of Cryoglobulin-related Leukocytoclastic Vasculitis with an Unexpected Etiology. Cureus, 2019, 11, e5783.	0.2	1
1007	Detection of hepatitis C virus among HIV patients in Port Harcourt, Rivers State. African Health Sciences, 2021, 21, 1010-1015.	0.3	0
1008	Hepatitis Đj in Russia and the Northwest federal region of Russia: results of the first stage the global programme of infection elimination. HIV Infection and Immunosuppressive Disorders, 2021, 13, 40-51.	0.1	2
1009	Telaprevir: An Emerging Protease Inhibitor for the Treatment of Hepatitis C. Clinical Medicine Reviews in Therapeutics, 0, 2, 31-40.	0.4	0

#	ARTICLE	IF	CITATIONS
1010	Epidemiology of Chronic HCV. , 2012, , 3-11.		0
1011	Immune Control of HCV Infection. , 2012, , 21-36.		0
1013	Guidelines for the Quantification of HIV and HCV in Small Volume Whole Blood Samples. Methods in Molecular Biology, 2012, 903, 35-50.	0.4	0
1015	Molecular adsorbent recirculating system therapy in a rare case of fulminant hepatitis. Journal of Biomedical Science and Engineering, 2012, 05, 270-275.	0.2	0
1017	The markers predicting response to Hepatitis C virus treatment and evaluation of treatment responses. Journal of Microbiology and Infectious Diseases, 2012, 2, 100-108.	0.1	0
1018	Serum and Ascitic Fluid Hcpidin in HCV Positive Liver Cirrhosis with and without HCC. European Journal of Preventive Medicine, 2013, 1, 63.	0.1	0
1019	Identification of HCV Inhibitors from a Cell-Based Sub-Genomic Replicon Screen. Open Journal of Medicinal Chemistry, 2013, 03, 16-25.	0.7	0
1020	Lessons from Viral Superinfections for HIV-1 Vaccine Design. Journal of AIDS & Clinical Research, 2013, 01, .	0.5	0
1021	Emerging therapies in pipeline for chronic hepatitis C. International Journal of Basic and Clinical Pharmacology, 2013, 2, 500.	0.0	0
1022	Insight and educational intervention concerning hepatitis among roadside barbers and their clients in Karachi, Pakistan. Journal of Infection in Developing Countries, 2013, 7, 125-129.	0.5	6
1023	Prevalence of Non Organ-Specific Auto Antibodies and its Effect on Response to Antiviral Therapy in Patients with Chronic Hepatitis C Virus Genotype 4. Afro-Egyptian Journal of Infectious and Endemic Diseases, 2013, 3, 34-42.	0.1	0
1024	Genotyping of Hepatitis C Virus (HCV) in Infected Patients from Yemen. European Journal of Basic Medical Sciences, 2013, 3, 78-82.	0.2	2
1025	Management of HCV Treatment-related Side-effects, Toxicity, and Drug-interactions. North American Journal of Medicine & Science, 2014, 07, 033.	3.8	0
1026	Improved Sustained Virological Response Following Treatment with Pegylated-Interferon Alpha-2b Compared with Alpha-2a, Both with Ribavirin, for Chronic Hepatitis C Infection with Genotypes 2 and 3. International Journal of Clinical Medicine, 2014, 05, 111-117.	0.1	0
1027	Hepatitis Viruses: Hepatitis C. , 2014, , 765-783.		0
1028	Liver and Gastrointestinal Tract Problems in Chronic Kidney Disease. , 2014, , 279-286.		0
1029	Role of Interleukin-28B Genetic Polymorphisms in Korean Patients with Hepatitis C Virus Infection. Gut and Liver, 2014, 8, 70-78.	1.4	6
1031	Epidemiology of Virus Infection and Human Cancer. , 2015, , 23-47.		1

#	ARTICLE	IF	CITATIONS
1032	Impact of Hepatitis C Virus (HCV) on CD4+ T-Lymphocyte Count < 200 cells/ÅµL among HIV-Positive Adults: A Longitudinal Evaluation. <i>British Journal of Medicine and Medical Research</i> , 2015, 8, 1-8.	0.2	0
1033	Hepatitis C Status in Karachi, Pakistan, a Five-Year Survey at Civil Hospital, Karachi, Pakistan. <i>International Journal of Clinical Medicine</i> , 2015, 06, 797-804.	0.1	2
1034	Hepatitis C Seroprevalence and Risk Factors in Adult Population of Chaharmahal and Bakhtiari Province of Iran in 2013. <i>Journal of Clinical and Diagnostic Research JCDR</i> , 2015, 9, LC13-7.	0.8	11
1035	Boceprevir in genotype 1 chronic hepatitis C: First experiences in Serbia. <i>Srpski Arhiv Za Celokupno Lekarstvo</i> , 2015, 143, 35-41.	0.1	0
1037	Can laboratory parameters be predictive factors for treatment effectiveness of patients suffering from viral hepatitis C?. <i>Annales Academiae Medicae Silesiensis</i> , 2015, 69, 91-98.	0.1	0
1039	Frequency of HCV Infection in Children of HCV Infected Mothers. <i>Journal of Medical Sciences (Faisalabad, Pakistan)</i> , 2015, 16, 25-31.	0.0	0
1040	How to Prevent Hepatitis B in Pakistan: Role of Social Marketing. <i>Journal of Infectious Diseases and Diagnosis</i> , 2016, 01, .	0.1	0
1041	Analysis of Erythrocyte Elements in Chronic Hepatitis C Patients Receiving PegIFN Monotherapy, Dual Therapy, and Triple Therapy using in-air MicroPIXE. <i>Kitakanto Medical Journal</i> , 2016, 66, 91-102.	0.0	0
1042	Hepatitis B Virus Infection among Chronic Renal Failure Predialysis Patients in Hodiedah, Yemen: Retrospective Study. <i>International Journal of Tropical Disease & Health</i> , 2016, 20, 1-6.	0.1	0
1043	Adipocytokine Imbalance and Ghrelin in the Development of Insulin Resistance in Patients with Chronic Hepatitis C. <i>International Journal of Biomedicine</i> , 2016, 6, 27-32.	0.1	0
1044	Prognostic value of the combination of blood group specificity and interleukin 28B gene polymorphism for estimation of efficiency of therapy with the use of pegylated interferon a-2 and ribavirin in patients with chronic genotype 1 hepatitis C. <i>Klinicheskaia Meditsina</i> , 2016, 94, 224-230.	0.2	1
1045	Association of IL28B Genotypes and Baseline Serum Interferon-Î³-Inducible-Protein-10 Levels with Treatment Response in Hepatitis C Virus Patients in China. <i>Gut and Liver</i> , 2016, 10, 446-55.	1.4	3
1046	Value and innovation of direct-acting antivirals: long-term health outcomes of the strategic plan for the management of hepatitis C in Spain. <i>Revista Espanola De Enfermedades Digestivas</i> , 2017, 109, 809-817.	0.1	19
1047	ADVANCES IN HCV TREATMENT-EFFECT OF HCV INFECTION/HCV TREATMENT (PEG-IFN/RIBAVIRIN) ON FERTILITY (OVARIAN RESERVE).. <i>Journal of Gynecology & Neonatal Biology</i> , 2017, 3, 1-3.	0.2	1
1049	HEPATITIS B AND C; AN IMMUNO-CHROMATOGRAPHIC STUDY OF HEPATITIS B AND C PREVALENCE IN SOUTHERN PUNJAB. <i>The Professional Medical Journal</i> , 2017, 24, 244-248.	0.0	0
1050	Prevalence of Hepatitis C Virus among Patients with Human Immunodeficiency and Its Association with Intra-Venous Drugs Addiction in Jeddah, Saudi Arabia. <i>The Egyptian Journal of Hospital Medicine</i> , 2017, 67, 514-517.	0.0	0
1051	The influence of correction of vitamin D deficiency on the formation of the stable virological response during therapy of genotype-1 chronic hepatitis C with PEGylated interferon-alpha-2 and ribavirin. <i>Klinicheskaia Meditsina</i> , 2017, 95, 438-444.	0.2	1
1052	Prevalence of NS5B Resistance Mutations in Hepatitis C Virus (HCV) Treatment Naive South Africans. <i>Hepatitis Monthly</i> , 2017, 17, .	0.1	2

#	ARTICLE	IF	CITATIONS
1053	CUMHURİYETİN İKİNCİ DÖNEMİNDE HEPATİTİS B, C VE HIV GÄRLERİNİN FARKINDALIK DEĞERLERİNİN İZLENİMİ. Atatürk Üniversitesi Diş Hekimliği Fakültesi Dergisi, 0, , 63-63.	0.0	0
1054	Awareness Survey of Prejudice and Discrimination in Hepatitis B and C Virus- Infected Individuals. Advanced Research in Gastroenterology & Hepatology, 2017, 7, .	0.1	1
1055	Prognostic value of blood group specificity and IL-28B genotype for the assessment of liver fibrosis in patients with chronic genotype 1 hepatitis C, non-responders to the treatment with pegylated interferon α -2 and ribavirin. Klinicheskaia Meditsina, 2017, 95, 847-854.	0.2	0
1056	Latent tuberculosis in patients with hepatitis C infection before receiving antiretroviral drugs. The Egyptian Journal of Chest Diseases and Tuberculosis, 2018, 67, 306.	0.1	0
1057	CHANGES OF ORAL MICROBIOCENOSIS IN PERIODONTAL DISEASES IN SETTINGS OF CHRONIC HEPATİTİS C. Bulletin of Problems Biology and Medicine, 2018, 2, 348.	0.0	0
1058	Frequency of Various Risk Factors in HCV Positive Patients in Initial Diagnostic Phase. Occupational Diseases and Environmental Medicine, 2018, 06, 23-36.	0.9	0
1059	Molecular Pathology Introduction and Research Review. , 2018, , 1-15.		0
1060	Biochemical markers and levels of physical activity related to the hepatic condition of patients infected by the hepatitis C virus. Biomedical Human Kinetics, 2018, 10, 15-18.	0.2	1
1062	Efficacy and safety of Peginterferon alfa-2b in the treatment of chronic hepatitis c in outpatients.. Klinicheskaia Meditsina, 2018, 95, 1022-1025.	0.2	0
1063	The effectiveness of different antiviral treatment regimens in patients with chronic hepatitis C infected with genotype 3 virus. Aktualna Infektologija, 2018, 6, 24-27.	0.1	0
1064	Twice-Daily Telaprevir for Posttransplant Genotype 1 Hepatitis C Virus: A Prospective Safety, Efficacy, and Pharmacokinetics Study. Experimental and Clinical Transplantation, 2018, 16, 182-190.	0.2	2
1065	GP205, a new hepatitis C virus NS3/4A protease inhibitor, displays higher metabolic stability in vitro and drug exposure in vivo. Acta Pharmacologica Sinica, 2018, 39, 1746-1752.	2.8	2
1066	CHRONIC HEPATİTİS C VIRUS;. The Professional Medical Journal, 2018, 21, 929-932.	0.0	0
1067	Applications of Artificial Intelligence and Machine Learning in Viral Biology. , 2019, , 1-39.		3
1068	GENERAL IMMUNOLOGICAL REACTIVITY OF PATIENT'S ORGANISM WITH CHRONIC HEPATİTİS B. Wiadomości Lekarskie, 2019, 72, 1310-1314.	0.1	0
1069	Circulating and inducible IL-32 in chronic hepatitis C virus infection. Canadian Liver Journal, 2019, 2, 23-30.	0.3	0
1070	Efficacy and Safety of Sofosbuvir and Ribavirin for Treating Chronic Hepatitis C, Genotype 3: Experience of a Tertiary Care Hospital at Karachi, Pakistan. Cureus, 2019, 11, e4458.	0.2	4
1071			

#	ARTICLE	IF	CITATIONS
1073	The Prevalence of Hepatitis C Infection in Blood Donors: A Meta-Analysis and Systematic Review. Iranian Red Crescent Medical Journal, 2020, 22, .	0.5	4
1074	Discovery and Chemical Development of Tesirine: An Antitumor Pyrrolobenzodiazepine Antibody-Drug Conjugate Drug-Linker. ACS Symposium Series, 2020, , 215-252.	0.5	1
1075	Noninvasive Biomarkers for Liver Fibrosis. , 2020, , 427-441.		0
1076	Cost-effectiveness analysis with direct-acting antivirals in a cohort of HCV-infected inmates in Italy. AboutOpen, 2020, 7, 103-111.	0.2	0
1077	Variations in IL-22, IL-27 and IL-35 serum levels in untreated and treated hepatitis C patients. European Cytokine Network, 2020, 31, 134-139.	1.1	3
1078	Discovery and Chemical Development of Grazoprevir: An HCV NS3/4a Protease Inhibitor for the Treatment of the Hepatitis C Virus Infection. ACS Symposium Series, 2020, , 285-312.	0.5	0
1080	Identification and Development of AMG 986: A Potent and Efficacious APJ Agonist for the Treatment of Heart Failure. ACS Symposium Series, 2020, , 127-155.	0.5	1
1082	Discovery and Chemical Development of S 44563, a Dual Bcl-2/Bcl-xL Inhibitor. ACS Symposium Series, 2020, , 179-214.	0.5	1
1084	Discovery and Chemical Development of Relebactam: A Potent Î²-Lactamase Inhibitor in Combination with Primaxin [®] for the Treatment of Serious and Antibiotic-Resistant Bacterial Infections. ACS Symposium Series, 2020, , 253-284.	0.5	0
1085	The Discovery and Chemical Development of BMS-919373: A Selective<i>I</i>_{Kur}Inhibitor for the Potential Treatment of Atrial Fibrillation. ACS Symposium Series, 2020, , 43-97.	0.5	0
1089	Discovery and Commercial Development of Cholesteryl Transfer Protein Inhibitor Evacetrapib. ACS Symposium Series, 2020, , 339-372.	0.5	1
1090	Discovery and Process Development of BIIB068: A Reversible Brutonâ€™s Tyrosine Kinase (BTK) Inhibitor for the Treatment of Autoimmune Diseases. ACS Symposium Series, 2020, , 313-337.	0.5	0
1091	Perfil EpidemiolÃ³gico dos portadores de Hepatite C atendidos nos ServiÃ§os de ReferÃªncia no Estado do PiauÃ: Research, Society and Development, 2020, 9, e71963457.	0.0	0
1092	HOPE in action: A prospective multicenter pilot study of liver transplantation from donors with HIV to recipients with HIV. American Journal of Transplantation, 2022, 22, 853-864.	2.6	30
1093	A prospective study in hepatitis C virus treatment-naïve patients showing rheumatologic extra-hepatic manifestations of hepatitis C with associated risk factors: efficacy and safety using sofosbuvir-based direct antiviral therapy. Egyptian Rheumatology and Rehabilitation, 2020, 47, .	0.2	0
1094	Cost-effectiveness analysis with direct-acting antivirals in a cohort of HCV-infected inmates in Italy. AboutOpen, 2020, 7, 103-111.	0.2	0
1095	Hepatitis C Virus Therapy-related Skin Manifestations. Gastroenterology and Hepatology, 2010, 6, 326-8.	0.2	1
1096	Significant epidemiological changes in chronic hepatitis C infection: results of the nationwide HEPNET-GREECE cohort study. Hippokratia, 2011, 15, 26-31.	0.3	26

#	ARTICLE	IF	CITATIONS
1097	Hepatitis C virus and lichen planus: the real association. <i>Hepatitis Monthly</i> , 2010, 10, 161-4.	0.1	18
1098	Surveillance system for hepatitis C infection: A practical approach. <i>International Journal of Preventive Medicine</i> , 2012, 3, S48-57.	0.2	2
1099	High Rate of Virological Response to Peginterferon α -2a-Ribavirin Among Non-Cirrhotic Iranian Hemophilia Patients With Chronic Hepatitis C. <i>Iranian Red Crescent Medical Journal</i> , 2012, 14, 466-9.	0.5	10
1100	The Role of IL28B Genotype Testing in the Era of Direct Acting Antiviral Agents. <i>European Gastroenterology & Hepatology Review</i> , 2012, 1, 33-39.	0.0	2
1101	Innate immunity: a new chapter for hepatitis C. <i>Annals of Gastroenterology</i> , 2012, 25, 232-240.	0.4	0
1102	Direct-acting antiviral agents in patients with hepatitis C cirrhosis. <i>Gastroenterology and Hepatology</i> , 2012, 8, 727-65.	0.2	4
1103	Frontiers in the treatment of hepatitis C virus infection. <i>Gastroenterology and Hepatology</i> , 2014, 10, 90-100.	0.2	7
1104	Hepatitis C virus; its implication for endodontists. <i>Iranian Endodontic Journal</i> , 2014, 9, 169-73.	0.8	1
1105	Sofosbuvir: a novel oral agent for chronic hepatitis C. <i>Annals of Gastroenterology</i> , 2014, 27, 331-337.	0.4	59
1107	Factors Associated with Hepatitis C Infection among Chronic HCV Egyptian Patients. <i>Iranian Journal of Public Health</i> , 2014, 43, 1510-8.	0.3	11
1108	Health status of newly arrived refugees in Toronto, Ont: Part 1: infectious diseases. <i>Canadian Family Physician</i> , 2015, 61, e303-9.	0.1	30
1109	Boceprevir for chronic HCV genotype 1 infection in treatment-experienced patients with severe fibrosis or cirrhosis: The Greek real-life experience. <i>Annals of Gastroenterology</i> , 2015, 28, 481-6.	0.4	2
1110	Viekira Pak (Ombitasvir, Paritaprevir, and Ritonavir Tablets; Dasabuvir Tablets): All-Oral Fixed Combination Approved for Genotype 1 Chronic Hepatitis C Infection. <i>American Health and Drug Benefits</i> , 2015, 8, 142-7.	0.5	64
1111	Once-a-Day Harvoni (Ledipasvir plus Sofosbuvir), a New Oral Combination for the Treatment of Patients with Genotype 1 Chronic Hepatitis C Infection. <i>American Health and Drug Benefits</i> , 2015, 8, 54-8.	0.5	8
1112	Molecular docking, ADMET analysis, and bioactivity studies of phytochemicals from <i>Phyllanthus niruri</i> as potential inhibitors of hepatitis C virus NS5B polymerase. <i>Journal of the Indian Chemical Society</i> , 2022, 99, 100321.	1.3	6
1113	Current Screening Strategy Poses Risk of Spreading of Hepatitis C Virus Infection. <i>The International Journal of Frontier Sciences</i> , 2020, 5, .	0.3	0
1114	Inosine Triphosphate Pyrophosphatase (ITPase): Functions, Mutations, Polymorphisms and Its Impact on Cancer Therapies. <i>Cells</i> , 2022, 11, 384.	1.8	3
1115	Aspects of cognitive assessments and spectroscopic magnetic resonance imaging in people with chronic hepatitis C: a systematic review. <i>Psychology, Health and Medicine</i> , 2022, , 1-17.	1.3	1

#	ARTICLE	IF	CITATIONS
1116	Trans-ancestral fine-mapping of MHC reveals key amino acids associated with spontaneous clearance of hepatitis C in HLA-DQ1 ²¹ . <i>American Journal of Human Genetics</i> , 2022, 109, 299-310.	2.6	6
1117	Hepatoprotective potential of selected medicinally important herbs: evidence from ethnomedicinal, toxicological and pharmacological evaluations. <i>Phytochemistry Reviews</i> , 2022, 21, 1863-1886.	3.1	11
1118	Simultaneous determination of HCV genotype and NS5B resistance associated substitutions using dried serum spots from São Paulo state, Brazil. <i>Access Microbiology</i> , 2022, 4, .	0.2	3
1119	HBV-positive and HIV-positive organs in transplantation: a clinical guide for the hepatologist. <i>Journal of Hepatology</i> , 2022, , .	1.8	4
1120	Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 396-415.	3.7	237
1123	Evaluation of HCV-Core Antigen in Diagnosis of Chronic Hepatitis C Patients under Direct-Acting Antiviral Treatment. <i>Viral Hepatitis Journal</i> , 2022, 28, 25-31.	0.1	0
1124	Determination of Risk Factors Associated with the Failure of 12 Weeks of Direct-Acting Antiviral Therapy in Patients with Hepatitis C: A Prospective Study. <i>BioMed Research International</i> , 2022, 2022, 1-10.	0.9	3
1125	Toll-like Receptor Response to Hepatitis C Virus Infection: A Recent Overview. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5475.	1.8	8
1126	Potential role of interleukin 28B-gene polymorphism and natural immune enhancer treatment response in chronic HCV patients. , 2015, 3, 15-20.		0
1127	Surface-enhanced Raman spectroscopic analysis of centrifugally filtered blood serum samples of hepatitis C patients. <i>Photodiagnosis and Photodynamic Therapy</i> , 2022, 39, 102949.	1.3	7
1128	Metabolic aspects of hepatitis C virus. <i>World Journal of Gastroenterology</i> , 2022, 28, 2429-2436.	1.4	3
1129	Structure-based pharmacophore modeling, virtual screening approaches to identifying the potent hepatitis C viral protease and polymerase novel inhibitors. <i>Journal of Cellular Biochemistry</i> , 2022, 123, 1366-1380.	1.2	1
1130	Hepatitis B and C infection among dentists – Risk, prevention, and management. , 0, 1, 31-36.		0
1131	Safety and Efficacy of Direct Antiviral Agents for Hepatitis C in Patients with Malignancies Other Than Liver Cancer: A Case Series. <i>Pathogens</i> , 2022, 11, 860.	1.2	1
1132	Global dynamics of an age-dependent multiscale hepatitis C virus model. <i>Journal of Mathematical Biology</i> , 2022, 85, .	0.8	1
1133	Design of a novel multi-epitope vaccine candidate against hepatitis C virus using structural and nonstructural proteins: An immunoinformatics approach. <i>PLoS ONE</i> , 2022, 17, e0272582.	1.1	13
1134	What is the Current Situation of HBV, HCV and HIV Seroprevalence Among Syrian Refugees? Patients Evaluated Preoperatively Over Ten Years. <i>Viral Hepatitis Journal</i> , 2022, 28, 55-60.	0.1	0
1135	Recent advances in electrochemical biosensors for detection of oncoviruses. <i>Biosensors and Bioelectronics: X</i> , 2022, , 100260.	0.9	0

#	ARTICLE	IF	CITATIONS
1136	Performance of algorithms for identifying patients with chronic hepatitis B or C infection in the french health insurance claims databases using the <scp>ANRS CO22 HEPATHER</scp> cohort. Journal of Viral Hepatitis, 2023, 30, 232-241.	1.0	2
1138	Infections in liver transplantation. , 2023, , 87-99.		0
1139	Research progress of indole-fused derivatives as allosteric modulators: Opportunities for drug development. Biomedicine and Pharmacotherapy, 2023, 162, 114574.	2.5	3
1140	Prognostic factors for outcome of liver transplantation hepatitis C cirrhosis. Chirurgia (Turin), 2023, 36, .	0.0	0
1141	ABT-333 (Dasabuvir) Increases Action Potential Duration and Provokes Early Afterdepolarizations in Canine Left Ventricular Cells via Inhibition of IKr. Pharmaceuticals, 2023, 16, 488.	1.7	0
1142	Promising hepatoprotective agents from the natural sources: a study of scientific evidence. Egyptian Liver Journal, 2023, 13, .	0.3	6
1144	Balance-Based Fuzzy Logic Approach for the Classification of Liver Diseases Due to Hepatitis C Virus. Studies in Fuzziness and Soft Computing, 2023, , 157-170.	0.6	0
1146	Hepatitis C Virus Structure and Diagnostic Methods. , 0, , .		1
1147	Liver and Gastrointestinal Tract Problems in Chronic Kidney Disease. , 2023, , 313-325.		0
1148	Use of living donors for HIV-positive transplant candidates. , 2024, , 1435-1442.		0